[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_4175":38,"_4176":4177,"_4178":4179,"_4180":4181},"routes/_app.podcast.$podcastSlug.$podcastUuid.$episodeSlug.$episodeUuid",{"_9":10,"_11":12,"_13":14},"podcastUuid","ee2eca40-3acb-0138-9727-0acc26574db2","episodeUuid","f8673b72-727f-4dd1-8c91-2c9bf64ce14d","dehydratedState",{"_15":16,"_17":18},"mutations",[],"queries",[19,20],{"_21":22,"_23":49,"_25":50,"_27":51},{"_21":22,"_23":24,"_25":26,"_27":28},"dehydratedAt",1789937345876,"state",{"_31":32,"_33":34,"_35":22,"_36":-5,"_37":38,"_39":38,"_40":38,"_41":-5,"_42":-5,"_43":44,"_45":46,"_47":48},"queryKey",[29,30,12],"queryHash","[\"episodeShowNotes\",\"detail\",\"f8673b72-727f-4dd1-8c91-2c9bf64ce14d\"]","episodeShowNotes","detail","data","

Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

","dataUpdateCount",1,"dataUpdatedAt","error","errorUpdateCount",0,"errorUpdatedAt","fetchFailureCount","fetchFailureReason","fetchMeta","isInvalidated",false,"status","success","fetchStatus","idle",{"_31":53,"_33":34,"_35":54,"_36":-5,"_37":38,"_39":38,"_40":38,"_41":-5,"_42":-5,"_43":44,"_45":46,"_47":48},[52,30,10],"[\"podcasts\",\"detail\",\"ee2eca40-3acb-0138-9727-0acc26574db2\"]","podcasts",{"_55":56,"_57":58,"_59":60,"_61":58,"_62":63,"_64":65,"_66":67,"_68":69,"_70":71,"_72":10,"_73":74,"_75":76,"_77":44,"_78":44,"_79":80,"_81":44,"_82":83,"_84":85,"_86":87,"_88":69,"_89":90},1789937345872,"url","https://www.uromigos.org","title","The Uromigos","slug","the-uromigos","author","description","Broadcasting the latest developments in GU cancer\n\nHosted by Brian Rini and Tom Powles \n\nBrian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center\nTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London","description_html","Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London","category","Health & Fitness\n Medicine","audio",true,"show_type","episodic","uuid","fundings",[],"guid","","is_private","transcript_eligible","episodes",[91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573],"explicit","episodeFrequency","Weekly","estimatedNextEpisodeAt","2026-09-07T01:53:00Z","episodeCount",483,"hasSeasons","seasonCount",3,{"_72":4168,"_57":4169,"_59":4170,"_55":4171,"_578":616,"_580":4172,"_582":4173,"_584":4174,"_586":587,"_588":44,"_9":10},{"_72":4161,"_57":4162,"_59":4163,"_55":4164,"_578":616,"_580":4165,"_582":4166,"_584":4167,"_586":587,"_588":44,"_9":10},{"_72":4154,"_57":4155,"_59":4156,"_55":4157,"_578":616,"_580":4158,"_582":4159,"_584":4160,"_586":587,"_588":44,"_9":10},{"_72":4147,"_57":4148,"_59":4149,"_55":4150,"_578":616,"_580":4151,"_582":4152,"_584":4153,"_586":587,"_588":44,"_9":10},{"_72":4140,"_57":4141,"_59":4142,"_55":4143,"_578":616,"_580":4144,"_582":4145,"_584":4146,"_586":587,"_588":44,"_9":10},{"_72":4134,"_57":4135,"_59":4136,"_55":4137,"_578":616,"_580":4138,"_582":1690,"_584":4139,"_586":587,"_588":44,"_9":10},{"_72":4127,"_57":4128,"_59":4129,"_55":4130,"_578":616,"_580":4131,"_582":4132,"_584":4133,"_586":587,"_588":44,"_9":10},{"_72":4120,"_57":4121,"_59":4122,"_55":4123,"_578":616,"_580":4124,"_582":4125,"_584":4126,"_586":587,"_588":44,"_9":10},{"_72":4113,"_57":4114,"_59":4115,"_55":4116,"_578":616,"_580":4117,"_582":4118,"_584":4119,"_586":587,"_588":44,"_9":10},{"_72":12,"_57":4107,"_59":4108,"_55":4109,"_578":616,"_580":4110,"_582":4111,"_584":4112,"_586":587,"_588":44,"_9":10},{"_72":4101,"_57":4102,"_59":4103,"_55":4104,"_578":616,"_580":4105,"_582":2659,"_584":4106,"_586":587,"_588":44,"_9":10},{"_72":4094,"_57":4095,"_59":4096,"_55":4097,"_578":616,"_580":4098,"_582":4099,"_584":4100,"_586":587,"_588":44,"_9":10},{"_72":4087,"_57":4088,"_59":4089,"_55":4090,"_578":616,"_580":4091,"_582":4092,"_584":4093,"_586":587,"_588":44,"_9":10},{"_72":4080,"_57":4081,"_59":4082,"_55":4083,"_578":616,"_580":4084,"_582":4085,"_584":4086,"_586":587,"_588":44,"_9":10},{"_72":4073,"_57":4074,"_59":4075,"_55":4076,"_578":616,"_580":4077,"_582":4078,"_584":4079,"_586":587,"_588":44,"_9":10},{"_72":4067,"_57":4068,"_59":4069,"_55":4070,"_578":616,"_580":4071,"_582":4059,"_584":4072,"_586":587,"_588":44,"_9":10},{"_72":4061,"_57":4062,"_59":4063,"_55":4064,"_578":616,"_580":4065,"_582":3636,"_584":4066,"_586":587,"_588":44,"_9":10},{"_72":4054,"_57":4055,"_59":4056,"_55":4057,"_578":616,"_580":4058,"_582":4059,"_584":4060,"_586":587,"_588":44,"_9":10},{"_72":4047,"_57":4048,"_59":4049,"_55":4050,"_578":616,"_580":4051,"_582":4052,"_584":4053,"_586":587,"_588":44,"_9":10},{"_72":4040,"_57":4041,"_59":4042,"_55":4043,"_578":616,"_580":4044,"_582":4045,"_584":4046,"_586":587,"_588":44,"_9":10},{"_72":4033,"_57":4034,"_59":4035,"_55":4036,"_578":616,"_580":4037,"_582":4038,"_584":4039,"_586":587,"_588":44,"_9":10},{"_72":4027,"_57":4028,"_59":4029,"_55":4030,"_578":616,"_580":4031,"_582":2870,"_584":4032,"_586":587,"_588":44,"_9":10},{"_72":4021,"_57":4022,"_59":4023,"_55":4024,"_578":616,"_580":4025,"_582":3388,"_584":4026,"_586":587,"_588":44,"_9":10},{"_72":4014,"_57":4015,"_59":4016,"_55":4017,"_578":616,"_580":4018,"_582":4019,"_584":4020,"_586":587,"_588":44,"_9":10},{"_72":4007,"_57":4008,"_59":4009,"_55":4010,"_578":616,"_580":4011,"_582":4012,"_584":4013,"_586":587,"_588":44,"_9":10},{"_72":4001,"_57":4002,"_59":4003,"_55":4004,"_578":616,"_580":4005,"_582":3999,"_584":4006,"_586":587,"_588":44,"_9":10},{"_72":3994,"_57":3995,"_59":3996,"_55":3997,"_578":579,"_580":3998,"_582":3999,"_584":4000,"_586":587,"_588":44,"_9":10},{"_72":3987,"_57":3988,"_59":3989,"_55":3990,"_578":616,"_580":3991,"_582":3992,"_584":3993,"_586":587,"_588":44,"_9":10},{"_72":3980,"_57":3981,"_59":3982,"_55":3983,"_578":616,"_580":3984,"_582":3985,"_584":3986,"_586":587,"_588":44,"_9":10},{"_72":3974,"_57":3975,"_59":3976,"_55":3977,"_578":616,"_580":3978,"_582":3979,"_584":3973,"_586":587,"_588":44,"_9":10},{"_72":3967,"_57":3968,"_59":3969,"_55":3970,"_578":616,"_580":3971,"_582":3972,"_584":3973,"_586":587,"_588":44,"_9":10},{"_72":3960,"_57":3961,"_59":3962,"_55":3963,"_578":616,"_580":3964,"_582":3965,"_584":3966,"_586":587,"_588":44,"_9":10},{"_72":3953,"_57":3954,"_59":3955,"_55":3956,"_578":616,"_580":3957,"_582":3958,"_584":3959,"_586":587,"_588":44,"_9":10},{"_72":3946,"_57":3947,"_59":3948,"_55":3949,"_578":616,"_580":3950,"_582":3951,"_584":3952,"_586":587,"_588":44,"_9":10},{"_72":3939,"_57":3940,"_59":3941,"_55":3942,"_578":616,"_580":3943,"_582":3944,"_584":3945,"_586":587,"_588":44,"_9":10},{"_72":3932,"_57":3933,"_59":3934,"_55":3935,"_578":616,"_580":3936,"_582":3937,"_584":3938,"_586":587,"_588":44,"_9":10},{"_72":3925,"_57":3926,"_59":3927,"_55":3928,"_578":616,"_580":3929,"_582":3930,"_584":3931,"_586":587,"_588":44,"_9":10},{"_72":3918,"_57":3919,"_59":3920,"_55":3921,"_578":616,"_580":3922,"_582":3923,"_584":3924,"_586":587,"_588":44,"_9":10},{"_72":3911,"_57":3912,"_59":3913,"_55":3914,"_578":616,"_580":3915,"_582":3916,"_584":3917,"_586":587,"_588":44,"_9":10},{"_72":3904,"_57":3905,"_59":3906,"_55":3907,"_578":616,"_580":3908,"_582":3909,"_584":3910,"_586":587,"_588":44,"_9":10},{"_72":3898,"_57":3899,"_59":3900,"_55":3901,"_578":616,"_580":3902,"_582":2289,"_584":3903,"_586":587,"_588":44,"_9":10},{"_72":3891,"_57":3892,"_59":3893,"_55":3894,"_578":616,"_580":3895,"_582":3896,"_584":3897,"_586":587,"_588":44,"_9":10},{"_72":3884,"_57":3885,"_59":3886,"_55":3887,"_578":616,"_580":3888,"_582":3889,"_584":3890,"_586":587,"_588":44,"_9":10},{"_72":3877,"_57":3878,"_59":3879,"_55":3880,"_578":616,"_580":3881,"_582":3882,"_584":3883,"_586":587,"_588":44,"_9":10},{"_72":3870,"_57":3871,"_59":3872,"_55":3873,"_578":616,"_580":3874,"_582":3875,"_584":3876,"_586":587,"_588":44,"_9":10},{"_72":3863,"_57":3864,"_59":3865,"_55":3866,"_578":616,"_580":3867,"_582":3868,"_584":3869,"_586":587,"_588":44,"_9":10},{"_72":3856,"_57":3857,"_59":3858,"_55":3859,"_578":616,"_580":3860,"_582":3861,"_584":3862,"_586":587,"_588":44,"_9":10},{"_72":3849,"_57":3850,"_59":3851,"_55":3852,"_578":616,"_580":3853,"_582":3854,"_584":3855,"_586":587,"_588":44,"_9":10},{"_72":3842,"_57":3843,"_59":3844,"_55":3845,"_578":616,"_580":3846,"_582":3847,"_584":3848,"_586":587,"_588":44,"_9":10},{"_72":3835,"_57":3836,"_59":3837,"_55":3838,"_578":616,"_580":3839,"_582":3840,"_584":3841,"_586":587,"_588":44,"_9":10},{"_72":3828,"_57":3829,"_59":3830,"_55":3831,"_578":616,"_580":3832,"_582":3833,"_584":3834,"_586":587,"_588":44,"_9":10},{"_72":3822,"_57":3823,"_59":3824,"_55":3825,"_578":616,"_580":3826,"_582":3307,"_584":3827,"_586":587,"_588":44,"_9":10},{"_72":3815,"_57":3816,"_59":3817,"_55":3818,"_578":616,"_580":3819,"_582":3820,"_584":3821,"_586":587,"_588":44,"_9":10},{"_72":3808,"_57":3809,"_59":3810,"_55":3811,"_578":616,"_580":3812,"_582":3813,"_584":3814,"_586":587,"_588":44,"_9":10},{"_72":3801,"_57":3802,"_59":3803,"_55":3804,"_578":616,"_580":3805,"_582":3806,"_584":3807,"_586":587,"_588":44,"_9":10},{"_72":3794,"_57":3795,"_59":3796,"_55":3797,"_578":616,"_580":3798,"_582":3799,"_584":3800,"_586":587,"_588":44,"_9":10},{"_72":3787,"_57":3788,"_59":3789,"_55":3790,"_578":616,"_580":3791,"_582":3792,"_584":3793,"_586":587,"_588":44,"_9":10},{"_72":3780,"_57":3781,"_59":3782,"_55":3783,"_578":616,"_580":3784,"_582":3785,"_584":3786,"_586":587,"_588":44,"_9":10},{"_72":3773,"_57":3774,"_59":3775,"_55":3776,"_578":616,"_580":3777,"_582":3778,"_584":3779,"_586":587,"_588":44,"_9":10},{"_72":3767,"_57":3768,"_59":3769,"_55":3770,"_578":616,"_580":3771,"_582":2375,"_584":3772,"_586":587,"_588":44,"_9":10},{"_72":3760,"_57":3761,"_59":3762,"_55":3763,"_578":579,"_580":3764,"_582":3765,"_584":3766,"_586":587,"_588":44,"_9":10},{"_72":3754,"_57":3755,"_59":3756,"_55":3757,"_578":616,"_580":3758,"_582":1990,"_584":3759,"_586":587,"_588":44,"_9":10},{"_72":3748,"_57":3749,"_59":3750,"_55":3751,"_578":616,"_580":3752,"_582":2575,"_584":3753,"_586":587,"_588":44,"_9":10},{"_72":3741,"_57":3742,"_59":3743,"_55":3744,"_578":616,"_580":3745,"_582":3746,"_584":3747,"_586":587,"_588":44,"_9":10},{"_72":3734,"_57":3735,"_59":3736,"_55":3737,"_578":616,"_580":3738,"_582":3739,"_584":3740,"_586":587,"_588":44,"_9":10},{"_72":3727,"_57":3728,"_59":3729,"_55":3730,"_578":616,"_580":3731,"_582":3732,"_584":3733,"_586":587,"_588":44,"_9":10},{"_72":3720,"_57":3721,"_59":3722,"_55":3723,"_578":616,"_580":3724,"_582":3725,"_584":3726,"_586":587,"_588":44,"_9":10},{"_72":3713,"_57":3714,"_59":3715,"_55":3716,"_578":616,"_580":3717,"_582":3718,"_584":3719,"_586":587,"_588":44,"_9":10},{"_72":3706,"_57":3707,"_59":3708,"_55":3709,"_578":616,"_580":3710,"_582":3711,"_584":3712,"_586":587,"_588":44,"_9":10},{"_72":3699,"_57":3700,"_59":3701,"_55":3702,"_578":616,"_580":3703,"_582":3704,"_584":3705,"_586":587,"_588":44,"_9":10},{"_72":3693,"_57":3694,"_59":3695,"_55":3696,"_578":616,"_580":3697,"_582":2769,"_584":3698,"_586":587,"_588":44,"_9":10},{"_72":3686,"_57":3687,"_59":3688,"_55":3689,"_578":616,"_580":3690,"_582":3691,"_584":3692,"_586":587,"_588":44,"_9":10},{"_72":3679,"_57":3680,"_59":3681,"_55":3682,"_578":616,"_580":3683,"_582":3684,"_584":3685,"_586":587,"_588":44,"_9":10},{"_72":3673,"_57":3674,"_59":3675,"_55":3676,"_578":616,"_580":3677,"_582":1840,"_584":3678,"_586":587,"_588":44,"_9":10},{"_72":3666,"_57":3667,"_59":3668,"_55":3669,"_578":616,"_580":3670,"_582":3671,"_584":3672,"_586":587,"_588":44,"_9":10},{"_72":3659,"_57":3660,"_59":3661,"_55":3662,"_578":616,"_580":3663,"_582":3664,"_584":3665,"_586":587,"_588":44,"_9":10},{"_72":3652,"_57":3653,"_59":3654,"_55":3655,"_578":616,"_580":3656,"_582":3657,"_584":3658,"_586":587,"_588":44,"_9":10},{"_72":3645,"_57":3646,"_59":3647,"_55":3648,"_578":616,"_580":3649,"_582":3650,"_584":3651,"_586":587,"_588":44,"_9":10},{"_72":3638,"_57":3639,"_59":3640,"_55":3641,"_578":616,"_580":3642,"_582":3643,"_584":3644,"_586":587,"_588":44,"_9":10},{"_72":3631,"_57":3632,"_59":3633,"_55":3634,"_578":616,"_580":3635,"_582":3636,"_584":3637,"_586":587,"_588":44,"_9":10},{"_72":3624,"_57":3625,"_59":3626,"_55":3627,"_578":616,"_580":3628,"_582":3629,"_584":3630,"_586":587,"_588":44,"_9":10},{"_72":3618,"_57":3619,"_59":3620,"_55":3621,"_578":616,"_580":3622,"_582":1094,"_584":3623,"_586":587,"_588":44,"_9":10},{"_72":3611,"_57":3612,"_59":3613,"_55":3614,"_578":616,"_580":3615,"_582":3616,"_584":3617,"_586":587,"_588":44,"_9":10},{"_72":3604,"_57":3605,"_59":3606,"_55":3607,"_578":616,"_580":3608,"_582":3609,"_584":3610,"_586":587,"_588":44,"_9":10},{"_72":3597,"_57":3598,"_59":3599,"_55":3600,"_578":616,"_580":3601,"_582":3602,"_584":3603,"_586":587,"_588":44,"_9":10},{"_72":3591,"_57":3592,"_59":3593,"_55":3594,"_578":616,"_580":3595,"_582":1308,"_584":3596,"_586":587,"_588":44,"_9":10},{"_72":3584,"_57":3585,"_59":3586,"_55":3587,"_578":616,"_580":3588,"_582":3589,"_584":3590,"_586":587,"_588":44,"_9":10},{"_72":3577,"_57":3578,"_59":3579,"_55":3580,"_578":616,"_580":3581,"_582":3582,"_584":3583,"_586":587,"_588":44,"_9":10},{"_72":3570,"_57":3571,"_59":3572,"_55":3573,"_578":616,"_580":3574,"_582":3575,"_584":3576,"_586":587,"_588":44,"_9":10},{"_72":3563,"_57":3564,"_59":3565,"_55":3566,"_578":616,"_580":3567,"_582":3568,"_584":3569,"_586":587,"_588":44,"_9":10},{"_72":3556,"_57":3557,"_59":3558,"_55":3559,"_578":616,"_580":3560,"_582":3561,"_584":3562,"_586":587,"_588":44,"_9":10},{"_72":3549,"_57":3550,"_59":3551,"_55":3552,"_578":616,"_580":3553,"_582":3554,"_584":3555,"_586":587,"_588":44,"_9":10},{"_72":3542,"_57":3543,"_59":3544,"_55":3545,"_578":616,"_580":3546,"_582":3547,"_584":3548,"_586":587,"_588":44,"_9":10},{"_72":3535,"_57":3536,"_59":3537,"_55":3538,"_578":616,"_580":3539,"_582":3540,"_584":3541,"_586":587,"_588":44,"_9":10},{"_72":3528,"_57":3529,"_59":3530,"_55":3531,"_578":616,"_580":3532,"_582":3533,"_584":3534,"_586":587,"_588":44,"_9":10},{"_72":3521,"_57":3522,"_59":3523,"_55":3524,"_578":616,"_580":3525,"_582":3526,"_584":3527,"_586":587,"_588":44,"_9":10},{"_72":3515,"_57":3516,"_59":3517,"_55":3518,"_578":616,"_580":3519,"_582":658,"_584":3520,"_586":587,"_588":44,"_9":10},{"_72":3508,"_57":3509,"_59":3510,"_55":3511,"_578":616,"_580":3512,"_582":3513,"_584":3514,"_586":587,"_588":44,"_9":10},{"_72":3501,"_57":3502,"_59":3503,"_55":3504,"_578":616,"_580":3505,"_582":3506,"_584":3507,"_586":587,"_588":44,"_9":10},{"_72":3494,"_57":3495,"_59":3496,"_55":3497,"_578":616,"_580":3498,"_582":3499,"_584":3500,"_586":587,"_588":44,"_9":10},{"_72":3487,"_57":3488,"_59":3489,"_55":3490,"_578":616,"_580":3491,"_582":3492,"_584":3493,"_586":587,"_588":44,"_9":10},{"_72":3481,"_57":3482,"_59":3483,"_55":3484,"_578":616,"_580":3485,"_582":1158,"_584":3486,"_586":587,"_588":44,"_9":10},{"_72":3474,"_57":3475,"_59":3476,"_55":3477,"_578":616,"_580":3478,"_582":3479,"_584":3480,"_586":587,"_588":44,"_9":10},{"_72":3467,"_57":3468,"_59":3469,"_55":3470,"_578":616,"_580":3471,"_582":3472,"_584":3473,"_586":587,"_588":44,"_9":10},{"_72":3460,"_57":3461,"_59":3462,"_55":3463,"_578":616,"_580":3464,"_582":3465,"_584":3466,"_586":587,"_588":44,"_9":10},{"_72":3453,"_57":3454,"_59":3455,"_55":3456,"_578":616,"_580":3457,"_582":3458,"_584":3459,"_586":587,"_588":44,"_9":10},{"_72":3446,"_57":3447,"_59":3448,"_55":3449,"_578":616,"_580":3450,"_582":3451,"_584":3452,"_586":587,"_588":44,"_9":10},{"_72":3439,"_57":3440,"_59":3441,"_55":3442,"_578":616,"_580":3443,"_582":3444,"_584":3445,"_586":587,"_588":44,"_9":10},{"_72":3432,"_57":3433,"_59":3434,"_55":3435,"_578":616,"_580":3436,"_582":3437,"_584":3438,"_586":587,"_588":44,"_9":10},{"_72":3425,"_57":3426,"_59":3427,"_55":3428,"_578":616,"_580":3429,"_582":3430,"_584":3431,"_586":587,"_588":44,"_9":10},{"_72":3418,"_57":3419,"_59":3420,"_55":3421,"_578":616,"_580":3422,"_582":3423,"_584":3424,"_586":587,"_588":44,"_9":10},{"_72":3411,"_57":3412,"_59":3413,"_55":3414,"_578":579,"_580":3415,"_582":3416,"_584":3417,"_586":587,"_588":44,"_9":10},{"_72":3404,"_57":3405,"_59":3406,"_55":3407,"_578":616,"_580":3408,"_582":3409,"_584":3410,"_586":587,"_588":44,"_9":10},{"_72":3397,"_57":3398,"_59":3399,"_55":3400,"_578":616,"_580":3401,"_582":3402,"_584":3403,"_586":587,"_588":44,"_9":10},{"_72":3390,"_57":3391,"_59":3392,"_55":3393,"_578":616,"_580":3394,"_582":3395,"_584":3396,"_586":587,"_588":44,"_9":10},{"_72":3383,"_57":3384,"_59":3385,"_55":3386,"_578":616,"_580":3387,"_582":3388,"_584":3389,"_586":587,"_588":44,"_9":10},{"_72":3376,"_57":3377,"_59":3378,"_55":3379,"_578":616,"_580":3380,"_582":3381,"_584":3382,"_586":587,"_588":44,"_9":10},{"_72":3369,"_57":3370,"_59":3371,"_55":3372,"_578":616,"_580":3373,"_582":3374,"_584":3375,"_586":587,"_588":44,"_9":10},{"_72":3363,"_57":3364,"_59":3365,"_55":3366,"_578":616,"_580":3367,"_582":3368,"_584":3356,"_586":587,"_588":44,"_9":10},{"_72":3357,"_57":3358,"_59":3359,"_55":3360,"_578":616,"_580":3361,"_582":3362,"_584":3356,"_586":587,"_588":44,"_9":10},{"_72":3350,"_57":3351,"_59":3352,"_55":3353,"_578":616,"_580":3354,"_582":3355,"_584":3356,"_586":587,"_588":44,"_9":10},{"_72":3344,"_57":3345,"_59":3346,"_55":3347,"_578":616,"_580":3348,"_582":2878,"_584":3349,"_586":587,"_588":44,"_9":10},{"_72":3337,"_57":3338,"_59":3339,"_55":3340,"_578":616,"_580":3341,"_582":3342,"_584":3343,"_586":587,"_588":44,"_9":10},{"_72":3330,"_57":3331,"_59":3332,"_55":3333,"_578":616,"_580":3334,"_582":3335,"_584":3336,"_586":587,"_588":44,"_9":10},{"_72":3323,"_57":3324,"_59":3325,"_55":3326,"_578":616,"_580":3327,"_582":3328,"_584":3329,"_586":587,"_588":44,"_9":10},{"_72":3316,"_57":3317,"_59":3318,"_55":3319,"_578":616,"_580":3320,"_582":3321,"_584":3322,"_586":587,"_588":44,"_9":10},{"_72":3309,"_57":3310,"_59":3311,"_55":3312,"_578":616,"_580":3313,"_582":3314,"_584":3315,"_586":587,"_588":44,"_9":10},{"_72":3302,"_57":3303,"_59":3304,"_55":3305,"_578":616,"_580":3306,"_582":3307,"_584":3308,"_586":587,"_588":44,"_9":10},{"_72":3296,"_57":3297,"_59":3298,"_55":3299,"_578":616,"_580":3300,"_582":928,"_584":3301,"_586":587,"_588":44,"_9":10},{"_72":3289,"_57":3290,"_59":3291,"_55":3292,"_578":616,"_580":3293,"_582":3294,"_584":3295,"_586":587,"_588":44,"_9":10},{"_72":3283,"_57":3284,"_59":3285,"_55":3286,"_578":616,"_580":3287,"_582":2329,"_584":3288,"_586":587,"_588":44,"_9":10},{"_72":3277,"_57":3278,"_59":3279,"_55":3280,"_578":579,"_580":3281,"_582":2536,"_584":3282,"_586":587,"_588":44,"_9":10},{"_72":3270,"_57":3271,"_59":3272,"_55":3273,"_578":616,"_580":3274,"_582":3275,"_584":3276,"_586":587,"_588":44,"_9":10},{"_72":3263,"_57":3264,"_59":3265,"_55":3266,"_578":616,"_580":3267,"_582":3268,"_584":3269,"_586":587,"_588":44,"_9":10},{"_72":3256,"_57":3257,"_59":3258,"_55":3259,"_578":616,"_580":3260,"_582":3261,"_584":3262,"_586":587,"_588":44,"_9":10},{"_72":3249,"_57":3250,"_59":3251,"_55":3252,"_578":616,"_580":3253,"_582":3254,"_584":3255,"_586":587,"_588":44,"_9":10},{"_72":3242,"_57":3243,"_59":3244,"_55":3245,"_578":616,"_580":3246,"_582":3247,"_584":3248,"_586":587,"_588":44,"_9":10},{"_72":3235,"_57":3236,"_59":3237,"_55":3238,"_578":616,"_580":3239,"_582":3240,"_584":3241,"_586":587,"_588":44,"_9":10},{"_72":3228,"_57":3229,"_59":3230,"_55":3231,"_578":616,"_580":3232,"_582":3233,"_584":3234,"_586":587,"_588":44,"_9":10},{"_72":3221,"_57":3222,"_59":3223,"_55":3224,"_578":616,"_580":3225,"_582":3226,"_584":3227,"_586":587,"_588":44,"_9":10},{"_72":3214,"_57":3215,"_59":3216,"_55":3217,"_578":616,"_580":3218,"_582":3219,"_584":3220,"_586":587,"_588":44,"_9":10},{"_72":3208,"_57":3209,"_59":3210,"_55":3211,"_578":616,"_580":3212,"_582":1174,"_584":3213,"_586":587,"_588":44,"_9":10},{"_72":3201,"_57":3202,"_59":3203,"_55":3204,"_578":616,"_580":3205,"_582":3206,"_584":3207,"_586":587,"_588":44,"_9":10},{"_72":3194,"_57":3195,"_59":3196,"_55":3197,"_578":616,"_580":3198,"_582":3199,"_584":3200,"_586":587,"_588":44,"_9":10},{"_72":3188,"_57":3189,"_59":3190,"_55":3191,"_578":616,"_580":3192,"_582":1166,"_584":3193,"_586":587,"_588":44,"_9":10},{"_72":3181,"_57":3182,"_59":3183,"_55":3184,"_578":616,"_580":3185,"_582":3186,"_584":3187,"_586":587,"_588":44,"_9":10},{"_72":3174,"_57":3175,"_59":3176,"_55":3177,"_578":616,"_580":3178,"_582":3179,"_584":3180,"_586":587,"_588":44,"_9":10},{"_72":3167,"_57":3168,"_59":3169,"_55":3170,"_578":616,"_580":3171,"_582":3172,"_584":3173,"_586":587,"_588":44,"_9":10},{"_72":3160,"_57":3161,"_59":3162,"_55":3163,"_578":616,"_580":3164,"_582":3165,"_584":3166,"_586":587,"_588":44,"_9":10},{"_72":3153,"_57":3154,"_59":3155,"_55":3156,"_578":616,"_580":3157,"_582":3158,"_584":3159,"_586":587,"_588":44,"_9":10},{"_72":3146,"_57":3147,"_59":3148,"_55":3149,"_578":616,"_580":3150,"_582":3151,"_584":3152,"_586":587,"_588":44,"_9":10},{"_72":3139,"_57":3140,"_59":3141,"_55":3142,"_578":616,"_580":3143,"_582":3144,"_584":3145,"_586":587,"_588":44,"_9":10},{"_72":3132,"_57":3133,"_59":3134,"_55":3135,"_578":616,"_580":3136,"_582":3137,"_584":3138,"_586":587,"_588":44,"_9":10},{"_72":3125,"_57":3126,"_59":3127,"_55":3128,"_578":616,"_580":3129,"_582":3130,"_584":3131,"_586":587,"_588":44,"_9":10},{"_72":3117,"_57":3118,"_59":3119,"_55":3120,"_578":579,"_580":3121,"_582":3122,"_584":3123,"_586":587,"_588":44,"_589":90,"_590":3124,"_9":10},{"_72":3109,"_57":3110,"_59":3111,"_55":3112,"_578":579,"_580":3113,"_582":3114,"_584":3115,"_586":587,"_588":44,"_589":90,"_590":3116,"_9":10},{"_72":3101,"_57":3102,"_59":3103,"_55":3104,"_578":579,"_580":3105,"_582":3106,"_584":3107,"_586":587,"_588":44,"_589":90,"_590":3108,"_9":10},{"_72":3093,"_57":3094,"_59":3095,"_55":3096,"_578":579,"_580":3097,"_582":3098,"_584":3099,"_586":587,"_588":44,"_589":90,"_590":3100,"_9":10},{"_72":3085,"_57":3086,"_59":3087,"_55":3088,"_578":579,"_580":3089,"_582":3090,"_584":3091,"_586":587,"_588":44,"_589":90,"_590":3092,"_9":10},{"_72":3077,"_57":3078,"_59":3079,"_55":3080,"_578":579,"_580":3081,"_582":3082,"_584":3083,"_586":587,"_588":44,"_589":90,"_590":3084,"_9":10},{"_72":3069,"_57":3070,"_59":3071,"_55":3072,"_578":579,"_580":3073,"_582":3074,"_584":3075,"_586":587,"_588":44,"_589":90,"_590":3076,"_9":10},{"_72":3062,"_57":3063,"_59":3064,"_55":3065,"_578":579,"_580":3066,"_582":3067,"_584":3068,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3055,"_57":3056,"_59":3057,"_55":3058,"_578":579,"_580":3059,"_582":3060,"_584":3061,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3048,"_57":3049,"_59":3050,"_55":3051,"_578":579,"_580":3052,"_582":3053,"_584":3054,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3041,"_57":3042,"_59":3043,"_55":3044,"_578":579,"_580":3045,"_582":3046,"_584":3047,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3034,"_57":3035,"_59":3036,"_55":3037,"_578":579,"_580":3038,"_582":3039,"_584":3040,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3028,"_57":3029,"_59":3030,"_55":3031,"_578":579,"_580":3032,"_582":2994,"_584":3033,"_586":587,"_588":44,"_589":90,"_590":38,"_9":10},{"_72":3020,"_57":3021,"_59":3022,"_55":3023,"_578":579,"_580":3024,"_582":3025,"_584":3026,"_586":587,"_588":44,"_589":90,"_590":3027,"_9":10},{"_72":3013,"_57":3014,"_59":3015,"_55":3016,"_578":579,"_580":3017,"_582":2636,"_584":3018,"_586":587,"_588":44,"_589":90,"_590":3019,"_9":10},{"_72":3005,"_57":3006,"_59":3007,"_55":3008,"_578":579,"_580":3009,"_582":3010,"_584":3011,"_586":587,"_588":44,"_589":90,"_590":3012,"_9":10},{"_72":2997,"_57":2998,"_59":2999,"_55":3000,"_578":579,"_580":3001,"_582":3002,"_584":3003,"_586":587,"_588":44,"_589":90,"_590":3004,"_9":10},{"_72":2989,"_57":2990,"_59":2991,"_55":2992,"_578":579,"_580":2993,"_582":2994,"_584":2995,"_586":587,"_588":44,"_589":90,"_590":2996,"_9":10},{"_72":2981,"_57":2982,"_59":2983,"_55":2984,"_578":579,"_580":2985,"_582":2986,"_584":2987,"_586":587,"_588":44,"_589":90,"_590":2988,"_9":10},{"_72":2974,"_57":2975,"_59":2976,"_55":2977,"_578":579,"_580":2978,"_582":728,"_584":2979,"_586":587,"_588":44,"_589":90,"_590":2980,"_9":10},{"_72":2966,"_57":2967,"_59":2968,"_55":2969,"_578":579,"_580":2970,"_582":2971,"_584":2972,"_586":587,"_588":44,"_589":90,"_590":2973,"_9":10},{"_72":2958,"_57":2959,"_59":2960,"_55":2961,"_578":579,"_580":2962,"_582":2963,"_584":2964,"_586":587,"_588":44,"_589":90,"_590":2965,"_9":10},{"_72":2950,"_57":2951,"_59":2952,"_55":2953,"_578":579,"_580":2954,"_582":2955,"_584":2956,"_586":587,"_588":44,"_589":90,"_590":2957,"_9":10},{"_72":2943,"_57":2944,"_59":2945,"_55":2946,"_578":579,"_580":2947,"_582":2777,"_584":2948,"_586":587,"_588":44,"_589":90,"_590":2949,"_9":10},{"_72":2935,"_57":2936,"_59":2937,"_55":2938,"_578":579,"_580":2939,"_582":2940,"_584":2941,"_586":587,"_588":44,"_589":90,"_590":2942,"_9":10},{"_72":2928,"_57":2929,"_59":2930,"_55":2931,"_578":579,"_580":2932,"_582":1982,"_584":2933,"_586":587,"_588":44,"_589":90,"_590":2934,"_9":10},{"_72":2920,"_57":2921,"_59":2922,"_55":2923,"_578":579,"_580":2924,"_582":2925,"_584":2926,"_586":587,"_588":44,"_589":90,"_590":2927,"_9":10},{"_72":2912,"_57":2913,"_59":2914,"_55":2915,"_578":579,"_580":2916,"_582":2917,"_584":2918,"_586":587,"_588":44,"_589":90,"_590":2919,"_9":10},{"_72":2905,"_57":2906,"_59":2907,"_55":2908,"_578":579,"_580":2909,"_582":2195,"_584":2910,"_586":587,"_588":44,"_589":90,"_590":2911,"_9":10},{"_72":2897,"_57":2898,"_59":2899,"_55":2900,"_578":579,"_580":2901,"_582":2902,"_584":2903,"_586":587,"_588":44,"_589":90,"_590":2904,"_9":10},{"_72":2889,"_57":2890,"_59":2891,"_55":2892,"_578":579,"_580":2893,"_582":2894,"_584":2895,"_586":587,"_588":44,"_589":90,"_590":2896,"_9":10},{"_72":2881,"_57":2882,"_59":2883,"_55":2884,"_578":579,"_580":2885,"_582":2886,"_584":2887,"_586":587,"_588":44,"_589":90,"_590":2888,"_9":10},{"_72":2873,"_57":2874,"_59":2875,"_55":2876,"_578":579,"_580":2877,"_582":2878,"_584":2879,"_586":587,"_588":44,"_589":90,"_590":2880,"_9":10},{"_72":2865,"_57":2866,"_59":2867,"_55":2868,"_578":579,"_580":2869,"_582":2870,"_584":2871,"_586":587,"_588":44,"_589":90,"_590":2872,"_9":10},{"_72":2857,"_57":2858,"_59":2859,"_55":2860,"_578":579,"_580":2861,"_582":2862,"_584":2863,"_586":587,"_588":44,"_589":90,"_590":2864,"_9":10},{"_72":2849,"_57":2850,"_59":2851,"_55":2852,"_578":579,"_580":2853,"_582":2854,"_584":2855,"_586":587,"_588":44,"_589":597,"_590":2856,"_9":10},{"_72":2841,"_57":2842,"_59":2843,"_55":2844,"_578":579,"_580":2845,"_582":2846,"_584":2847,"_586":587,"_588":44,"_589":597,"_590":2848,"_9":10},{"_72":2833,"_57":2834,"_59":2835,"_55":2836,"_578":579,"_580":2837,"_582":2838,"_584":2839,"_586":587,"_588":44,"_589":597,"_590":2840,"_9":10},{"_72":2825,"_57":2826,"_59":2827,"_55":2828,"_578":616,"_580":2829,"_582":2830,"_584":2831,"_586":587,"_588":44,"_589":597,"_590":2832,"_9":10},{"_72":2817,"_57":2818,"_59":2819,"_55":2820,"_578":579,"_580":2821,"_582":2822,"_584":2823,"_586":587,"_588":44,"_589":597,"_590":2824,"_9":10},{"_72":2809,"_57":2810,"_59":2811,"_55":2812,"_578":579,"_580":2813,"_582":2814,"_584":2815,"_586":587,"_588":44,"_589":597,"_590":2816,"_9":10},{"_72":2802,"_57":2803,"_59":2804,"_55":2805,"_578":579,"_580":2806,"_582":1667,"_584":2807,"_586":587,"_588":44,"_589":597,"_590":2808,"_9":10},{"_72":2795,"_57":2796,"_59":2797,"_55":2798,"_578":616,"_580":2799,"_582":2187,"_584":2800,"_586":587,"_588":44,"_589":597,"_590":2801,"_9":10},{"_72":2788,"_57":2789,"_59":2790,"_55":2791,"_578":579,"_580":2792,"_582":1574,"_584":2793,"_586":587,"_588":44,"_589":597,"_590":2794,"_9":10},{"_72":2780,"_57":2781,"_59":2782,"_55":2783,"_578":579,"_580":2784,"_582":2785,"_584":2786,"_586":587,"_588":44,"_589":597,"_590":2787,"_9":10},{"_72":2772,"_57":2773,"_59":2774,"_55":2775,"_578":616,"_580":2776,"_582":2777,"_584":2778,"_586":587,"_588":44,"_589":597,"_590":2779,"_9":10},{"_72":2764,"_57":2765,"_59":2766,"_55":2767,"_578":579,"_580":2768,"_582":2769,"_584":2770,"_586":587,"_588":44,"_589":597,"_590":2771,"_9":10},{"_72":2756,"_57":2757,"_59":2758,"_55":2759,"_578":579,"_580":2760,"_582":2761,"_584":2762,"_586":587,"_588":44,"_589":597,"_590":2763,"_9":10},{"_72":2748,"_57":2749,"_59":2750,"_55":2751,"_578":579,"_580":2752,"_582":2753,"_584":2754,"_586":587,"_588":44,"_589":597,"_590":2755,"_9":10},{"_72":2740,"_57":2741,"_59":2742,"_55":2743,"_578":579,"_580":2744,"_582":2745,"_584":2746,"_586":587,"_588":44,"_589":597,"_590":2747,"_9":10},{"_72":2732,"_57":2733,"_59":2734,"_55":2735,"_578":616,"_580":2736,"_582":2737,"_584":2738,"_586":587,"_588":44,"_589":597,"_590":2739,"_9":10},{"_72":2724,"_57":2725,"_59":2726,"_55":2727,"_578":579,"_580":2728,"_582":2729,"_584":2730,"_586":587,"_588":44,"_589":597,"_590":2731,"_9":10},{"_72":2716,"_57":2717,"_59":2718,"_55":2719,"_578":579,"_580":2720,"_582":2721,"_584":2722,"_586":587,"_588":44,"_589":597,"_590":2723,"_9":10},{"_72":2708,"_57":2709,"_59":2710,"_55":2711,"_578":579,"_580":2712,"_582":2713,"_584":2714,"_586":587,"_588":44,"_589":597,"_590":2715,"_9":10},{"_72":2702,"_57":2703,"_59":2704,"_55":2705,"_578":616,"_580":2706,"_582":1401,"_584":2707,"_586":587,"_588":44,"_9":10},{"_72":2694,"_57":2695,"_59":2696,"_55":2697,"_578":579,"_580":2698,"_582":2699,"_584":2700,"_586":587,"_588":44,"_589":597,"_590":2701,"_9":10},{"_72":2686,"_57":2687,"_59":2688,"_55":2689,"_578":579,"_580":2690,"_582":2691,"_584":2692,"_586":587,"_588":44,"_589":597,"_590":2693,"_9":10},{"_72":2678,"_57":2679,"_59":2680,"_55":2681,"_578":579,"_580":2682,"_582":2683,"_584":2684,"_586":587,"_588":44,"_589":597,"_590":2685,"_9":10},{"_72":2670,"_57":2671,"_59":2672,"_55":2673,"_578":616,"_580":2674,"_582":2675,"_584":2676,"_586":587,"_588":44,"_589":597,"_590":2677,"_9":10},{"_72":2662,"_57":2663,"_59":2664,"_55":2665,"_578":579,"_580":2666,"_582":2667,"_584":2668,"_586":587,"_588":44,"_589":597,"_590":2669,"_9":10},{"_72":2654,"_57":2655,"_59":2656,"_55":2657,"_578":616,"_580":2658,"_582":2659,"_584":2660,"_586":587,"_588":44,"_589":597,"_590":2661,"_9":10},{"_72":2646,"_57":2647,"_59":2648,"_55":2649,"_578":616,"_580":2650,"_582":2651,"_584":2652,"_586":587,"_588":44,"_589":597,"_590":2653,"_9":10},{"_72":2638,"_57":2639,"_59":2640,"_55":2641,"_578":616,"_580":2642,"_582":2643,"_584":2644,"_586":587,"_588":44,"_589":597,"_590":2645,"_9":10},{"_72":2631,"_57":2632,"_59":2633,"_55":2634,"_578":616,"_580":2635,"_582":2636,"_584":2637,"_586":587,"_588":44,"_589":597,"_590":2630,"_9":10},{"_72":2623,"_57":2624,"_59":2625,"_55":2626,"_578":616,"_580":2627,"_582":2628,"_584":2629,"_586":587,"_588":44,"_589":597,"_590":2630,"_9":10},{"_72":2617,"_57":2618,"_59":2619,"_55":2620,"_578":616,"_580":2621,"_582":2399,"_584":2622,"_586":587,"_588":44,"_589":597,"_590":2608,"_9":10},{"_72":2609,"_57":2610,"_59":2611,"_55":2612,"_578":616,"_580":2613,"_582":2614,"_584":2615,"_586":587,"_588":44,"_589":597,"_590":2616,"_9":10},{"_72":2601,"_57":2602,"_59":2603,"_55":2604,"_578":616,"_580":2605,"_582":2606,"_584":2607,"_586":587,"_588":44,"_589":597,"_590":2608,"_9":10},{"_72":2593,"_57":2594,"_59":2595,"_55":2596,"_578":616,"_580":2597,"_582":2598,"_584":2599,"_586":587,"_588":44,"_589":597,"_590":2600,"_9":10},{"_72":2585,"_57":2586,"_59":2587,"_55":2588,"_578":579,"_580":2589,"_582":2590,"_584":2591,"_586":587,"_588":44,"_589":597,"_590":2592,"_9":10},{"_72":2577,"_57":2578,"_59":2579,"_55":2580,"_578":616,"_580":2581,"_582":2582,"_584":2583,"_586":587,"_588":44,"_589":597,"_590":2584,"_9":10},{"_72":2570,"_57":2571,"_59":2572,"_55":2573,"_578":616,"_580":2574,"_582":2575,"_584":2576,"_586":587,"_588":44,"_589":597,"_590":2569,"_9":10},{"_72":2562,"_57":2563,"_59":2564,"_55":2565,"_578":616,"_580":2566,"_582":2567,"_584":2568,"_586":587,"_588":44,"_589":597,"_590":2569,"_9":10},{"_72":2554,"_57":2555,"_59":2556,"_55":2557,"_578":616,"_580":2558,"_582":2559,"_584":2560,"_586":587,"_588":44,"_589":597,"_590":2561,"_9":10},{"_72":2547,"_57":2548,"_59":2549,"_55":2550,"_578":579,"_580":2551,"_582":1110,"_584":2552,"_586":587,"_588":44,"_589":597,"_590":2553,"_9":10},{"_72":2539,"_57":2540,"_59":2541,"_55":2542,"_578":579,"_580":2543,"_582":2544,"_584":2545,"_586":587,"_588":44,"_589":597,"_590":2546,"_9":10},{"_72":2531,"_57":2532,"_59":2533,"_55":2534,"_578":579,"_580":2535,"_582":2536,"_584":2537,"_586":587,"_588":44,"_589":597,"_590":2538,"_9":10},{"_72":2523,"_57":2524,"_59":2525,"_55":2526,"_578":579,"_580":2527,"_582":2528,"_584":2529,"_586":587,"_588":44,"_589":597,"_590":2530,"_9":10},{"_72":2515,"_57":2516,"_59":2517,"_55":2518,"_578":579,"_580":2519,"_582":2520,"_584":2521,"_586":587,"_588":44,"_589":597,"_590":2522,"_9":10},{"_72":2507,"_57":2508,"_59":2509,"_55":2510,"_578":579,"_580":2511,"_582":2512,"_584":2513,"_586":587,"_588":44,"_589":597,"_590":2514,"_9":10},{"_72":2499,"_57":2500,"_59":2501,"_55":2502,"_578":579,"_580":2503,"_582":2504,"_584":2505,"_586":587,"_588":44,"_589":597,"_590":2506,"_9":10},{"_72":2492,"_57":2493,"_59":2494,"_55":2495,"_578":579,"_580":2496,"_582":2497,"_584":2498,"_586":587,"_588":44,"_9":10},{"_72":2485,"_57":2486,"_59":2487,"_55":2488,"_578":579,"_580":2489,"_582":1950,"_584":2490,"_586":587,"_588":44,"_589":597,"_590":2491,"_9":10},{"_72":2477,"_57":2478,"_59":2479,"_55":2480,"_578":579,"_580":2481,"_582":2482,"_584":2483,"_586":587,"_588":44,"_589":597,"_590":2484,"_9":10},{"_72":2469,"_57":2470,"_59":2471,"_55":2472,"_578":579,"_580":2473,"_582":2474,"_584":2475,"_586":587,"_588":44,"_589":597,"_590":2476,"_9":10},{"_72":2462,"_57":2463,"_59":2464,"_55":2465,"_578":616,"_580":2466,"_582":2467,"_584":2468,"_586":587,"_588":44,"_9":10},{"_72":2455,"_57":2456,"_59":2457,"_55":2458,"_578":616,"_580":2459,"_582":2460,"_584":2461,"_586":587,"_588":44,"_9":10},{"_72":2449,"_57":2450,"_59":2451,"_55":2452,"_578":616,"_580":2453,"_582":2281,"_584":2454,"_586":587,"_588":44,"_9":10},{"_72":2443,"_57":2444,"_59":2445,"_55":2446,"_578":616,"_580":2447,"_582":1284,"_584":2448,"_586":587,"_588":44,"_9":10},{"_72":2436,"_57":2437,"_59":2438,"_55":2439,"_578":579,"_580":2440,"_582":2441,"_584":2442,"_586":587,"_588":44,"_9":10},{"_72":2429,"_57":2430,"_59":2431,"_55":2432,"_578":579,"_580":2433,"_582":2434,"_584":2435,"_586":587,"_588":44,"_9":10},{"_72":2422,"_57":2423,"_59":2424,"_55":2425,"_578":616,"_580":2426,"_582":2427,"_584":2428,"_586":587,"_588":44,"_9":10},{"_72":2415,"_57":2416,"_59":2417,"_55":2418,"_578":616,"_580":2419,"_582":2420,"_584":2421,"_586":587,"_588":44,"_9":10},{"_72":2408,"_57":2409,"_59":2410,"_55":2411,"_578":616,"_580":2412,"_582":2413,"_584":2414,"_586":587,"_588":44,"_9":10},{"_72":2401,"_57":2402,"_59":2403,"_55":2404,"_578":616,"_580":2405,"_582":2406,"_584":2407,"_586":587,"_588":44,"_9":10},{"_72":2394,"_57":2395,"_59":2396,"_55":2397,"_578":616,"_580":2398,"_582":2399,"_584":2400,"_586":587,"_588":44,"_9":10},{"_72":2386,"_57":2387,"_59":2388,"_55":2389,"_578":579,"_580":2390,"_582":2391,"_584":2392,"_586":587,"_588":44,"_589":597,"_590":2393,"_9":10},{"_72":2378,"_57":2379,"_59":2380,"_55":2381,"_578":579,"_580":2382,"_582":2383,"_584":2384,"_586":587,"_588":44,"_589":597,"_590":2385,"_9":10},{"_72":2370,"_57":2371,"_59":2372,"_55":2373,"_578":579,"_580":2374,"_582":2375,"_584":2376,"_586":587,"_588":44,"_589":597,"_590":2377,"_9":10},{"_72":2362,"_57":2363,"_59":2364,"_55":2365,"_578":579,"_580":2366,"_582":2367,"_584":2368,"_586":587,"_588":44,"_589":597,"_590":2369,"_9":10},{"_72":2354,"_57":2355,"_59":2356,"_55":2357,"_578":579,"_580":2358,"_582":2359,"_584":2360,"_586":587,"_588":44,"_589":597,"_590":2361,"_9":10},{"_72":2347,"_57":2348,"_59":2349,"_55":2350,"_578":579,"_580":2351,"_582":1690,"_584":2352,"_586":587,"_588":44,"_589":597,"_590":2353,"_9":10},{"_72":2340,"_57":2341,"_59":2342,"_55":2343,"_578":579,"_580":2344,"_582":1276,"_584":2345,"_586":587,"_588":44,"_589":597,"_590":2346,"_9":10},{"_72":2332,"_57":2333,"_59":2334,"_55":2335,"_578":579,"_580":2336,"_582":2337,"_584":2338,"_586":587,"_588":44,"_589":597,"_590":2339,"_9":10},{"_72":2324,"_57":2325,"_59":2326,"_55":2327,"_578":579,"_580":2328,"_582":2329,"_584":2330,"_586":587,"_588":44,"_589":597,"_590":2331,"_9":10},{"_72":2316,"_57":2317,"_59":2318,"_55":2319,"_578":579,"_580":2320,"_582":2321,"_584":2322,"_586":587,"_588":44,"_589":597,"_590":2323,"_9":10},{"_72":2308,"_57":2309,"_59":2310,"_55":2311,"_578":579,"_580":2312,"_582":2313,"_584":2314,"_586":587,"_588":44,"_589":597,"_590":2315,"_9":10},{"_72":2300,"_57":2301,"_59":2302,"_55":2303,"_578":579,"_580":2304,"_582":2305,"_584":2306,"_586":587,"_588":44,"_589":597,"_590":2307,"_9":10},{"_72":2292,"_57":2293,"_59":2294,"_55":2295,"_578":579,"_580":2296,"_582":2297,"_584":2298,"_586":587,"_588":44,"_589":597,"_590":2299,"_9":10},{"_72":2284,"_57":2285,"_59":2286,"_55":2287,"_578":579,"_580":2288,"_582":2289,"_584":2290,"_586":587,"_588":44,"_589":597,"_590":2291,"_9":10},{"_72":2276,"_57":2277,"_59":2278,"_55":2279,"_578":579,"_580":2280,"_582":2281,"_584":2282,"_586":587,"_588":44,"_589":597,"_590":2283,"_9":10},{"_72":2268,"_57":2269,"_59":2270,"_55":2271,"_578":579,"_580":2272,"_582":2273,"_584":2274,"_586":587,"_588":44,"_589":597,"_590":2275,"_9":10},{"_72":2260,"_57":2261,"_59":2262,"_55":2263,"_578":579,"_580":2264,"_582":2265,"_584":2266,"_586":587,"_588":44,"_589":597,"_590":2267,"_9":10},{"_72":2252,"_57":2253,"_59":2254,"_55":2255,"_578":579,"_580":2256,"_582":2257,"_584":2258,"_586":587,"_588":44,"_589":597,"_590":2259,"_9":10},{"_72":2244,"_57":2245,"_59":2246,"_55":2247,"_578":579,"_580":2248,"_582":2249,"_584":2250,"_586":587,"_588":44,"_589":597,"_590":2251,"_9":10},{"_72":2237,"_57":2238,"_59":2239,"_55":2240,"_578":579,"_580":2241,"_582":1887,"_584":2242,"_586":587,"_588":44,"_589":597,"_590":2243,"_9":10},{"_72":2229,"_57":2230,"_59":2231,"_55":2232,"_578":579,"_580":2233,"_582":2234,"_584":2235,"_586":587,"_588":44,"_589":597,"_590":2236,"_9":10},{"_72":2222,"_57":2223,"_59":2224,"_55":2225,"_578":579,"_580":2226,"_582":1166,"_584":2227,"_586":587,"_588":44,"_589":597,"_590":2228,"_9":10},{"_72":2214,"_57":2215,"_59":2216,"_55":2217,"_578":579,"_580":2218,"_582":2219,"_584":2220,"_586":587,"_588":44,"_589":597,"_590":2221,"_9":10},{"_72":2206,"_57":2207,"_59":2208,"_55":2209,"_578":579,"_580":2210,"_582":2211,"_584":2212,"_586":587,"_588":44,"_589":597,"_590":2213,"_9":10},{"_72":2198,"_57":2199,"_59":2200,"_55":2201,"_578":579,"_580":2202,"_582":2203,"_584":2204,"_586":587,"_588":44,"_589":597,"_590":2205,"_9":10},{"_72":2190,"_57":2191,"_59":2192,"_55":2193,"_578":579,"_580":2194,"_582":2195,"_584":2196,"_586":587,"_588":44,"_589":597,"_590":2197,"_9":10},{"_72":2182,"_57":2183,"_59":2184,"_55":2185,"_578":579,"_580":2186,"_582":2187,"_584":2188,"_586":587,"_588":44,"_589":597,"_590":2189,"_9":10},{"_72":2174,"_57":2175,"_59":2176,"_55":2177,"_578":579,"_580":2178,"_582":2179,"_584":2180,"_586":587,"_588":44,"_589":597,"_590":2181,"_9":10},{"_72":2167,"_57":2168,"_59":2169,"_55":2170,"_578":579,"_580":2171,"_582":2172,"_584":2173,"_586":587,"_588":44,"_9":10},{"_72":2159,"_57":2160,"_59":2161,"_55":2162,"_578":579,"_580":2163,"_582":2164,"_584":2165,"_586":587,"_588":44,"_589":597,"_590":2166,"_9":10},{"_72":2152,"_57":2153,"_59":2154,"_55":2155,"_578":579,"_580":2156,"_582":728,"_584":2157,"_586":587,"_588":44,"_589":597,"_590":2158,"_9":10},{"_72":2144,"_57":2145,"_59":2146,"_55":2147,"_578":579,"_580":2148,"_582":2149,"_584":2150,"_586":587,"_588":44,"_589":597,"_590":2151,"_9":10},{"_72":2137,"_57":2138,"_59":2139,"_55":2140,"_578":579,"_580":2141,"_582":2127,"_584":2142,"_586":587,"_588":44,"_589":597,"_590":2143,"_9":10},{"_72":2130,"_57":2131,"_59":2132,"_55":2133,"_578":579,"_580":2134,"_582":864,"_584":2135,"_586":587,"_588":44,"_589":597,"_590":2136,"_9":10},{"_72":2122,"_57":2123,"_59":2124,"_55":2125,"_578":579,"_580":2126,"_582":2127,"_584":2128,"_586":587,"_588":44,"_589":38,"_590":2129,"_9":10},{"_72":2114,"_57":2115,"_59":2116,"_55":2117,"_578":579,"_580":2118,"_582":2119,"_584":2120,"_586":587,"_588":44,"_589":597,"_590":2121,"_9":10},{"_72":2107,"_57":2108,"_59":2109,"_55":2110,"_578":579,"_580":2111,"_582":2112,"_584":2113,"_586":587,"_588":44,"_589":34,"_590":583,"_9":10},{"_72":2100,"_57":2101,"_59":2102,"_55":2103,"_578":579,"_580":2104,"_582":1134,"_584":2105,"_586":587,"_588":44,"_589":34,"_590":2106,"_9":10},{"_72":2093,"_57":2094,"_59":2095,"_55":2096,"_578":579,"_580":2097,"_582":2098,"_584":2099,"_586":587,"_588":44,"_9":10},{"_72":2085,"_57":2086,"_59":2087,"_55":2088,"_578":579,"_580":2089,"_582":2090,"_584":2091,"_586":587,"_588":44,"_589":34,"_590":2092,"_9":10},{"_72":2078,"_57":2079,"_59":2080,"_55":2081,"_578":579,"_580":2082,"_582":1521,"_584":2083,"_586":587,"_588":44,"_589":34,"_590":2084,"_9":10},{"_72":2072,"_57":2073,"_59":2074,"_55":2075,"_578":579,"_580":2076,"_582":1903,"_584":2077,"_586":587,"_588":44,"_9":10},{"_72":2064,"_57":2065,"_59":2066,"_55":2067,"_578":579,"_580":2068,"_582":2069,"_584":2070,"_586":587,"_588":44,"_589":34,"_590":2071,"_9":10},{"_72":2056,"_57":2057,"_59":2058,"_55":2059,"_578":579,"_580":2060,"_582":2061,"_584":2062,"_586":587,"_588":44,"_589":34,"_590":2063,"_9":10},{"_72":2048,"_57":2049,"_59":2050,"_55":2051,"_578":579,"_580":2052,"_582":2053,"_584":2054,"_586":587,"_588":44,"_589":34,"_590":2055,"_9":10},{"_72":2040,"_57":2041,"_59":2042,"_55":2043,"_578":579,"_580":2044,"_582":2045,"_584":2046,"_586":587,"_588":44,"_589":34,"_590":2047,"_9":10},{"_72":2032,"_57":2033,"_59":2034,"_55":2035,"_578":579,"_580":2036,"_582":2037,"_584":2038,"_586":587,"_588":44,"_589":34,"_590":2039,"_9":10},{"_72":2024,"_57":2025,"_59":2026,"_55":2027,"_578":579,"_580":2028,"_582":2029,"_584":2030,"_586":587,"_588":44,"_589":34,"_590":2031,"_9":10},{"_72":2016,"_57":2017,"_59":2018,"_55":2019,"_578":579,"_580":2020,"_582":2021,"_584":2022,"_586":587,"_588":44,"_589":34,"_590":2023,"_9":10},{"_72":2008,"_57":2009,"_59":2010,"_55":2011,"_578":579,"_580":2012,"_582":2013,"_584":2014,"_586":587,"_588":44,"_589":34,"_590":2015,"_9":10},{"_72":2001,"_57":2002,"_59":2003,"_55":2004,"_578":579,"_580":2005,"_582":1887,"_584":2006,"_586":587,"_588":44,"_589":34,"_590":2007,"_9":10},{"_72":1993,"_57":1994,"_59":1995,"_55":1996,"_578":579,"_580":1997,"_582":1998,"_584":1999,"_586":587,"_588":44,"_589":34,"_590":2000,"_9":10},{"_72":1985,"_57":1986,"_59":1987,"_55":1988,"_578":579,"_580":1989,"_582":1990,"_584":1991,"_586":587,"_588":44,"_589":34,"_590":1992,"_9":10},{"_72":1977,"_57":1978,"_59":1979,"_55":1980,"_578":579,"_580":1981,"_582":1982,"_584":1983,"_586":587,"_588":44,"_589":34,"_590":1984,"_9":10},{"_72":1969,"_57":1970,"_59":1971,"_55":1972,"_578":579,"_580":1973,"_582":1974,"_584":1975,"_586":587,"_588":44,"_589":34,"_590":1976,"_9":10},{"_72":1961,"_57":1962,"_59":1963,"_55":1964,"_578":579,"_580":1965,"_582":1966,"_584":1967,"_586":587,"_588":44,"_589":34,"_590":1968,"_9":10},{"_72":1953,"_57":1954,"_59":1955,"_55":1956,"_578":579,"_580":1957,"_582":1958,"_584":1959,"_586":587,"_588":44,"_589":34,"_590":1960,"_9":10},{"_72":1945,"_57":1946,"_59":1947,"_55":1948,"_578":579,"_580":1949,"_582":1950,"_584":1951,"_586":587,"_588":44,"_589":34,"_590":1952,"_9":10},{"_72":1937,"_57":1938,"_59":1939,"_55":1940,"_578":579,"_580":1941,"_582":1942,"_584":1943,"_586":587,"_588":44,"_589":34,"_590":1944,"_9":10},{"_72":1930,"_57":1931,"_59":1932,"_55":1933,"_578":579,"_580":1934,"_582":1817,"_584":1935,"_586":587,"_588":44,"_589":34,"_590":1936,"_9":10},{"_72":1922,"_57":1923,"_59":1924,"_55":1925,"_578":579,"_580":1926,"_582":1927,"_584":1928,"_586":587,"_588":44,"_589":34,"_590":1929,"_9":10},{"_72":1914,"_57":1915,"_59":1916,"_55":1917,"_578":579,"_580":1918,"_582":1919,"_584":1920,"_586":587,"_588":44,"_589":34,"_590":1921,"_9":10},{"_72":1906,"_57":1907,"_59":1908,"_55":1909,"_578":579,"_580":1910,"_582":1911,"_584":1912,"_586":587,"_588":44,"_589":34,"_590":1913,"_9":10},{"_72":1898,"_57":1899,"_59":1900,"_55":1901,"_578":579,"_580":1902,"_582":1903,"_584":1904,"_586":587,"_588":44,"_589":34,"_590":1905,"_9":10},{"_72":1890,"_57":1891,"_59":1892,"_55":1893,"_578":579,"_580":1894,"_582":1895,"_584":1896,"_586":587,"_588":44,"_589":34,"_590":1897,"_9":10},{"_72":1882,"_57":1883,"_59":1884,"_55":1885,"_578":579,"_580":1886,"_582":1887,"_584":1888,"_586":587,"_588":44,"_589":34,"_590":1889,"_9":10},{"_72":1874,"_57":1875,"_59":1876,"_55":1877,"_578":579,"_580":1878,"_582":1879,"_584":1880,"_586":587,"_588":44,"_589":34,"_590":1881,"_9":10},{"_72":1866,"_57":1867,"_59":1868,"_55":1869,"_578":579,"_580":1870,"_582":1871,"_584":1872,"_586":587,"_588":44,"_589":34,"_590":1873,"_9":10},{"_72":1859,"_57":1860,"_59":1861,"_55":1862,"_578":579,"_580":1863,"_582":1094,"_584":1864,"_586":587,"_588":44,"_589":34,"_590":1865,"_9":10},{"_72":1851,"_57":1852,"_59":1853,"_55":1854,"_578":579,"_580":1855,"_582":1856,"_584":1857,"_586":587,"_588":44,"_589":34,"_590":1858,"_9":10},{"_72":1843,"_57":1844,"_59":1845,"_55":1846,"_578":579,"_580":1847,"_582":1848,"_584":1849,"_586":587,"_588":44,"_589":34,"_590":1850,"_9":10},{"_72":1835,"_57":1836,"_59":1837,"_55":1838,"_578":579,"_580":1839,"_582":1840,"_584":1841,"_586":587,"_588":44,"_589":34,"_590":1842,"_9":10},{"_72":1828,"_57":1829,"_59":1830,"_55":1831,"_578":579,"_580":1832,"_582":1833,"_584":1834,"_586":587,"_588":44,"_9":10},{"_72":1820,"_57":1821,"_59":1822,"_55":1823,"_578":579,"_580":1824,"_582":1825,"_584":1826,"_586":587,"_588":44,"_589":34,"_590":1827,"_9":10},{"_72":1812,"_57":1813,"_59":1814,"_55":1815,"_578":579,"_580":1816,"_582":1817,"_584":1818,"_586":587,"_588":44,"_589":34,"_590":1819,"_9":10},{"_72":1805,"_57":1806,"_59":1807,"_55":1808,"_578":579,"_580":1809,"_582":1810,"_584":1811,"_586":587,"_588":44,"_589":34,"_590":1790,"_9":10},{"_72":1798,"_57":1799,"_59":1800,"_55":1801,"_578":579,"_580":1802,"_582":596,"_584":1803,"_586":587,"_588":44,"_589":34,"_590":1804,"_9":10},{"_72":1791,"_57":1792,"_59":1793,"_55":1794,"_578":579,"_580":1795,"_582":1796,"_584":1797,"_586":587,"_588":44,"_589":34,"_590":1790,"_9":10},{"_72":1784,"_57":1785,"_59":1786,"_55":1787,"_578":579,"_580":1788,"_582":1126,"_584":1789,"_586":587,"_588":44,"_589":34,"_590":1790,"_9":10},{"_72":1776,"_57":1777,"_59":1778,"_55":1779,"_578":579,"_580":1780,"_582":1781,"_584":1782,"_586":587,"_588":44,"_589":34,"_590":1783,"_9":10},{"_72":1769,"_57":1770,"_59":1771,"_55":1772,"_578":579,"_580":1773,"_582":1054,"_584":1774,"_586":587,"_588":44,"_589":34,"_590":1775,"_9":10},{"_72":1761,"_57":1762,"_59":1763,"_55":1764,"_578":579,"_580":1765,"_582":1766,"_584":1767,"_586":587,"_588":44,"_589":34,"_590":1768,"_9":10},{"_72":1754,"_57":1755,"_59":1756,"_55":1757,"_578":579,"_580":1758,"_582":1759,"_584":1760,"_586":587,"_588":44,"_589":34,"_590":1746,"_9":10},{"_72":1747,"_57":1748,"_59":1749,"_55":1750,"_578":579,"_580":1751,"_582":1752,"_584":1753,"_586":587,"_588":44,"_9":10},{"_72":1739,"_57":1740,"_59":1741,"_55":1742,"_578":579,"_580":1743,"_582":1744,"_584":1745,"_586":587,"_588":44,"_589":34,"_590":1746,"_9":10},{"_72":1732,"_57":1733,"_59":1734,"_55":1735,"_578":579,"_580":1736,"_582":1490,"_584":1737,"_586":587,"_588":44,"_589":34,"_590":1738,"_9":10},{"_72":1725,"_57":1726,"_59":1727,"_55":1728,"_578":579,"_580":1729,"_582":1730,"_584":1731,"_586":587,"_588":44,"_589":34,"_590":1708,"_9":10},{"_72":1717,"_57":1718,"_59":1719,"_55":1720,"_578":579,"_580":1721,"_582":1722,"_584":1723,"_586":587,"_588":44,"_589":34,"_590":1724,"_9":10},{"_72":1709,"_57":1710,"_59":1711,"_55":1712,"_578":579,"_580":1713,"_582":1714,"_584":1715,"_586":587,"_588":44,"_589":34,"_590":1716,"_9":10},{"_72":1701,"_57":1702,"_59":1703,"_55":1704,"_578":579,"_580":1705,"_582":1706,"_584":1707,"_586":587,"_588":44,"_589":34,"_590":1708,"_9":10},{"_72":1693,"_57":1694,"_59":1695,"_55":1696,"_578":579,"_580":1697,"_582":1698,"_584":1699,"_586":587,"_588":44,"_589":34,"_590":1700,"_9":10},{"_72":1685,"_57":1686,"_59":1687,"_55":1688,"_578":579,"_580":1689,"_582":1690,"_584":1691,"_586":587,"_588":44,"_589":34,"_590":1692,"_9":10},{"_72":1677,"_57":1678,"_59":1679,"_55":1680,"_578":579,"_580":1681,"_582":1682,"_584":1683,"_586":587,"_588":44,"_589":34,"_590":1684,"_9":10},{"_72":1670,"_57":1671,"_59":1672,"_55":1673,"_578":579,"_580":1674,"_582":1544,"_584":1675,"_586":587,"_588":44,"_589":34,"_590":1676,"_9":10},{"_72":1662,"_57":1663,"_59":1664,"_55":1665,"_578":579,"_580":1666,"_582":1667,"_584":1668,"_586":587,"_588":44,"_589":34,"_590":1669,"_9":10},{"_72":1655,"_57":1656,"_59":1657,"_55":1658,"_578":579,"_580":1659,"_582":824,"_584":1660,"_586":587,"_588":44,"_589":34,"_590":1661,"_9":10},{"_72":1648,"_57":1649,"_59":1650,"_55":1651,"_578":579,"_580":1652,"_582":1467,"_584":1653,"_586":587,"_588":44,"_589":34,"_590":1654,"_9":10},{"_72":1640,"_57":1641,"_59":1642,"_55":1643,"_578":579,"_580":1644,"_582":1645,"_584":1646,"_586":587,"_588":44,"_589":34,"_590":1647,"_9":10},{"_72":1632,"_57":1633,"_59":1634,"_55":1635,"_578":579,"_580":1636,"_582":1637,"_584":1638,"_586":587,"_588":44,"_589":34,"_590":1639,"_9":10},{"_72":1625,"_57":1626,"_59":1627,"_55":1628,"_578":579,"_580":1629,"_582":1630,"_584":1631,"_586":587,"_588":44,"_589":34,"_590":1608,"_9":10},{"_72":1617,"_57":1618,"_59":1619,"_55":1620,"_578":579,"_580":1621,"_582":1622,"_584":1623,"_586":587,"_588":44,"_589":34,"_590":1624,"_9":10},{"_72":1609,"_57":1610,"_59":1611,"_55":1612,"_578":579,"_580":1613,"_582":1614,"_584":1615,"_586":587,"_588":44,"_589":34,"_590":1616,"_9":10},{"_72":1601,"_57":1602,"_59":1603,"_55":1604,"_578":579,"_580":1605,"_582":1606,"_584":1607,"_586":587,"_588":44,"_589":34,"_590":1608,"_9":10},{"_72":1593,"_57":1594,"_59":1595,"_55":1596,"_578":579,"_580":1597,"_582":1598,"_584":1599,"_586":587,"_588":44,"_589":34,"_590":1600,"_9":10},{"_72":1585,"_57":1586,"_59":1587,"_55":1588,"_578":579,"_580":1589,"_582":1590,"_584":1591,"_586":587,"_588":44,"_589":34,"_590":1592,"_9":10},{"_72":1577,"_57":1578,"_59":1579,"_55":1580,"_578":579,"_580":1581,"_582":1582,"_584":1583,"_586":587,"_588":44,"_589":34,"_590":1584,"_9":10},{"_72":1569,"_57":1570,"_59":1571,"_55":1572,"_578":579,"_580":1573,"_582":1574,"_584":1575,"_586":587,"_588":44,"_589":34,"_590":1576,"_9":10},{"_72":1562,"_57":1563,"_59":1564,"_55":1565,"_578":579,"_580":1566,"_582":1023,"_584":1567,"_586":587,"_588":44,"_589":34,"_590":1568,"_9":10},{"_72":1554,"_57":1555,"_59":1556,"_55":1557,"_578":579,"_580":1558,"_582":1559,"_584":1560,"_586":587,"_588":44,"_589":34,"_590":1561,"_9":10},{"_72":1546,"_57":1547,"_59":1548,"_55":1549,"_578":579,"_580":1550,"_582":1551,"_584":1552,"_586":587,"_588":44,"_589":34,"_590":1553,"_9":10},{"_72":1539,"_57":1540,"_59":1541,"_55":1542,"_578":579,"_580":1543,"_582":1544,"_584":1545,"_586":587,"_588":44,"_589":34,"_590":1530,"_9":10},{"_72":1531,"_57":1532,"_59":1533,"_55":1534,"_578":579,"_580":1535,"_582":1536,"_584":1537,"_586":587,"_588":44,"_589":34,"_590":1538,"_9":10},{"_72":1524,"_57":1525,"_59":1526,"_55":1527,"_578":579,"_580":1528,"_582":1393,"_584":1529,"_586":587,"_588":44,"_589":34,"_590":1530,"_9":10},{"_72":1516,"_57":1517,"_59":1518,"_55":1519,"_578":579,"_580":1520,"_582":1521,"_584":1522,"_586":587,"_588":44,"_589":34,"_590":1523,"_9":10},{"_72":1509,"_57":1510,"_59":1511,"_55":1512,"_578":579,"_580":1513,"_582":1415,"_584":1514,"_586":587,"_588":44,"_589":34,"_590":1515,"_9":10},{"_72":1501,"_57":1502,"_59":1503,"_55":1504,"_578":579,"_580":1505,"_582":1506,"_584":1507,"_586":587,"_588":44,"_589":34,"_590":1508,"_9":10},{"_72":1493,"_57":1494,"_59":1495,"_55":1496,"_578":579,"_580":1497,"_582":1498,"_584":1499,"_586":587,"_588":44,"_589":34,"_590":1500,"_9":10},{"_72":1485,"_57":1486,"_59":1487,"_55":1488,"_578":579,"_580":1489,"_582":1490,"_584":1491,"_586":587,"_588":44,"_589":34,"_590":1492,"_9":10},{"_72":1477,"_57":1478,"_59":1479,"_55":1480,"_578":579,"_580":1481,"_582":1482,"_584":1483,"_586":587,"_588":44,"_589":34,"_590":1484,"_9":10},{"_72":1470,"_57":1471,"_59":1472,"_55":1473,"_578":579,"_580":1474,"_582":1475,"_584":1476,"_586":587,"_588":44,"_589":34,"_590":1430,"_9":10},{"_72":1462,"_57":1463,"_59":1464,"_55":1465,"_578":579,"_580":1466,"_582":1467,"_584":1468,"_586":587,"_588":44,"_589":34,"_590":1469,"_9":10},{"_72":1454,"_57":1455,"_59":1456,"_55":1457,"_578":579,"_580":1458,"_582":1459,"_584":1460,"_586":587,"_588":44,"_589":34,"_590":1461,"_9":10},{"_72":1447,"_57":1448,"_59":1449,"_55":1450,"_578":579,"_580":1451,"_582":1452,"_584":1453,"_586":587,"_588":44,"_589":34,"_590":1430,"_9":10},{"_72":1439,"_57":1440,"_59":1441,"_55":1442,"_578":579,"_580":1443,"_582":1444,"_584":1445,"_586":587,"_588":44,"_589":34,"_590":1446,"_9":10},{"_72":1431,"_57":1432,"_59":1433,"_55":1434,"_578":579,"_580":1435,"_582":1436,"_584":1437,"_586":587,"_588":44,"_589":34,"_590":1438,"_9":10},{"_72":1423,"_57":1424,"_59":1425,"_55":1426,"_578":579,"_580":1427,"_582":1428,"_584":1429,"_586":587,"_588":44,"_589":34,"_590":1430,"_9":10},{"_72":1417,"_57":1418,"_59":1419,"_55":1420,"_578":579,"_580":1421,"_582":832,"_584":1422,"_586":587,"_588":44,"_589":34,"_590":1409,"_9":10},{"_72":1410,"_57":1411,"_59":1412,"_55":1413,"_578":579,"_580":1414,"_582":1415,"_584":1416,"_586":587,"_588":44,"_589":34,"_590":1401,"_9":10},{"_72":1402,"_57":1403,"_59":1404,"_55":1405,"_578":579,"_580":1406,"_582":1407,"_584":1408,"_586":587,"_588":44,"_589":34,"_590":1409,"_9":10},{"_72":1395,"_57":1396,"_59":1397,"_55":1398,"_578":579,"_580":1399,"_582":943,"_584":1400,"_586":587,"_588":44,"_589":34,"_590":1401,"_9":10},{"_72":1388,"_57":1389,"_59":1390,"_55":1391,"_578":616,"_580":1392,"_582":1393,"_584":1394,"_586":587,"_588":44,"_589":34,"_590":1380,"_9":10},{"_72":1381,"_57":1382,"_59":1383,"_55":1384,"_578":579,"_580":1385,"_582":800,"_584":1386,"_586":587,"_588":44,"_589":34,"_590":1387,"_9":10},{"_72":1374,"_57":1375,"_59":1376,"_55":1377,"_578":579,"_580":1378,"_582":1292,"_584":1379,"_586":587,"_588":44,"_589":34,"_590":1380,"_9":10},{"_72":1366,"_57":1367,"_59":1368,"_55":1369,"_578":579,"_580":1370,"_582":1371,"_584":1372,"_586":587,"_588":44,"_589":34,"_590":1373,"_9":10},{"_72":1358,"_57":1359,"_59":1360,"_55":1361,"_578":579,"_580":1362,"_582":1363,"_584":1364,"_586":587,"_588":44,"_589":34,"_590":1365,"_9":10},{"_72":1350,"_57":1351,"_59":1352,"_55":1353,"_578":579,"_580":1354,"_582":1355,"_584":1356,"_586":587,"_588":44,"_589":34,"_590":1357,"_9":10},{"_72":1342,"_57":1343,"_59":1344,"_55":1345,"_578":579,"_580":1346,"_582":1347,"_584":1348,"_586":587,"_588":44,"_589":34,"_590":1349,"_9":10},{"_72":1334,"_57":1335,"_59":1336,"_55":1337,"_578":579,"_580":1338,"_582":1339,"_584":1340,"_586":587,"_588":44,"_589":34,"_590":1341,"_9":10},{"_72":1326,"_57":1327,"_59":1328,"_55":1329,"_578":579,"_580":1330,"_582":1331,"_584":1332,"_586":587,"_588":44,"_589":34,"_590":1333,"_9":10},{"_72":1318,"_57":1319,"_59":1320,"_55":1321,"_578":579,"_580":1322,"_582":1323,"_584":1324,"_586":587,"_588":44,"_589":34,"_590":1325,"_9":10},{"_72":1311,"_57":1312,"_59":1313,"_55":1314,"_578":579,"_580":1315,"_582":1222,"_584":1316,"_586":587,"_588":44,"_589":34,"_590":1317,"_9":10},{"_72":1303,"_57":1304,"_59":1305,"_55":1306,"_578":579,"_580":1307,"_582":1308,"_584":1309,"_586":587,"_588":44,"_589":34,"_590":1310,"_9":10},{"_72":1295,"_57":1296,"_59":1297,"_55":1298,"_578":579,"_580":1299,"_582":1300,"_584":1301,"_586":587,"_588":44,"_589":34,"_590":1302,"_9":10},{"_72":1287,"_57":1288,"_59":1289,"_55":1290,"_578":579,"_580":1291,"_582":1292,"_584":1293,"_586":587,"_588":44,"_589":34,"_590":1294,"_9":10},{"_72":1279,"_57":1280,"_59":1281,"_55":1282,"_578":579,"_580":1283,"_582":1284,"_584":1285,"_586":587,"_588":44,"_589":34,"_590":1286,"_9":10},{"_72":1271,"_57":1272,"_59":1273,"_55":1274,"_578":579,"_580":1275,"_582":1276,"_584":1277,"_586":587,"_588":44,"_589":34,"_590":1278,"_9":10},{"_72":1263,"_57":1264,"_59":1265,"_55":1266,"_578":579,"_580":1267,"_582":1268,"_584":1269,"_586":587,"_588":44,"_589":34,"_590":1270,"_9":10},{"_72":1255,"_57":1256,"_59":1257,"_55":1258,"_578":579,"_580":1259,"_582":1260,"_584":1261,"_586":587,"_588":44,"_589":34,"_590":1262,"_9":10},{"_72":1247,"_57":1248,"_59":1249,"_55":1250,"_578":579,"_580":1251,"_582":1252,"_584":1253,"_586":587,"_588":44,"_589":34,"_590":1254,"_9":10},{"_72":1239,"_57":1240,"_59":1241,"_55":1242,"_578":579,"_580":1243,"_582":1244,"_584":1245,"_586":587,"_588":44,"_589":34,"_590":1246,"_9":10},{"_72":1231,"_57":1232,"_59":1233,"_55":1234,"_578":579,"_580":1235,"_582":1236,"_584":1237,"_586":587,"_588":44,"_589":34,"_590":1238,"_9":10},{"_72":1225,"_57":1226,"_59":1227,"_55":1228,"_578":579,"_580":1229,"_582":642,"_584":1223,"_586":587,"_588":44,"_589":34,"_590":1230,"_9":10},{"_72":1217,"_57":1218,"_59":1219,"_55":1220,"_578":579,"_580":1221,"_582":1222,"_584":1223,"_586":587,"_588":44,"_589":34,"_590":1224,"_9":10},{"_72":1209,"_57":1210,"_59":1211,"_55":1212,"_578":579,"_580":1213,"_582":1214,"_584":1215,"_586":587,"_588":44,"_589":34,"_590":1216,"_9":10},{"_72":1201,"_57":1202,"_59":1203,"_55":1204,"_578":579,"_580":1205,"_582":1206,"_584":1207,"_586":587,"_588":44,"_589":34,"_590":1208,"_9":10},{"_72":1193,"_57":1194,"_59":1195,"_55":1196,"_578":579,"_580":1197,"_582":1198,"_584":1199,"_586":587,"_588":44,"_589":34,"_590":1200,"_9":10},{"_72":1185,"_57":1186,"_59":1187,"_55":1188,"_578":579,"_580":1189,"_582":1190,"_584":1191,"_586":587,"_588":44,"_589":34,"_590":1192,"_9":10},{"_72":1177,"_57":1178,"_59":1179,"_55":1180,"_578":579,"_580":1181,"_582":1182,"_584":1183,"_586":587,"_588":44,"_589":34,"_590":1184,"_9":10},{"_72":1169,"_57":1170,"_59":1171,"_55":1172,"_578":579,"_580":1173,"_582":1174,"_584":1175,"_586":587,"_588":44,"_589":34,"_590":1176,"_9":10},{"_72":1161,"_57":1162,"_59":1163,"_55":1164,"_578":579,"_580":1165,"_582":1166,"_584":1167,"_586":587,"_588":44,"_589":34,"_590":1168,"_9":10},{"_72":1153,"_57":1154,"_59":1155,"_55":1156,"_578":579,"_580":1157,"_582":1158,"_584":1159,"_586":587,"_588":44,"_589":34,"_590":1160,"_9":10},{"_72":1145,"_57":1146,"_59":1147,"_55":1148,"_578":579,"_580":1149,"_582":1150,"_584":1151,"_586":587,"_588":44,"_589":34,"_590":1152,"_9":10},{"_72":1137,"_57":1138,"_59":1139,"_55":1140,"_578":579,"_580":1141,"_582":1142,"_584":1143,"_586":587,"_588":44,"_589":34,"_590":1144,"_9":10},{"_72":1129,"_57":1130,"_59":1131,"_55":1132,"_578":579,"_580":1133,"_582":1134,"_584":1135,"_586":587,"_588":44,"_589":34,"_590":1136,"_9":10},{"_72":1121,"_57":1122,"_59":1123,"_55":1124,"_578":579,"_580":1125,"_582":1126,"_584":1127,"_586":587,"_588":44,"_589":34,"_590":1128,"_9":10},{"_72":1113,"_57":1114,"_59":1115,"_55":1116,"_578":579,"_580":1117,"_582":1118,"_584":1119,"_586":587,"_588":44,"_589":34,"_590":1120,"_9":10},{"_72":1105,"_57":1106,"_59":1107,"_55":1108,"_578":579,"_580":1109,"_582":1110,"_584":1111,"_586":587,"_588":44,"_589":34,"_590":1112,"_9":10},{"_72":1097,"_57":1098,"_59":1099,"_55":1100,"_578":579,"_580":1101,"_582":1102,"_584":1103,"_586":587,"_588":44,"_589":34,"_590":1104,"_9":10},{"_72":1089,"_57":1090,"_59":1091,"_55":1092,"_578":579,"_580":1093,"_582":1094,"_584":1095,"_586":587,"_588":44,"_589":34,"_590":1096,"_9":10},{"_72":1081,"_57":1082,"_59":1083,"_55":1084,"_578":579,"_580":1085,"_582":1086,"_584":1087,"_586":587,"_588":44,"_589":34,"_590":1088,"_9":10},{"_72":1073,"_57":1074,"_59":1075,"_55":1076,"_578":579,"_580":1077,"_582":1078,"_584":1079,"_586":587,"_588":44,"_589":34,"_590":1080,"_9":10},{"_72":1065,"_57":1066,"_59":1067,"_55":1068,"_578":579,"_580":1069,"_582":1070,"_584":1071,"_586":587,"_588":44,"_589":34,"_590":1072,"_9":10},{"_72":1057,"_57":1058,"_59":1059,"_55":1060,"_578":579,"_580":1061,"_582":1062,"_584":1063,"_586":587,"_588":44,"_589":34,"_590":1064,"_9":10},{"_72":1049,"_57":1050,"_59":1051,"_55":1052,"_578":579,"_580":1053,"_582":1054,"_584":1055,"_586":587,"_588":44,"_589":34,"_590":1056,"_9":10},{"_72":1041,"_57":1042,"_59":1043,"_55":1044,"_578":579,"_580":1045,"_582":1046,"_584":1047,"_586":587,"_588":44,"_589":34,"_590":1048,"_9":10},{"_72":1034,"_57":1035,"_59":1036,"_55":1037,"_578":579,"_580":1038,"_582":1039,"_584":1040,"_586":587,"_588":44,"_9":10},{"_72":1026,"_57":1027,"_59":1028,"_55":1029,"_578":579,"_580":1030,"_582":1031,"_584":1032,"_586":587,"_588":44,"_589":34,"_590":1033,"_9":10},{"_72":1018,"_57":1019,"_59":1020,"_55":1021,"_578":616,"_580":1022,"_582":1023,"_584":1024,"_586":587,"_588":44,"_589":34,"_590":1025,"_9":10},{"_72":1010,"_57":1011,"_59":1012,"_55":1013,"_578":579,"_580":1014,"_582":1015,"_584":1016,"_586":587,"_588":44,"_589":34,"_590":1017,"_9":10},{"_72":1002,"_57":1003,"_59":1004,"_55":1005,"_578":616,"_580":1006,"_582":1007,"_584":1008,"_586":587,"_588":44,"_589":34,"_590":1009,"_9":10},{"_72":994,"_57":995,"_59":996,"_55":997,"_578":579,"_580":998,"_582":999,"_584":1000,"_586":587,"_588":44,"_589":34,"_590":1001,"_9":10},{"_72":986,"_57":987,"_59":988,"_55":989,"_578":579,"_580":990,"_582":991,"_584":992,"_586":587,"_588":44,"_589":34,"_590":993,"_9":10},{"_72":978,"_57":979,"_59":980,"_55":981,"_578":579,"_580":982,"_582":983,"_584":984,"_586":587,"_588":44,"_589":34,"_590":985,"_9":10},{"_72":970,"_57":971,"_59":972,"_55":973,"_578":579,"_580":974,"_582":975,"_584":976,"_586":587,"_588":44,"_589":34,"_590":977,"_9":10},{"_72":962,"_57":963,"_59":964,"_55":965,"_578":579,"_580":966,"_582":967,"_584":968,"_586":587,"_588":44,"_589":34,"_590":969,"_9":10},{"_72":954,"_57":955,"_59":956,"_55":957,"_578":579,"_580":958,"_582":959,"_584":960,"_586":587,"_588":44,"_589":34,"_590":961,"_9":10},{"_72":946,"_57":947,"_59":948,"_55":949,"_578":579,"_580":950,"_582":951,"_584":952,"_586":587,"_588":44,"_589":34,"_590":953,"_9":10},{"_72":938,"_57":939,"_59":940,"_55":941,"_578":579,"_580":942,"_582":943,"_584":944,"_586":587,"_588":44,"_589":34,"_590":945,"_9":10},{"_72":931,"_57":932,"_59":933,"_55":934,"_578":579,"_580":935,"_582":936,"_584":937,"_586":587,"_588":44,"_9":10},{"_72":923,"_57":924,"_59":925,"_55":926,"_578":579,"_580":927,"_582":928,"_584":929,"_586":587,"_588":44,"_589":34,"_590":930,"_9":10},{"_72":915,"_57":916,"_59":917,"_55":918,"_578":579,"_580":919,"_582":920,"_584":921,"_586":587,"_588":44,"_589":34,"_590":922,"_9":10},{"_72":907,"_57":908,"_59":909,"_55":910,"_578":579,"_580":911,"_582":912,"_584":913,"_586":587,"_588":44,"_589":34,"_590":914,"_9":10},{"_72":899,"_57":900,"_59":901,"_55":902,"_578":579,"_580":903,"_582":904,"_584":905,"_586":587,"_588":44,"_589":34,"_590":906,"_9":10},{"_72":891,"_57":892,"_59":893,"_55":894,"_578":579,"_580":895,"_582":896,"_584":897,"_586":587,"_588":44,"_589":34,"_590":898,"_9":10},{"_72":883,"_57":884,"_59":885,"_55":886,"_578":579,"_580":887,"_582":888,"_584":889,"_586":587,"_588":44,"_589":34,"_590":890,"_9":10},{"_72":875,"_57":876,"_59":877,"_55":878,"_578":579,"_580":879,"_582":880,"_584":881,"_586":587,"_588":44,"_589":34,"_590":882,"_9":10},{"_72":867,"_57":868,"_59":869,"_55":870,"_578":579,"_580":871,"_582":872,"_584":873,"_586":587,"_588":44,"_589":34,"_590":874,"_9":10},{"_72":859,"_57":860,"_59":861,"_55":862,"_578":579,"_580":863,"_582":864,"_584":865,"_586":587,"_588":44,"_589":34,"_590":866,"_9":10},{"_72":851,"_57":852,"_59":853,"_55":854,"_578":579,"_580":855,"_582":856,"_584":857,"_586":587,"_588":44,"_589":34,"_590":858,"_9":10},{"_72":843,"_57":844,"_59":845,"_55":846,"_578":579,"_580":847,"_582":848,"_584":849,"_586":587,"_588":44,"_589":34,"_590":850,"_9":10},{"_72":835,"_57":836,"_59":837,"_55":838,"_578":579,"_580":839,"_582":840,"_584":841,"_586":587,"_588":44,"_589":34,"_590":842,"_9":10},{"_72":827,"_57":828,"_59":829,"_55":830,"_578":579,"_580":831,"_582":832,"_584":833,"_586":587,"_588":44,"_589":34,"_590":834,"_9":10},{"_72":819,"_57":820,"_59":821,"_55":822,"_578":579,"_580":823,"_582":824,"_584":825,"_586":587,"_588":44,"_589":34,"_590":826,"_9":10},{"_72":811,"_57":812,"_59":813,"_55":814,"_578":579,"_580":815,"_582":816,"_584":817,"_586":587,"_588":44,"_589":34,"_590":818,"_9":10},{"_72":803,"_57":804,"_59":805,"_55":806,"_578":579,"_580":807,"_582":808,"_584":809,"_586":587,"_588":44,"_589":34,"_590":810,"_9":10},{"_72":795,"_57":796,"_59":797,"_55":798,"_578":579,"_580":799,"_582":800,"_584":801,"_586":587,"_588":44,"_589":34,"_590":802,"_9":10},{"_72":787,"_57":788,"_59":789,"_55":790,"_578":579,"_580":791,"_582":792,"_584":793,"_586":587,"_588":44,"_589":34,"_590":794,"_9":10},{"_72":779,"_57":780,"_59":781,"_55":782,"_578":579,"_580":783,"_582":784,"_584":785,"_586":587,"_588":44,"_589":34,"_590":786,"_9":10},{"_72":771,"_57":772,"_59":773,"_55":774,"_578":579,"_580":775,"_582":776,"_584":777,"_586":587,"_588":44,"_589":34,"_590":778,"_9":10},{"_72":763,"_57":764,"_59":765,"_55":766,"_578":616,"_580":767,"_582":768,"_584":769,"_586":587,"_588":44,"_589":34,"_590":770,"_9":10},{"_72":755,"_57":756,"_59":757,"_55":758,"_578":616,"_580":759,"_582":760,"_584":761,"_586":587,"_588":44,"_589":34,"_590":762,"_9":10},{"_72":747,"_57":748,"_59":749,"_55":750,"_578":616,"_580":751,"_582":752,"_584":753,"_586":587,"_588":44,"_589":34,"_590":754,"_9":10},{"_72":739,"_57":740,"_59":741,"_55":742,"_578":616,"_580":743,"_582":744,"_584":745,"_586":587,"_588":44,"_589":34,"_590":746,"_9":10},{"_72":731,"_57":732,"_59":733,"_55":734,"_578":616,"_580":735,"_582":736,"_584":737,"_586":587,"_588":44,"_589":34,"_590":738,"_9":10},{"_72":723,"_57":724,"_59":725,"_55":726,"_578":579,"_580":727,"_582":728,"_584":729,"_586":587,"_588":44,"_589":34,"_590":730,"_9":10},{"_72":715,"_57":716,"_59":717,"_55":718,"_578":616,"_580":719,"_582":720,"_584":721,"_586":587,"_588":44,"_589":34,"_590":722,"_9":10},{"_72":707,"_57":708,"_59":709,"_55":710,"_578":616,"_580":711,"_582":712,"_584":713,"_586":587,"_588":44,"_589":34,"_590":714,"_9":10},{"_72":699,"_57":700,"_59":701,"_55":702,"_578":616,"_580":703,"_582":704,"_584":705,"_586":587,"_588":44,"_589":34,"_590":706,"_9":10},{"_72":691,"_57":692,"_59":693,"_55":694,"_578":616,"_580":695,"_582":696,"_584":697,"_586":587,"_588":44,"_589":34,"_590":698,"_9":10},{"_72":683,"_57":684,"_59":685,"_55":686,"_578":616,"_580":687,"_582":688,"_584":689,"_586":587,"_588":44,"_589":34,"_590":690,"_9":10},{"_72":675,"_57":676,"_59":677,"_55":678,"_578":616,"_580":679,"_582":680,"_584":681,"_586":587,"_588":44,"_589":34,"_590":682,"_9":10},{"_72":667,"_57":668,"_59":669,"_55":670,"_578":616,"_580":671,"_582":672,"_584":673,"_586":587,"_588":44,"_589":34,"_590":674,"_9":10},{"_72":660,"_57":661,"_59":662,"_55":663,"_578":579,"_580":664,"_582":665,"_584":666,"_586":587,"_588":44,"_9":10},{"_72":653,"_57":654,"_59":655,"_55":656,"_578":579,"_580":657,"_582":658,"_584":659,"_586":587,"_588":44,"_9":10},{"_72":645,"_57":646,"_59":647,"_55":648,"_578":579,"_580":649,"_582":650,"_584":651,"_586":587,"_588":44,"_589":34,"_590":652,"_9":10},{"_72":637,"_57":638,"_59":639,"_55":640,"_578":579,"_580":641,"_582":642,"_584":643,"_586":587,"_588":44,"_589":34,"_590":644,"_9":10},{"_72":629,"_57":630,"_59":631,"_55":632,"_578":579,"_580":633,"_582":634,"_584":635,"_586":587,"_588":44,"_589":34,"_590":636,"_9":10},{"_72":621,"_57":622,"_59":623,"_55":624,"_578":616,"_580":625,"_582":626,"_584":627,"_586":587,"_588":44,"_589":34,"_590":628,"_9":10},{"_72":612,"_57":613,"_59":614,"_55":615,"_578":616,"_580":617,"_582":618,"_584":619,"_586":587,"_588":44,"_589":34,"_590":620,"_9":10},{"_72":604,"_57":605,"_59":606,"_55":607,"_578":579,"_580":608,"_582":609,"_584":610,"_586":587,"_588":44,"_589":34,"_590":611,"_9":10},{"_72":598,"_57":599,"_59":600,"_55":601,"_578":579,"_580":602,"_582":603,"_584":585,"_586":587,"_588":44,"_589":34,"_590":90,"_9":10},{"_72":591,"_57":592,"_59":593,"_55":594,"_578":579,"_580":595,"_582":596,"_584":585,"_586":587,"_588":44,"_589":34,"_590":597,"_9":10},{"_72":574,"_57":575,"_59":576,"_55":577,"_578":579,"_580":581,"_582":583,"_584":585,"_586":587,"_588":44,"_589":34,"_590":34,"_9":10},"fdfb79c1-185d-41c9-8e7d-df2cf488a4f5","Episode 1: Introduction to Uromigos Podcasts","episode-1-introduction-to-uromigos-podcasts","https://anchor.fm/s/13347ea8/podcast/play/10308331/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-11%2F47915664-44100-2-e4b6e642256fa.mp3","file_type","audio/mp3","file_size",2901664,"duration",200,"published","2020-02-11T17:00:00Z","type","full","has_generated_transcript","season","number","95cfcf76-5b02-411e-87b7-8bbc0d2a2059","Episode 2: The Current role of IO in Front-line Advanced Urothelial Cancer","episode-2-the-current-role-of-io-in-front-line-advanced-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/10308553/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-11%2F47917110-44100-2-7b8275fee920b.mp3",24621561,1818,2,"45182450-10dc-418e-a151-2bbcc5071e9c","Episode 3: Pembrolizumab in Non-Muscle Invasive Bladder Cancer","episode-3-pembrolizumab-in-non-muscle-invasive-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/10308615/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-11%2F47917696-44100-2-b0de47b6dfec3.mp3",27190064,1982,"f03db541-fd42-4920-8046-ff55fcc6b24c","Episode 4: Treatment Choices in Front Line Advanced Renal Cancer","episode-4-treatment-choices-in-front-line-advanced-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/10316577/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-11%2F48003845-44100-2-b4a9cbcb29bf6.mp3",25595028,1599,"2020-02-11T18:59:55Z",4,"f163cf30-8e61-4d79-a7fe-8c19b26c2f3a","Episode 5: Renal Highlights from ASCO GU 2020","episode-5-renal-highlights-from-asco-gu-2020","https://anchor.fm/s/13347ea8/podcast/play/10586444/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-1-24%2F52045261-44100-2-076f7f74598bf.m4a","audio/x-m4a",9934076,614,"2020-02-24T11:07:58Z",5,"8fbaf06b-d431-42c0-8fc0-5770855c4259","Episode 6: Urothelial Cancer Highlights from ASCO GU 2020","episode-6-urothelial-cancer-highlights-from-asco-gu-2020","https://anchor.fm/s/13347ea8/podcast/play/10634818/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-26%2F52561273-22050-1-5a2af658f5a54.m4a",19444803,1208,"2020-02-26T10:05:27Z",6,"d0c502ea-b16a-4d68-96e4-42b085ba923a","Episode 7: The First Uromigos Prostate Cancer Podcast","episode-7-the-first-uromigos-prostate-cancer-podcast","https://anchor.fm/s/13347ea8/podcast/play/10665916/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-1-27%2F52824153-44100-2-aa370d8887f1a.mp3",27391109,1532,"2020-02-27T16:41:11Z",7,"e7687726-9c2b-4c04-b4ab-7aede2a88ae0","Episode 8: COVID-19 and Cancer Patients","episode-8-covid-19-and-cancer-patients","https://anchor.fm/s/13347ea8/podcast/play/11068446/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-2-13%2F56392920-44100-2-80c939983987f.mp3",18550419,1314,"2020-03-13T13:48:15Z",8,"5af55fda-ea9f-41b3-a7ea-6baa04ce251b","Episode 9: COVID-19 and Cancer: An International Perspective","episode-9-covid-19-and-cancer-an-international-perspective","https://anchor.fm/s/13347ea8/podcast/play/11144977/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-2-16%2F56845649-44100-2-cf6b6d6443b99.mp3",17908041,1318,"2020-03-16T12:57:09Z",9,"e25cf905-22d0-44d6-a51c-3876fc1bc72e","Episode 10: COVID-19 and Renal Cancer: A Patient's Perspective","episode-10-covid-19-and-renal-cancer-a-patients-perspective","https://anchor.fm/s/13347ea8/podcast/play/11147098/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-2-16%2F56855144-44100-2-64a400e9a77c.mp3",29168773,1629,"2020-03-16T12:59:50Z","6ab6926a-961d-4aea-ad94-b52b97a8fb5a","Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer","episode-11-covid-19-and-immune-checkpoint-inhibitors-for-the-treatment-of-cancer","https://anchor.fm/s/13347ea8/podcast/play/11147155/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-2-16%2F56855369-44100-2-c2db2c51126d4.mp3",19055436,1063,"2020-03-16T13:02:19Z","8820e2f6-99a2-4bd4-84d5-bc35cb3440e7","Episode 12: COVID-19 in Cancer Patients - The Seattle Experience","episode-12-covid-19-in-cancer-patients-the-seattle-experience","https://anchor.fm/s/13347ea8/podcast/play/11297655/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-2-20%2F57665808-44100-2-3ca1ebfb47f82.m4a",25538169,1579,"2020-03-20T12:59:12Z",12,"b940aec2-1981-4d3a-aeb9-6c9300f1af42","Episode 13: COVID-19 and Hydroxychloroquinine Existing Data and Ongoing Trials","episode-13-covid-19-and-hydroxychloroquinine-existing-data-and-ongoing-trials","https://anchor.fm/s/13347ea8/podcast/play/11411773/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-2-22%2F58202276-44100-2-c489eeea60dfc.m4a",18188118,1124,"2020-03-23T10:54:15Z",13,"2d97d0ae-c741-4e9e-ac8f-17996bfeec95","Episode 14: A Discussion about Tocilizumab and COVID-19 with Dr. Nick Mark from Seattle","episode-14-a-discussion-about-tocilizumab-and-covid-19-with-dr-nick-mark-from-seattle","https://anchor.fm/s/13347ea8/podcast/play/11459777/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-2-23%2F58451611-44100-2-d1f598abdd21d.m4a",14624372,904,"2020-03-24T11:52:10Z",14,"d8ed6186-74e1-4dc7-a453-76f6c9ce7f37","Episode 15: COVID-19 and Bladder Cancer Surgery","episode-15-covid-19-and-bladder-cancer-surgery","https://anchor.fm/s/13347ea8/podcast/play/11653862/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-2-27%2F59556004-44100-2-98579a3f15598.m4a",14431707,892,"2020-03-28T10:14:22Z",15,"3237a9d3-860b-4fa3-ac66-aaf6f47c7f16","Episode 16: Treatments and Trials for COVID-19","episode-16-treatments-and-trials-for-covid-19","https://anchor.fm/s/13347ea8/podcast/play/11802696/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-2-30%2F60311494-44100-2-6f465572219d9.m4a",24765722,1531,"2020-03-31T12:01:49Z",16,"dbb811e0-226d-44d0-90dd-f4eab3e41056","Episode 17: Dr. Toni Choueiri discusses cancer trials and meetings during COVID-19","episode-17-dr-toni-choueiri-discusses-cancer-trials-and-meetings-during-covid-19","https://anchor.fm/s/13347ea8/podcast/play/11892448/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-1%2F60803100-44100-2-c13036ca97bd6.m4a",20920488,1293,"2020-04-02T09:34:23Z",17,"589c0d0f-68e8-4c6c-8cd2-248758b3288d","Episode 18: COVID-19: Addressing Renal Cancer Patients’ Concerns","episode-18-covid-19-addressing-renal-cancer-patients-concerns","https://anchor.fm/s/13347ea8/podcast/play/12067982/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-5%2F61866221-44100-2-45d0bf26e9f8.m4a",24042831,1486,"2020-04-06T10:40:38Z",18,"a6a0076c-05f3-4e3b-aa9a-17f42cc2c7a2","Episode 19: Professor Monty Pal discusses the treatment of non-clear cell renal cancer","episode-19-professor-monty-pal-discusses-the-treatment-of-non-clear-cell-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/12451380/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-3-15%2F64716138-44100-2-38de2db36309e.mp3",20580087,1097,"2020-04-15T11:36:11Z",19,"50148339-af24-4dc9-91a0-591dba53f1ce","Episode 20: Treating GU Cancer Patients with acute COVID-19 Infection","episode-20-treating-gu-cancer-patients-with-acute-covid-19-infection","https://anchor.fm/s/13347ea8/podcast/play/12458412/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-14%2F64560682-44100-2-92983134e15f8.m4a",12742653,787,"2020-04-15T15:03:17Z",20,"0abf8ee4-d116-4a40-99e8-1e0c546008af","Episode 21: Treating cancer patients over the next year in the era of COVID-19","episode-21-treating-cancer-patients-over-the-next-year-in-the-era-of-covid-19","https://anchor.fm/s/13347ea8/podcast/play/12458578/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-14%2F64589794-44100-2-75b416d367311.m4a",12190917,753,"2020-04-15T15:07:33Z",21,"290092ad-d5cc-41d8-afdd-5d3acc1919e1","Episode 22: COVID-19 and Cardiovascular Disease","episode-22-covid-19-and-cardiovascular-disease","https://anchor.fm/s/13347ea8/podcast/play/12771459/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-22%2F66600944-44100-2-1452f28d8b61.m4a",17925950,1108,"2020-04-22T16:09:29Z",22,"24a5c69f-aad3-4a1e-9dd9-a58ca51cd206","Episode 23: Atezolizumab and Enzalutamide versus Enzalutamide Prostate Cancer","episode-23-atezolizumab-and-enzalutamide-versus-enzalutamide-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/13014756/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-28%2F68306210-44100-2-a3e882d6b7e72.m4a",21925626,1355,"2020-04-28T10:21:43Z",23,"e63e28e8-d180-4e0e-afb6-5638c0f6bd76","Episode 24: A Study of COVID-19 in Lung Cancer Shows High Mortality","episode-24-a-study-of-covid-19-in-lung-cancer-shows-high-mortality","https://anchor.fm/s/13347ea8/podcast/play/13024819/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-3-28%2F68370558-44100-2-08d00ac7efe71.m4a",19263230,1191,"2020-04-28T15:11:57Z",24,"decec816-d271-4781-9333-8858f1411bae","Episode 25: Dr. Tian Zhang discusses first line treatment for renal cancer and the PDIGREE Trial","episode-25-dr-tian-zhang-discusses-first-line-treatment-for-renal-cancer-and-the-pdigree-trial","https://anchor.fm/s/13347ea8/podcast/play/13974634/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-19%2F74634235-44100-2-7168ac154384e.mp3",12451281,887,"2020-05-19T09:49:27Z",25,"4430839e-fff2-4e0b-a041-a5d193ef10ea","Episode 26: Joaquim Bellmunt and Muscle Invasive Bladder Cancer prior to ASCO 2020","episode-26-joaquim-bellmunt-and-muscle-invasive-bladder-cancer-prior-to-asco-2020","https://anchor.fm/s/13347ea8/podcast/play/13976740/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-19%2F74643942-44100-2-3b17082709223.mp3",18057812,1343,"2020-05-19T11:02:06Z",26,"a0ff2ba0-a894-44d3-96fa-ae64946ac169","Episode 27: COVID-19 in > 1000 Cancer Patients with Jeremy Warner (CCC-19)","episode-27-covid-19-in-1000-cancer-patients-with-jeremy-warner-ccc-19","https://anchor.fm/s/13347ea8/podcast/play/14463622/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77763275-44100-2-5bf3f3b7924d5.mp3",19176301,1304,"2020-05-29T14:08:53Z",27,"19827f5d-e9d9-4eb4-a238-c6e681467d1e","Episode 28: Targeting VHL Syndrome Renal Cancer with a HIF Inhibitor - A Game Changer","episode-28-targeting-vhl-syndrome-renal-cancer-with-a-hif-inhibitor-a-game-changer","https://anchor.fm/s/13347ea8/podcast/play/14464808/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77769273-44100-2-cd9870c213bd2.mp3",11641417,811,"2020-05-29T14:33:19Z",28,"05fd4e78-63c2-4408-947a-ac2c2a443e36","Episode 29: PSMA PET at ASCO 2020 with Mike Morris","episode-29-psma-pet-at-asco-2020-with-mike-morris","https://anchor.fm/s/13347ea8/podcast/play/14466107/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77775511-44100-2-f24e26308d17e.mp3",21494252,1427,"2020-05-29T15:00:02Z",29,"4f8407c2-e2ee-41fe-a0a3-bb39d316b263","Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)","episode-30-update-on-axitinib-plus-pembrolizumab-in-renal-cancer-keynote-426","https://anchor.fm/s/13347ea8/podcast/play/14467030/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77781912-44100-2-1739f0741102a.mp3",16685588,1203,"2020-05-29T15:21:41Z",30,"c6ed72ea-f99f-40b5-beb3-5cd42d7dc074","Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer","episode-31-a-phase-2-study-of-nivolumab-with-the-addition-of-ipilimumab-upon-progression-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/14469040/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77792454-44100-2-278f0e513f9c.mp3",21524170,1518,"2020-05-29T16:00:21Z",31,"d5b23220-28ba-4b2b-81aa-4cbd797967c6","Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020","episode-32-a-phase-2-study-of-psma-pet-in-prostate-cancer-with-thomas-hope-from-asco-2020","https://anchor.fm/s/13347ea8/podcast/play/14473222/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77819916-44100-2-f3560770a6569.mp3",21991533,1449,"2020-05-29T17:32:09Z",32,"583f09c4-ffad-4230-a055-b4dc945681bb","Episode 33: Adjuvant Atezolizumab in Urothelial Cancer","episode-33-adjuvant-atezolizumab-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/14474546/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-29%2F77828649-44100-2-093b28e478f36.mp3",15588328,1199,"2020-05-29T18:00:11Z",33,"396fa226-0111-43d3-b01d-af395a2fa911","Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough?","episode-34-savolitinib-in-renal-papillary-cancer-a-major-breakthrough","https://anchor.fm/s/13347ea8/podcast/play/14514364/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-30%2F78085684-44100-2-9e2b388a15e79.mp3",16261108,1240,"2020-05-30T16:33:48Z",34,"c40ee1b3-1b25-46bf-a6c1-084c5fb5bc93","Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1)","episode-35-maintenance-avelumab-in-bladder-cancer-lba1","https://anchor.fm/s/13347ea8/podcast/play/14553669/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-4-31%2F78337049-44100-2-3b4867175f834.mp3",14265400,1061,"2020-05-31T17:00:00Z",35,"9509fc1b-23cd-4649-99c0-07f765d1f894","Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations","episode-36-dr-tian-zhang-discusses-three-asco-bladder-cancer-abstracts-with-immune-therapytargeted-therapy-combinations","https://anchor.fm/s/13347ea8/podcast/play/14585892/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-1%2F78557400-44100-2-be2431f018e4c.mp3",16330793,1258,"2020-06-01T10:27:41Z",36,"4d7914ce-78d1-4dd4-ab23-49a57b8cb8f9","Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg","episode-37-regoratinib-fgfr-inhibitor-and-atezolizumab-in-uc-with-jonathan-rosenberg","https://anchor.fm/s/13347ea8/podcast/play/14586297/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-1%2F78559504-44100-2-ef5f4ec9948f5.mp3",15278853,1091,"2020-06-01T10:44:33Z",37,"d225dc5d-7ec0-4836-b164-396ba82cddc1","Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC","episode-38-the-uromigos-virtual-world-tour-starting-in-vancouver-with-atezolizumab-in-nmibc","https://anchor.fm/s/13347ea8/podcast/play/15267988/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-16%2F82731610-44100-2-5ac133904f02a.mp3",17144731,1221,"2020-06-16T13:39:42Z",38,"99166205-53f6-4be1-956b-fddb22ab2779","Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary","episode-39-the-uromigos-world-tour-renal-cancer-and-imdc-risk-with-danny-heng-in-calgary","https://anchor.fm/s/13347ea8/podcast/play/15374416/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-18%2F83366381-44100-2-4abd10165fbdd.mp3",16777370,1217,"2020-06-18T15:38:38Z",39,"bf5a3d0b-fe03-479b-91d3-b67f9a483ad7","Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib","episode-40-the-uromigos-world-tour-moves-to-france-bernard-escudier-discusses-2nd-line-therapy-in-renal-cancer-and-tivozanib","https://anchor.fm/s/13347ea8/podcast/play/15537965/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-22%2F84330429-44100-2-70af95a7aefb9.mp3",17269471,1202,"2020-06-22T09:43:33Z",40,"dbfd496d-ff19-4aed-8daa-a2cdce81361f","Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil","episode-41-the-uromigos-world-tour-lands-in-brazil-fernando-maluf-talks-about-prostate-cancer-and-recent-research-in-brazil","https://anchor.fm/s/13347ea8/podcast/play/15699032/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-25%2F85227886-44100-2-5904d9c0ab295.mp3",19577071,1444,"2020-06-25T14:29:38Z",41,"01cb1580-0be8-4bc9-b757-e23ea33be2e6","Episode 42: The Uromigos in Argentina","episode-42-the-uromigos-in-argentina","https://anchor.fm/s/13347ea8/podcast/play/15823809/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-28%2F85952878-44100-2-8f846a05fc563.mp3",10342319,728,"2020-06-28T10:10:16Z",42,"4d91accd-99e9-4b3a-9588-be21301c4586","Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran","episode-43-the-uromigos-world-tour-in-singapore-with-ravi-kanesvaran","https://anchor.fm/s/13347ea8/podcast/play/15884805/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-5-29%2F86279031-44100-2-a26431eac472e.mp3",16771638,1100,"2020-06-29T16:08:00Z",43,"4c3d43cd-bcaa-4315-8efe-245eaeb41698","Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP","episode-44-the-uromigos-world-tour-in-australia-talking-with-ian-davis-about-prostate-cancer-and-anzup","https://anchor.fm/s/13347ea8/podcast/play/16064083/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-6-3%2F87317589-44100-2-a0036df853aa3.mp3",25710872,1911,"2020-07-03T14:24:26Z",44,"1fbee7ee-e25b-43d1-a46b-cfce9ed3b3fc","Episode 45: The Uromigos World Tour arrives in Japan","episode-45-the-uromigos-world-tour-arrives-in-japan","https://anchor.fm/s/13347ea8/podcast/play/16069095/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2F2020-6-3%2F87343796-44100-2-62ef53824b977.mp3",17162134,1229,"2020-07-03T16:19:58Z","fd70613d-ac50-44be-b5ad-7baf2dddaf5a","Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez","episode-46-the-uromigos-world-tour-in-spain-discussing-sogug-and-renal-cancer-with-cristina-suarez","https://anchor.fm/s/13347ea8/podcast/play/16335738/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-9%2Fd0427e11-ebfd-5ca0-5787-c2ad621dc1c4.mp3",16653619,1178,"2020-07-09T15:53:43Z",46,"45d051a4-1f23-4db4-a883-4f139b92cb73","Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer","episode-48-and-then-germany-jürgen-gschwend-discusses-cystectomy-for-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/16380864/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-10%2F20eddebe-4fbf-91c8-3787-420e8b60cc53.mp3",16650665,1238,"2020-07-10T14:51:19Z",48,"e6d1b8ce-96ab-4d40-a9a0-a0ddb6a9bbfd","Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer","episode-49-the-tour-remains-in-germany-with-oliver-grimm-and-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/16561768/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-14%2Fa8e6dfaf-9d92-31bc-21f3-a60e89526da9.mp3",18766813,1335,"2020-07-14T14:16:13Z",49,"703241f3-042e-403c-85e3-b6a952c99fa4","Episode 50: The Uromigos World Tour in London with renal cancer surgery","episode-50-the-uromigos-world-tour-in-london-with-renal-cancer-surgery","https://anchor.fm/s/13347ea8/podcast/play/16612225/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-15%2Faf3ae3ac-5ae3-cf2d-521f-d9c57fa05ca8.mp3",19046371,1373,"2020-07-15T14:46:50Z",50,"f4f7fe0d-50c3-48ff-afd5-02714e35f326","Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer","episode-51-the-uromigos-world-tour-is-in-norway-with-jan-oldenburg-discussing-key-topics-in-testis-cancer","https://anchor.fm/s/13347ea8/podcast/play/16750228/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-18%2F9cc6d3e7-d5f3-acaa-d86b-f0c141b817f6.mp3",18004919,1372,"2020-07-18T14:22:53Z",51,"d0db1baf-c6ca-49a4-990c-13c6ea159b22","Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy","episode-52-the-final-stop-boston-david-mcdermott-discusses-biomarkers-in-renal-cancer-in-the-era-of-immune-therapy","https://anchor.fm/s/13347ea8/podcast/play/17027100/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-24%2Facfe4a11-4f2c-293d-d412-20c5e3ae7e22.mp3",16438780,1201,"2020-07-24T11:02:26Z",52,"8257cfb5-e97b-47de-acf2-29b416a3ebfa","Episode 53: Still in Boston - biomarkers in bladder cancer","episode-53-still-in-boston-biomarkers-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/17027629/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-24%2F6203afe4-a582-edc8-c4da-4d3b142b67a5.mp3",15988285,1123,"2020-07-24T11:25:32Z",53,"eebff38d-8b94-4abd-81c3-4d9ce71d5d50","Episode 54: Biomarkers in prostate cancer with Chris Sweeney","episode-54-biomarkers-in-prostate-cancer-with-chris-sweeney","https://anchor.fm/s/13347ea8/podcast/play/17028213/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-6-24%2F67b751b7-2610-a9ae-05da-87c682da2ef6.mp3",21371897,1505,"2020-07-24T11:45:17Z",54,"6b485ab1-0932-45ca-ae56-7175507842bf","Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo","episode-55-the-uromigos-paper-of-the-month-cabozantinib-in-bladder-cancer-by-dr-andrea-apolo","https://anchor.fm/s/13347ea8/podcast/play/18856372/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-7-31%2F103135607-44100-2-cf05ca6129d78.m4a",22744333,1406,"2020-08-31T14:42:50Z",55,"9e16767b-3cee-4bdb-9430-1273d9d5123a","Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer","episode-56-matt-galsky-and-tom-powles-discuss-esmo-2020-immune-therapy-data-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/19861836/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-19%2Fd0452ae3-fe4c-cf2e-c47a-772530d45975.mp3",23079974,1660,"2020-09-19T18:03:19Z",56,"93caa467-ef37-4b0b-8614-885197fd5c95","Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer","episode-57-toni-choueiri-cabo-nivo-vs-sunitinib-in-metastatic-clear-cell-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/19865756/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-19%2F109248982-44100-2-6d44e3b1b3e36.m4a",25428857,1572,"2020-09-19T18:56:36Z",57,"2c4c5d54-e84e-40cf-b7e8-190343d606ce","Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362","episode-58-brilliant-esmo-discussant-richard-cathomas-talks-to-brian-and-tom-about-the-meaning-of-danube-and-kn362","https://anchor.fm/s/13347ea8/podcast/play/19869011/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-19%2F2bbaa78d-b204-9ed7-9f65-76d6d8a6dde9.mp3",29114927,1604,"2020-09-19T20:46:08Z",58,"89f40850-e710-491d-a75b-cbc42db0ed09","Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer","episode-59-ipatercertib-in-biomarker-positive-castrate-resistant-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/19901374/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-20%2F1931bba5-fda2-de20-a67b-31d25ebca3e7.mp3",22516590,1533,"2020-09-20T17:55:14Z","ed9440da-4290-4d67-b61e-f81a0d82f5e0","Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer","episode-60-cora-sternberg-discusses-amg-160-a-bispecific-antibody-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/19899637/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-20%2F56932f60-a26a-3f83-95f7-64b98ff5f0f1.mp3",12175899,898,"2020-09-21T13:57:37Z",60,"a9719da3-ab07-436c-884d-24196234febb","Episode 61: Nick James discusses the latest update of the STAMPEDE study","episode-61-nick-james-discusses-the-latest-update-of-the-stampede-study","https://anchor.fm/s/13347ea8/podcast/play/19900233/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-8-20%2Fb8c0ea6e-b76e-946a-4542-44df39db292d.mp3",14081609,1036,"2020-09-21T13:58:06Z",61,"c3bdf22c-6877-466d-9662-0e870602c55e","Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo","episode-62-james-easthams-uromigos-paper-of-the-month-prostatectomy-neoadjuvant-chemo","https://anchor.fm/s/13347ea8/podcast/play/20686011/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-9-6%2F2be1ff43-b6de-8bc4-48fa-e454b30ffa51.mp3",23394358,1664,"2020-10-06T09:10:17Z",62,"750b7876-62e7-437d-83d3-cfbc0c0df1fb","Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer","episode-63-the-first-uromigos-debate-front-line-immune-therapy-vs-maintenance-avelumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/20839908/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-9-9%2F51f99b2c-2bdd-407a-87c8-9135bbed6c10.mp3",17521107,1279,"2020-10-09T10:19:49Z",63,"ff83c9e4-2a3e-4ed9-a2df-6db686dfd77e","Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC","episode-64-the-second-uromigos-debate-with-nobel-laureate-bill-kaelin-on-new-biomarker-vs-new-drugs-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/21760654/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-9-28%2Fe43281c5-1d7a-1fe6-bf20-adc14d0efca2.mp3",23887737,1737,"2020-10-28T12:24:16Z",64,"d38771fa-afa4-4618-b398-8b8d146c01f6","Episode 65: Review of the International Kidney Cancer Symposium","episode-65-review-of-the-international-kidney-cancer-symposium","https://anchor.fm/s/13347ea8/podcast/play/21995509/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-10-2%2Fd77c96c9-e5d1-d6d7-5506-88fb0620ae52.mp3",19425099,1351,"2020-11-02T14:52:29Z",65,"9c27bcf1-0a81-4661-9c46-e2c237e21ae4","Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer","episode-66-uromigos-paper-of-the-month-two-papers-in-nature-medicine-on-neoadjuvant-immune-combinations-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/22321184/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-10-9%2F59de7f06-3d7b-5881-4f98-0e94a1908897.mp3",26652775,1849,"2020-11-09T11:19:18Z",66,"9f4918a3-419c-44da-b221-d4e74dc8f258","Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer","episode-67-the-third-uromigos-debate-pd1vegf-vs-pd1ctla4-for-front-line-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/22717490/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-10-17%2F440c42ed-3708-0d32-e6f6-2110e7698463.mp3",24333060,1728,"2020-11-17T17:07:10Z",67,"9abac7e2-ffe7-42fd-afed-c7d435484dcd","Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell","episode-68-uromigos-paper-of-the-month-a-molecular-classification-of-renal-cancer-in-cancer-cell","https://anchor.fm/s/13347ea8/podcast/play/23682839/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-11-8%2Fadd1d436-1fdf-9f44-ab4a-6c7e4c508e92.mp3",20777809,1584,"2020-12-08T13:28:13Z",68,"bc6046e3-bd96-4518-b62b-2efa746c7c6c","Episode 69: Testis Cancer Christmas Special: 2020 year in review","episode-69-testis-cancer-christmas-special-2020-year-in-review","https://anchor.fm/s/13347ea8/podcast/play/23740039/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-11-9%2F934854f2-aae9-1772-fd96-6ec9718617f7.mp3",19886018,1516,"2020-12-09T16:21:41Z",69,"36309d4c-1c1a-4196-8f31-997d5d26a1f9","Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan","episode-70-the-uromigos-prostate-cancer-christmas-special-with-chuck-ryan","https://anchor.fm/s/13347ea8/podcast/play/23831033/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-11-11%2F5db129f8-43f0-35cb-70b9-87e27bc47468.mp3",22043913,1556,"2020-12-11T12:55:03Z",70,"4a17fb49-616c-4f87-a765-a033f87e1b57","Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky","episode-71-bladder-cancer-uromigos-christmas-special-with-matt-galsky","https://anchor.fm/s/13347ea8/podcast/play/24153005/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-11-18%2Fce87cccf-bf25-6548-2d4d-f1d3ba7e0ac3.mp3",21426326,1497,"2020-12-18T14:43:44Z",71,"d3faa624-c9bb-46f0-95ea-7791e9727f0c","Episode 72: Uromigos Christmas Special - Renal cancer year in review","episode-72-uromigos-christmas-special-renal-cancer-year-in-review","https://anchor.fm/s/13347ea8/podcast/play/24258009/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2020-11-21%2F1f2966a8-3fd5-ac7f-088e-c273d523481a.mp3",19217912,1465,"2020-12-21T12:10:18Z",72,"b4643ae2-8e26-43fb-8598-1362614eeee7","Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano","episode-73-the-uromigos-meet-apccc-in-a-discussion-on-oligometastatic-prostate-cancer-apccc_lugano","https://anchor.fm/s/13347ea8/podcast/play/24914398/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-0-8%2Fb5a82d79-8565-d886-2ed4-9fe715768bf1.mp3",20776327,1511,"2021-01-08T11:32:25Z",73,"303c4414-610e-4be0-a0bb-1328d4d14b98","Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza","episode-74-the-uromigos-meet-apccc-round-2-first-line-treatment-low-vs-high-volume-chemo-vs-abienza","https://anchor.fm/s/13347ea8/podcast/play/25035016/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-0-11%2Fe7787548-6f4d-64b8-f392-08e327fd5d37.mp3",27269312,1925,"2021-01-11T09:31:50Z",74,"32b9562b-3465-4c1d-a24f-399e512a6453","Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal","episode-75-the-uromigos-meet-apccc-bone-health-and-bone-disease-in-prostate-cancer-with-bertrand-tombal","https://anchor.fm/s/13347ea8/podcast/play/25178168/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-0-14%2Fbd901d29-6222-19e0-d657-ebec1bcf3ab6.mp3",28239324,1547,"2021-01-14T10:05:12Z",75,"8eb166da-ad58-4bf6-8892-8e547473d2fe","Episode 76: Tom Hutson discusses lenvatinib and everolimus","episode-76-tom-hutson-discusses-lenvatinib-and-everolimus","https://anchor.fm/s/13347ea8/podcast/play/25571707/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-0-22%2F63271ce1-4bde-f64f-3460-88e4e9a022be.mp3",18980392,1431,"2021-01-22T16:40:48Z",76,"064941db-f861-4210-a6fe-33b2c713a014","Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC","episode-77-the-uromigos-paper-of-the-month-nadofaragene-for-bcg-unresponsive-nmibc","https://anchor.fm/s/13347ea8/podcast/play/26302420/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-6%2Fdb436c40-12f4-13cf-f73a-00ac89455e69.mp3",14109411,1041,"2021-02-06T13:21:30Z",77,"1c422d7e-2484-4179-9855-eb8064d884fc","Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer","episode-78-enfortumab-vedotin-special-ev301-randomised-trial-and-ev201-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/26626817/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-12%2F525ad118-6c9c-e6a0-4f30-5fd447162b83.mp3",23900590,1359,"2021-02-12T21:47:30Z",78,"860e902b-86a0-47e7-8a35-75624600fb4d","Episode 79: Adjuvant nivolumab in operable urothelial cancer","episode-79-adjuvant-nivolumab-in-operable-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/26648759/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2F83095e48-caae-9f8c-f651-900c681025a5.mp3",20738907,1476,"2021-02-13T11:40:41Z",79,"c388ad60-8ff0-427d-a361-c0393e35f7b6","Episode 80: Results for Darolutamide in non-metastatic CRPC - the Aramis trial","episode-80-results-for-darolutamide-in-non-metastatic-crpc-the-aramis-trial","https://anchor.fm/s/13347ea8/podcast/play/26650141/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2F3a76d457-a986-8a2a-e267-7207643c4302.mp3",15896351,1192,"2021-02-13T12:32:54Z",80,"b0fddf7e-e772-4844-9426-50ee3ead1775","Episode 81: Noah Hahn discusses front line cisplatin-ineligible PD-L1 data from 361 and 130","episode-81-noah-hahn-discusses-front-line-cisplatin-ineligible-pd-l1-data-from-361-and-130","https://anchor.fm/s/13347ea8/podcast/play/26651032/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2F04e4c315-d26f-6ad9-228b-29ae7c74c7a3.mp3",17654911,1282,"2021-02-13T13:12:31Z",81,"95d44750-85a3-4ed1-bb1f-6e6c8553e984","Episode 82: Which is the best VEGF/immune combination for first line metastatic renal cancer?","episode-82-which-is-the-best-vegfimmune-combination-for-first-line-metastatic-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/26662889/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2Fe38dda2b-0dfe-0a92-9283-73bfb94b935d.mp3",21489483,1480,"2021-02-13T20:00:00Z",82,"7059fc5a-89cc-43a3-8417-215866058bd9","Episode 83: Is cabozantinib the new standard of care in papillary renal cancer?","episode-83-is-cabozantinib-the-new-standard-of-care-in-papillary-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/26664288/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2Ff859bd60-24e5-5d5c-149a-0f67d1806bc4.mp3",19358445,83,"be53fea4-d687-4f2d-b5c7-0faa77dac80d","Episode 84: Prostate cancer highlights from ASCO #GU21 with Chris Sweeney","episode-84-prostate-cancer-highlights-from-asco-gu21-with-chris-sweeney","https://anchor.fm/s/13347ea8/podcast/play/26665168/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-13%2F2a4c628b-1d6c-fc2d-3cbe-f6ed637c688c.mp3",14607744,1044,"2021-02-13T20:16:06Z",84,"784395ef-b981-4058-ac56-f8c8b21171f6","Episode 85: The CLEAR Trial","episode-85-the-clear-trial","https://anchor.fm/s/13347ea8/podcast/play/26698464/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-14%2F9dd1c8f8-f995-6bc8-ebd7-99a27985346a.mp3",23598220,1782,"2021-02-14T17:08:26Z",85,"7a6b87bc-a8b1-4c58-b09e-6f37a0fbaca6","Episode 86: Career Development in Academic Oncology Part 1 - Moshe Ornstein","episode-86-career-development-in-academic-oncology-part-1-moshe-ornstein","https://anchor.fm/s/13347ea8/podcast/play/27463981/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-26%2F2087b00c-fe54-e016-84d6-89fed1b2b465.mp3",16097810,1255,"2021-02-26T18:23:54Z",86,"c0ef303c-e99f-4817-88e6-6beb3f1650f6","Episode 87: Career Development in Academic Oncology Part 2 - Monty Pal","episode-87-career-development-in-academic-oncology-part-2-monty-pal","https://anchor.fm/s/13347ea8/podcast/play/27465463/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-26%2Fc4f66aee-1950-b413-6c37-d7151660c88e.mp3",19671495,1337,"2021-02-26T18:53:57Z",87,"2039761d-bab6-45d8-b2e6-f39fb294dcda","Episode 88: Career Development in Academic Oncology Part 3 - Walter Stadler","episode-88-career-development-in-academic-oncology-part-3-walter-stadler","https://anchor.fm/s/13347ea8/podcast/play/27466078/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-1-26%2F00ecd813-fdd7-c505-3fd8-1f605401db51.mp3",20697057,1394,"2021-02-26T19:07:11Z",88,"8b2524a3-466c-48c1-9d9a-3ef564a353bf","Episode 89: The Uromigos Paper of the Month - Pembrolizumab in clear cell and non-clear cell renal cancer","episode-89-the-uromigos-paper-of-the-month-pembrolizumab-in-clear-cell-and-non-clear-cell-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/27907760/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-2-4%2F5240902e-fb4b-d0e0-8ee8-d516043a6e0a.mp3",23843409,1694,"2021-03-04T17:36:51Z",89,"d8ef7fc4-d322-48a4-b610-32e6b0bea404","Episode 90: The Uromigos Podcast with QOL Expert David Cella","episode-90-the-uromigos-podcast-with-qol-expert-david-cella","https://anchor.fm/s/13347ea8/podcast/play/28781843/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-2-12%2F99f15d82-5658-499c-152e-08613720ed44.mp3",22624384,1666,"2021-03-12T15:33:11Z",90,"513cf873-45b1-40d9-a8ca-1928218b6658","Episode 91: The Uromigos Paper of the Month - Adjuvant atezolizumab in bladder cancer","episode-91-the-uromigos-paper-of-the-month-adjuvant-atezolizumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/30031738/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-2-26%2Fc211554e-f9b4-b4dd-1454-13628d36d84e.mp3",22965261,1745,"2021-03-26T17:44:52Z",91,"1501b359-9107-4c5d-a827-4754fbc2396a","Episode 92: Second line therapy in advanced RCC","episode-92-second-line-therapy-in-advanced-rcc","https://anchor.fm/s/13347ea8/podcast/play/31043087/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-3-9%2F9a2d72c5-5f36-d458-302b-3904ff529f14.mp3",22425099,1651,"2021-04-09T09:00:23Z",92,"a0dbe9e5-42b3-4e99-8cf8-0785eedb8922","Episode 93: The Uromigos Paper of the Month - A new risk classification for germ cell cancer","episode-93-the-uromigos-paper-of-the-month-a-new-risk-classification-for-germ-cell-cancer","https://anchor.fm/s/13347ea8/podcast/play/31391100/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-3-14%2Fce4d7e65-0160-ec98-8e6a-fbd12a54ddf6.mp3",19823622,1429,"2021-04-14T08:52:50Z",93,"a6f653eb-4131-4621-b496-da90f4218000","Episode 94: EIKCS Summary of Day 1","episode-94-eikcs-summary-of-day-1","https://anchor.fm/s/13347ea8/podcast/play/32072162/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-3-23%2Fc6255470-8802-b11d-8820-266dc79904dd.mp3",20444235,"2021-04-23T19:40:02Z",94,"a7686062-a972-4453-8345-870f9d1a20bc","Episode 95: ODAC Overview and Bladder Accelerated Approval Meetings with Jorge Garcia","episode-95-odac-overview-and-bladder-accelerated-approval-meetings-with-jorge-garcia","https://anchor.fm/s/13347ea8/podcast/play/32433364/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-3-28%2Fb4a25ed9-8bc3-5e66-1bdc-91ff94baeade.mp3",23782556,1615,"2021-04-28T22:12:12Z",95,"621be8a2-4dc7-4e3a-a38e-83066c40a3bf","Episode 96: ODAC Bladder Cancer Accelerated Approval Meetings with Andrea Apolo","episode-96-odac-bladder-cancer-accelerated-approval-meetings-with-andrea-apolo","https://anchor.fm/s/13347ea8/podcast/play/32434685/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-3-28%2F3312bb3e-fe83-a58c-aa95-21be545f4397.mp3",22722576,1583,"2021-04-28T22:37:50Z",96,"082bb976-9597-47d9-871f-168817d8d593","Episode 97: Sacituzumab Govitecan in Bladder Cancer","episode-97-sacituzumab-govitecan-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/32795980/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-4%2F51294e69-7e15-a348-9549-4e3f2fcc6feb.mp3",15282655,1101,"2021-05-04T09:49:56Z",97,"b2515fa8-83c5-41cf-90a1-31e26c856a6f","Episode 98: Bladder cancer from a patient perspective","episode-98-bladder-cancer-from-a-patient-perspective","https://anchor.fm/s/13347ea8/podcast/play/33817174/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-19%2F78f3be31-d3ee-0d95-a44c-ea07287389f5.mp3",19478674,1415,"2021-05-19T14:51:49Z",98,"cd784fd0-7671-4bc1-ad7a-8a3e1708f04d","Episode 99: Navigating social media from a patients' perspective","episode-99-navigating-social-media-from-a-patients-perspective","https://anchor.fm/s/13347ea8/podcast/play/33819279/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-19%2F921ab5e0-7414-02e2-34c7-92f3a34c1ee7.mp3",20356844,1498,"2021-05-19T15:17:45Z",99,"3c22f90a-4798-4a8b-8756-454dff92ec63","Episode 100: The Uromigos 100th Podcast - Looking to the Future","episode-100-the-uromigos-100th-podcast-looking-to-the-future","https://anchor.fm/s/13347ea8/podcast/play/33959960/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-21%2F5b09dda6-c182-0fd1-3e8b-6c5853088c94.mp3",30348246,2184,"2021-05-21T14:33:22Z",100,"a97d164d-44cd-469c-8eaa-8bddf8f70b81","Episode 101: The Uromigos Paper of the Month - Belzutifan in renal cancer","episode-101-the-uromigos-paper-of-the-month-belzutifan-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/34278708/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-26%2F2539d017-612f-b57b-eef6-4f263e58fc01.mp3",24025022,1619,"2021-05-26T14:49:34Z",101,"82f5e9b0-2f47-4522-aaa0-c52132bd69f1","Episode 102: Adjuvant therapy in melanoma - how it will help inform the renal community","episode-102-adjuvant-therapy-in-melanoma-how-it-will-help-inform-the-renal-community","https://anchor.fm/s/13347ea8/podcast/play/34419748/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-4-28%2F6f49e6ad-8c0f-d23b-b9b9-f61a46082e14.mp3",24177524,"2021-05-28T16:11:47Z",104,"a3096e08-3ff9-4afa-8710-6972f3c05f98","Episode 103: Targeting the microbiome to increase the activity of immune therapy in renal cancer","episode-103-targeting-the-microbiome-to-increase-the-activity-of-immune-therapy-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/34950370/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-6%2Fa6ef58e3-3dc7-5cfc-d2ff-020ae31175c4.mp3",11880220,"2021-06-06T17:43:22Z",103,"1e98e65b-631a-4e98-8f95-049ed176c21c","Episode 104: Plenary Session 177lu-PSMA-617 in Prostate Cancer","episode-104-plenary-session-177lu-psma-617-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/34950720/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-08-09%2F52678272654cbff061bd72c1132eec02.m4a",29592239,1817,"2021-06-06T19:12:40Z","50fb9c1c-0f18-4a1a-ac04-68630e3fb366","Episode 105: A Phase 2 study of novel immune combinations (ICOS) in bladder cancer","episode-105-a-phase-2-study-of-novel-immune-combinations-icos-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/35008061/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-7%2F695756c7-a07a-674c-a178-23d159d45b08.mp3",17707179,"2021-06-07T14:57:39Z",107,"defcde88-7694-410c-bdb7-bec477c2ca74","Episode 106: Summary of the three bladder sparing neoadjuvant trials at ASCO 2021","episode-106-summary-of-the-three-bladder-sparing-neoadjuvant-trials-at-asco-2021","https://anchor.fm/s/13347ea8/podcast/play/35008730/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-7%2F66f7dd56-fa67-24dc-4985-52f82e4837f5.mp3",21154249,1561,"2021-06-07T15:09:29Z",108,"63704946-4215-4630-9624-c5b113dddfed","Episode 107: ASCO 2021: Neoadjuvant chemo/nivolumab as bladder sparing","episode-107-asco-2021-neoadjuvant-chemonivolumab-as-bladder-sparing","https://anchor.fm/s/13347ea8/podcast/play/35009716/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-7%2Fbf7ff7cd-009d-fa2c-d2d6-ccb2058a15bd.mp3",14368955,1008,"2021-06-07T15:24:27Z","ab97fdad-54a3-4a7a-8b84-e76b5d4a9350","Episode 108: Peter O'Donnell gives five year follow-up data on front line pembrolizumab in urothelial cancer","episode-108-peter-odonnell-gives-five-year-follow-up-data-on-front-line-pembrolizumab-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/35011004/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-7%2Ff8d9b889-8f3a-f485-7005-cb65ab3d17c6.mp3",19961163,"2021-06-07T15:45:27Z","e4fc8ede-7ee0-45fa-9221-3e3226da3db1","Episode 109: Adjuvant pembrolizumab in renal cancer","episode-109-adjuvant-pembrolizumab-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/35015370/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-7%2F8fce9a46-f609-2e97-5c95-c00fb6fec079.mp3",25847694,1845,"2021-06-07T16:56:59Z",112,"9850be93-207d-4c10-9697-3ade7f25fffd","Episode 110: PEACE1 - Triplet therapy in prostate cancer","episode-110-peace1-triplet-therapy-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/35091828/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-8%2F69849bc4-5fa4-ab09-481b-8286344eb9f0.mp3",22077231,1671,"2021-06-08T16:56:22Z",110,"85e70343-733e-42d7-b119-f12e77f15a14","Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer","episode-111-the-randomised-phase-3-cantata-in-metastatic-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/35093223/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-8%2Fbf6777cd-5ddf-d31d-35c3-33022f1d3bda.mp3",26255530,1743,"2021-06-08T17:07:36Z",111,"8742a594-f873-4ab0-a7ff-e5919890868b","Episode 113: ASCO 2021 Enazlutamide +/- Radium-223","episode-113-asco-2021-enazlutamide-radium-223","https://anchor.fm/s/13347ea8/podcast/play/35731459/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-18%2F5ebe9be4-c92c-b177-7c98-de9be22c69b2.mp3",9622074,663,"2021-06-18T11:54:56Z","0d1e5c6d-5a5a-4022-8b89-b2796f2bf443","Episode 114: Radionucleotides in prostate cancer","episode-114-radionucleotides-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/35731866/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-5-18%2Fd6c3823d-cefb-42ad-0cac-d47eb34b803b.mp3",16190687,1136,"2021-06-18T12:05:50Z",113,"504acb96-7bbd-4b9c-b02a-a029f5927913","Episode 115: Triplet therapy for 1st line metastatic prostate cancer","episode-115-triplet-therapy-for-1st-line-metastatic-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/36509243/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-1%2F26166f87-0ce6-6107-4a9e-b33b1c144f09.mp3",18034696,1400,"2021-07-01T10:35:05Z",115,"aba44997-2832-42e0-a810-08ff9b9b655c","Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population","episode-112-genomic-classifier-of-high-risk-african-american-men-with-prostate-cancer-identifying-a-high-risk-population","https://anchor.fm/s/13347ea8/podcast/play/36707795/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-5%2F84752f55-fb95-4cf5-91a3-1be34315b7b3.mp3",18153188,1252,"2021-07-05T10:13:31Z","704c9439-f5f0-48c8-9131-6b66bf8f395b","Episode 116: Renal cancer surgery controversies at EAU","episode-116-renal-cancer-surgery-controversies-at-eau","https://anchor.fm/s/13347ea8/podcast/play/37230117/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-14%2Fafd9f81f-b6d3-9445-4ef5-cac9580d979b.mp3",19410104,1371,"2021-07-14T16:25:14Z",116,"fe406f52-20a0-4ba2-afa5-107dec294e26","Episode 117: PD1/VEGF adverse event management in renal cancer","episode-117-pd1vegf-adverse-event-management-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/37535918/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-20%2Ffde52e33-4b74-9630-d37c-797032918fe3.mp3",22907660,1649,"2021-07-20T10:11:02Z",117,"e195d58b-5da9-46ee-8ba1-397d0de146b5","Episode 118: Prostate cancer highlights at EAU","episode-118-prostate-cancer-highlights-at-eau","https://anchor.fm/s/13347ea8/podcast/play/37536711/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-20%2Fb31651b8-b668-5f3b-6992-69e61a79f2e9.mp3",16295351,1237,"2021-07-20T21:55:00Z",118,"a10696f2-5163-43bc-8429-c163ee99758b","Episode 119: EAU - Surgery in urothelial cancer","episode-119-eau-surgery-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/37700884/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-6-23%2Fa741056c-bb69-7475-7bce-0b8a568b5d1d.mp3",20972769,1460,"2021-07-23T10:58:27Z",119,"ccd6379f-5e6e-4427-911d-2afad848f8d1","Episode 121: Conflicts of Interest with the podcasts","episode-121-conflicts-of-interest-with-the-podcasts","https://anchor.fm/s/13347ea8/podcast/play/38283237/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-4%2F5282f8f4-c646-eea6-e407-165befa052a5.mp3",13931630,"2021-08-04T11:41:01Z",121,"2c5bb258-3b0b-470c-8e26-df1e62d665fc","Episode 122: Nick Vogelzang - The Uromigos Legends in GU Cancer series","episode-122-nick-vogelzang-the-uromigos-legends-in-gu-cancer-series","https://anchor.fm/s/13347ea8/podcast/play/38870114/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-16%2Fbfeb8807-cab7-13fc-713a-0cb11217dc30.mp3",23417463,1942,"2021-08-16T16:16:38Z",122,"f3ab982e-eea5-41bb-abbc-a564af327627","Episode 123: Maha Hussain - The Uromigos Legends in GU Cancer series","episode-123-maha-hussain-the-uromigos-legends-in-gu-cancer-series","https://anchor.fm/s/13347ea8/podcast/play/39074870/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-20%2F8d392c79-a372-db5c-b257-9227d8e0b32d.mp3",25973807,"2021-08-20T14:31:37Z",125,"427acf30-ba61-46b9-bdff-4734d9c4296b","Episode 124: Dean Bajorin - The Uromigos Legends in GU Cancer series","episode-124-dean-bajorin-the-uromigos-legends-in-gu-cancer-series","https://anchor.fm/s/13347ea8/podcast/play/39200125/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-23%2Fcf2369f5-5b23-7b21-7ac5-a2e8f718c0fe.mp3",26703595,2009,"2021-08-23T10:17:39Z",124,"58faa77f-8af3-4d34-94d6-4743b4006922","Episode 125: The Uromigos Paper of the Month - MRI screening for prostate cancer","episode-125-the-uromigos-paper-of-the-month-mri-screening-for-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/39432604/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-27%2F7436204d-8690-d90e-27d6-3b56e2e4d519.mp3",23599481,1690,"2021-08-27T16:08:16Z","f6fdac58-f1f2-4199-85c8-d8fcbadf6902","Episode 126: APCCC - germ line testing and molecular testing in prostate cancer","episode-126-apccc-germ-line-testing-and-molecular-testing-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/39599785/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-31%2F83ac2fa0-6607-7916-aa63-5d0341e932e0.mp3",17335079,1310,"2021-08-31T11:04:11Z",126,"c53afafd-4bfb-4e0c-af3c-218753196cae","Episode 127: APCCC - Adjuvant radiotherapy post prostatectomy","episode-127-apccc-adjuvant-radiotherapy-post-prostatectomy","https://anchor.fm/s/13347ea8/podcast/play/39600626/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-31%2Fa0001797-6408-9417-f175-c96c36b995ab.mp3",23916573,1682,"2021-08-31T11:34:57Z",127,"1b77928a-13ee-46aa-9613-38885bbc67ff","Episode 128: APCCC - PSA relapse post prostatectomy","episode-128-apccc-psa-relapse-post-prostatectomy","https://anchor.fm/s/13347ea8/podcast/play/39601026/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-7-31%2F1b5b8645-86ed-8802-92b1-2e181a26d81f.mp3",25104779,"2021-08-31T11:47:25Z",128,"df20faa9-2a55-4890-920d-9ff5d498675f","Episode 129: Phil Kantoff - The Uromigos Legends in GU Cancer series","episode-129-phil-kantoff-the-uromigos-legends-in-gu-cancer-series","https://anchor.fm/s/13347ea8/podcast/play/39707274/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-2%2F80a2f1a6-8626-f7e6-2618-0822a9932ac0.mp3",28065366,1875,"2021-09-02T10:26:21Z",129,"ddfe909b-695c-4d4c-802a-d0de80350009","Episode 130: Larry Einhorn - The Uromigos Legends in GU Cancer series","episode-130-larry-einhorn-the-uromigos-legends-in-gu-cancer-series","https://anchor.fm/s/13347ea8/podcast/play/39884254/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-6%2Fb9d2a11b-12b4-83a7-724d-6526eb49a729.mp3",27374588,2017,"2021-09-06T12:55:25Z",130,"02ed9527-5c06-4117-a04b-240619028806","Episode 131: ESMO 2021: The NORSE Study - Erdafitinib vs Erdafitinib/Cetrelimab","episode-131-esmo-2021-the-norse-study-erdafitinib-vs-erdafitinibcetrelimab","https://anchor.fm/s/13347ea8/podcast/play/40426113/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-17%2Fc6b0682f-61c7-32d6-0a70-971a05efc55b.mp3",20344420,1364,"2021-09-17T12:29:20Z",131,"25bdd4ae-1a3d-413e-b735-df341cba4f54","Episode 132: ESMO 2021: Pembro + sEphB4-HAS in bladder cancer","episode-132-esmo-2021-pembro-sephb4-has-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/40435907/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-17%2Fbd1e20b8-0118-1fd0-f329-251cfc81b94e.mp3",10147985,707,"2021-09-17T16:19:32Z",132,"27fe1eaa-2452-465d-84ec-28965602be4d","Episode 133: ESMO 2021: Cabozantinib and atezolizumab in prostate cancer","episode-133-esmo-2021-cabozantinib-and-atezolizumab-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/40476873/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-18%2F33dca120-f78f-6c00-3f4e-1bba3248adaa.mp3",23078704,1675,"2021-09-18T17:41:20Z",136,"08edcf34-a174-4945-bca2-45709400c462","Episode 134: ESMO 2021: The PRISM Study","episode-134-esmo-2021-the-prism-study","https://anchor.fm/s/13347ea8/podcast/play/40507684/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-19%2Ffb546844-e190-44e8-5ad5-e35d6851dfb0.mp3",20248761,1451,"2021-09-19T13:14:16Z",134,"4d1482a9-e854-470d-ab62-0cdb0a69d9cf","Episode 135: ESMO 2021: The STAR Study","episode-135-esmo-2021-the-star-study","https://anchor.fm/s/13347ea8/podcast/play/40508165/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-19%2F5c956477-2cdc-0a97-1a73-8eebe3e2b471.mp3",25584627,1908,"2021-09-19T13:29:49Z",135,"23b0a287-c5c0-4da0-b7b3-94b3d5a8a3e7","Episode 136: ESMO 2021: STAMPEDE Abiraterone for high-risk non-metastatic prostate cancer","episode-136-esmo-2021-stampede-abiraterone-for-high-risk-non-metastatic-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/40508818/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-19%2Fc27257fa-2e85-0e14-8c91-2a80359b1f53.mp3",15719753,1135,"2021-09-19T13:49:18Z","78a2746b-dd91-4a2f-9be9-4e2c4cb401c5","Episode 137: ESMO 2021: PEACE1 overall survival in prostate cancer","episode-137-esmo-2021-peace1-overall-survival-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/40509439/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-8-19%2Fb016499d-8f33-f414-1f25-216e9c05a9c7.mp3",19994840,1478,"2021-09-19T14:09:09Z",137,"8d38ea27-98d0-4f1d-8218-5d2d2770924a","Episode 138: Renal Cancer ESMO Guidelines Update","episode-138-renal-cancer-esmo-guidelines-update","https://anchor.fm/s/13347ea8/podcast/play/42178428/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-9-22%2F236dd662-9c8f-ebf2-426c-242bc9227202.mp3",24997886,1752,"2021-10-22T16:05:42Z",138,"35bd544a-7a47-47b1-af09-a55c99d681f0","Episode 139: The Uromigos Paper of the Month - Talazoparib in biomarker positive prostate cancer","episode-139-the-uromigos-paper-of-the-month-talazoparib-in-biomarker-positive-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/42405534/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-9-27%2Fdfeaabbc-6534-b97d-45a4-934950682a47.mp3",19551898,"2021-10-27T10:31:18Z",139,"5da39827-91c2-4d33-9e0f-2ec96bc5889e","Episode 140: What is the role of ipilimumab in renal cancer?","episode-140-what-is-the-role-of-ipilimumab-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/42516473/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-9-29%2Fd8e3ff69-9dfd-b442-0a9b-3bd152b7c040.mp3",20652758,"2021-10-29T11:26:30Z",140,"cd26e577-688b-42d1-9b05-2a2579cff9ed","Episode 141: Movember - Past, Present and Future","episode-141-movember-past-present-and-future","https://anchor.fm/s/13347ea8/podcast/play/42860056/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-10-5%2F0dc9d881-7c58-86e9-b1e3-aa99af75690e.mp3",19403730,1341,"2021-11-05T13:19:16Z",141,"20c3bdaf-9cc2-46c6-b455-beec08d792e2","Episode 143: The Uromigos Paper of the Month - Determinants of anti- PD-1 response and resistance in clear cell renal cell carcinoma","episode-143-the-uromigos-paper-of-the-month-determinants-of-anti-pd-1-response-and-resistance-in-clear-cell-renal-cell-carcinoma","https://anchor.fm/s/13347ea8/podcast/play/43491254/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-10-17%2F95e88395-f8c2-fbce-551d-6bd5d10b5b9d.mp3",22586843,"2021-11-17T15:02:48Z",143,"6978b9c2-7110-4687-9486-390ea10e7bef","Episode 144: Pembrolizumab for bladder cancer","episode-144-pembrolizumab-for-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/44253774/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-2%2F9c235dc9-853b-6550-5dc2-3565016c78b0.mp3",24601372,1659,"2021-12-02T15:10:07Z",144,"ec97cb5a-74b6-45bf-a63f-33a30d88432f","Episode 145: Prostate Cancer Christmas Special","episode-145-prostate-cancer-christmas-special","https://anchor.fm/s/13347ea8/podcast/play/44438804/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-6%2F27da818e-1595-8b54-30e9-14ad7202d305.mp3",26081674,1872,"2021-12-06T14:45:37Z",145,"b4a550ac-ef55-43d0-81e8-b8440989eeda","Episode 146: Bladder Cancer Christmas Special","episode-146-bladder-cancer-christmas-special","https://anchor.fm/s/13347ea8/podcast/play/44779653/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-13%2F97e7ae3c-036f-f33c-27d8-949873c5f694.mp3",21555153,1494,"2021-12-13T13:15:11Z",146,"c77a317e-6a67-480c-93ef-b28dc19df10c","Episode 147: Renal Cancer Christmas Special","episode-147-renal-cancer-christmas-special","https://anchor.fm/s/13347ea8/podcast/play/44993416/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-17%2F13cfbcfb-6e8f-631c-b672-8f6dc458777e.mp3",25665833,1895,"2021-12-17T13:38:09Z",150,"d278128a-ca4e-4ae0-a0cb-ddda8f71f314","Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer","episode-148-the-uromigos-paper-of-the-month-stereotactic-radiotherapy-for-advanced-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/45155210/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-21%2F191b4542-b842-7604-d4e2-37991b596a9f.mp3",22720746,1648,"2021-12-21T11:15:29Z",148,"34c634d2-9479-4275-b973-0dc2c973bbdf","Episode 149: Treatment-free survival for ipilimumab and nivolumab","episode-149-treatment-free-survival-for-ipilimumab-and-nivolumab","https://anchor.fm/s/13347ea8/podcast/play/45401097/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2021-11-28%2Fb5281988-ecc2-cea9-e8a4-d360a9d2b0da.mp3",26052936,1807,"2021-12-28T10:42:15Z",149,"efc84296-99c9-4253-ba53-7e5925376f8d","Episode 150: Comparing the quality of life data in renal trials","episode-150-comparing-the-quality-of-life-data-in-renal-trials","https://anchor.fm/s/13347ea8/podcast/play/46601311/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-0-24%2Fa89a6a4f-f41f-16f8-96aa-771103302262.mp3",21084613,1867,"2022-01-24T12:32:47Z","cbfb4273-875f-4fd5-ae22-abe7d11907ec","Episode 151: Bladder Cancer ESMO Guidelines update","episode-151-bladder-cancer-esmo-guidelines-update","https://anchor.fm/s/13347ea8/podcast/play/46952161/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-0-31%2Fa1f53f1a-110b-c2a8-c0a4-13b27ea468e6.mp3",22889563,"2022-01-31T15:11:19Z",153,"6e6354c5-1943-4b9f-bbd7-41b6e820f97f","Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging","episode-152-the-uromigos-paper-of-the-month-zr-pembrolizumab-pet-imaging","https://anchor.fm/s/13347ea8/podcast/play/47302379/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-7%2Fc3f3a7ce-898e-af98-045e-f9e2d92c92fd.mp3",16952811,1305,"2022-02-07T11:00:36Z",155,"cd3d0f1b-8b93-40a9-8f89-9e12732ad387","Episode 153: Overview of PARP inhibition in prostate cancer","episode-153-overview-of-parp-inhibition-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/47304804/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-7%2F1d25a276-2f27-86d0-8ec8-e0045f413ba4.mp3",21515929,1834,"2022-02-10T07:25:39Z","7c8b9c07-96dd-40e0-bbe5-7eb30e59b4a0","Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer","episode-155-asco-gu-2022-arasens-trial-of-darolutamide-plus-chemo-vs-chemo-alone-in-hormone-sensitive-advanced-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/47823050/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-17%2Fc0be6357-e42b-202d-4002-dc61c09d2c53.mp3",12306085,1064,"2022-02-17T22:40:17Z","ec3c3b68-e2de-4bec-8653-703bb5bf488e","Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC","episode-154-asco-gu-2022-magnitude-trial-of-niraparib-and-abiraterone-in-metastatic-crpc","https://anchor.fm/s/13347ea8/podcast/play/47822967/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-17%2F5e549f81-3ff0-7815-3ef7-607376db3532.mp3",23779649,1832,"2022-02-17T22:40:23Z",154,"299fbb84-c0b0-4bdb-8c1c-8beb636d495c","Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer","episode-157-asco-gu-2022-sasatuzimab-and-pembrolizumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/47872652/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-18%2F01863e65-ac36-72b4-78f4-c57d9ab32ca7.mp3",14107714,"2022-02-18T22:16:03Z",157,"db8c0b94-5179-4094-867c-c7f8205516d9","Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer","episode-156-asco-gu-2022-1st-line-olaparib-and-durvalumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/47872327/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-18%2F9edc7b6e-99c1-6ed9-d32c-1faddb4155e3.mp3",18916039,1249,"2022-02-18T22:52:46Z",156,"0826107c-299b-4800-80ec-b2b0cd3f153c","Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer","episode-158-asco-gu-2022-propel-phase-iii-olaparib-and-abiraterone-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/47910287/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-19%2F9102bc01-31d2-f6eb-d051-f2a9fc2126ff.mp3",21718531,"2022-02-19T21:16:53Z",161,"53331a4d-d052-463c-b1da-a3e00187992e","Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer","episode-159-asco-gu-2022-adjuvant-and-neoadjuvant-therapy-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/47914420/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-19%2Fa22d4652-4613-8ef8-2b0c-334a6c9537bc.mp3",18678029,1268,"2022-02-19T23:08:41Z","1adc39ab-5516-4b96-b833-b2eb19798d82","Episode 160: APCCC - PMSA PET as a diagnostic","episode-160-apccc-pmsa-pet-as-a-diagnostic","https://anchor.fm/s/13347ea8/podcast/play/48331236/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-1-28%2F2f751a50-f010-e399-e309-8b610c57c4d0.mp3",25480834,"2022-02-28T14:57:14Z",160,"4e154847-4251-48f0-8e41-fd9af880a754","Episode 161: Platinum eligibility in urothelial cancer","episode-161-platinum-eligibility-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/48685461/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-2-7%2F82f3476e-d059-564d-2f34-626e487be0f7.mp3",20030557,1424,"2022-03-07T17:48:11Z","5ed8e506-ab4f-4703-ab27-4a032dadf343","Episode 162: Debate - Adjuvant nivolumab for bladder cancer","episode-162-debate-adjuvant-nivolumab-for-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/49026655/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-2-14%2F81afe712-018a-1a99-e43d-b5debe588731.mp3",17392600,1207,"2022-03-14T20:54:30Z",162,"d6010e79-7799-4763-af6b-0b1744e34e75","Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer","episode-163-the-uromigos-debate-treatment-of-favorable-risk-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/49380478/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-2-21%2F7e942f11-4dc0-9e3a-13a3-abcc097cfcfd.mp3",24711001,2040,"2022-03-21T20:08:54Z",163,"b1c18d3a-4475-45a2-b7ce-bc823f3cb41a","Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer","episode-164-paper-of-the-month-what-can-we-learn-from-r3-ipilimumabnivolumab-in-gastric-cancer","https://anchor.fm/s/13347ea8/podcast/play/49972565/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-3-1%2F19e6b7bf-2597-5d56-112e-6d66fe9fff99.mp3",15043345,1339,"2022-04-01T20:18:08Z","1980b43c-0357-4cb5-8364-3f4f7daa4205","Episode 165: Paper of the Month - ENZAMET quality of life data","episode-165-paper-of-the-month-enzamet-quality-of-life-data","https://anchor.fm/s/13347ea8/podcast/play/50190377/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-3-6%2F835b9976-7bfd-164c-a3d9-08eeb5f85662.mp3",23386080,1669,"2022-04-06T09:48:51Z",165,"de2d803c-6761-4b28-a8bc-419532372c9b","Episode 166: Prostate cancer debate: doublet vs triplet first line therapy","episode-166-prostate-cancer-debate-doublet-vs-triplet-first-line-therapy","https://anchor.fm/s/13347ea8/podcast/play/50743617/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-3-18%2F48792205-b06d-88bb-48ba-68540ee80612.mp3",26904052,2002,"2022-04-18T14:58:40Z",166,"fef777a2-6253-4c84-9ca3-f3167be3679f","Episode 167: Highlights from EIKCS oral session","episode-167-highlights-from-eikcs-oral-session","https://anchor.fm/s/13347ea8/podcast/play/50942320/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-3-22%2F02e20491-a9c1-4380-a20e-59a1218694e9.mp3",21858211,1513,"2022-04-22T14:25:19Z",167,"2ce0991a-cf0b-4125-91a0-f1a95056d733","Episode 168: Mechanisms of response to PD1 therapy in renal cancer","episode-168-mechanisms-of-response-to-pd1-therapy-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/51396939/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-4-2%2F44d5d1c3-2fa2-388d-a8de-efdc788f5e0a.mp3",25600107,"2022-05-02T10:18:55Z",168,"5b7b3b39-0060-4b20-af6c-ecea4ae1fe35","Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC","episode-169-the-uromigos-paper-of-the-month-novel-neoadjuvant-approaches-in-uc","https://anchor.fm/s/13347ea8/podcast/play/51742710/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-4-9%2Ff6a5009c-418e-f56b-61c7-dc9994cb1962.mp3",19758844,1441,"2022-05-09T15:10:29Z",169,"c0b609da-e9ad-41b7-8ce6-00f5a9ee76fa","Episode 170: APCCC Meeting Summary","episode-170-apccc-meeting-summary","https://anchor.fm/s/13347ea8/podcast/play/52067442/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-4-16%2F229bdb66-60be-2daf-89a7-750472eb6ff9.mp3",23243180,1679,"2022-05-16T11:28:55Z",170,"65fe5286-6b0f-4d1f-8196-8cd040c5bb62","Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects","episode-171-antibody-drug-conjugates-in-bladder-cancer-managing-adverse-effects","https://anchor.fm/s/13347ea8/podcast/play/52419103/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-4-23%2Fc2804a59-80ae-4cb4-3f02-a64e5e08f965.mp3",24078927,1549,"2022-05-23T11:44:07Z",171,"54a11876-e3ab-4fc3-b06c-a815d2cc68d8","Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer","episode-172-asco-2022-adjuvant-everolimus-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/52987928/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-3%2F163926f5-be3a-6176-1391-367a678d881d.mp3",17500471,1220,"2022-06-03T21:14:09Z",172,"1ae0dd04-763e-46f6-bc2b-ea0abc266c76","Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer","episode-173-asco-2022-the-atlantis-trial-maintenance-cabozantinib-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/52987476/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-3%2Fae91b7c1-8933-35c0-d009-7294f11e5d81.mp3",18383510,1225,"2022-06-03T21:14:32Z",173,"62e37e42-68ee-4b07-bd52-6f78391ce74b","Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer","episode-174-asco-2022-cell-free-dna-as-a-biomarker-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/52988592/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-3%2Ffb86c8fd-44ca-1cfe-6365-473e1e6652a4.mp3",19763614,1479,"2022-06-03T23:38:13Z",174,"0e447d3f-92d1-4ed4-bfba-480f37c8edc7","Episode 175: ASCO 2022: Targeting the microbiome in renal cancer","episode-175-asco-2022-targeting-the-microbiome-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/52988263/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-3%2F95be5bd7-01ff-94a5-e0ba-ff82ba7c5629.mp3",16242713,1212,"2022-06-04T21:35:16Z",175,"20727098-5d4e-416a-97cc-e630c06e99c8","Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer","episode-176-asco-2022-her-2-adcs-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/53054637/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-5%2Ff20e8b0e-1108-352b-8d58-ae030cbc8c20.mp3",16545588,1176,"2022-06-05T17:48:29Z",176,"4023e581-35c7-4681-ad94-0f5a299916b7","Episode 177: ASCO 2022: ENZAMET survival update","episode-177-asco-2022-enzamet-survival-update","https://anchor.fm/s/13347ea8/podcast/play/53057729/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-5%2F26ecaab9-b1c6-fc92-bddc-0fcb77e70f01.mp3",16902620,"2022-06-05T20:24:47Z",177,"b6cafdcf-aab2-4436-b73a-c12dcc824ad6","Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer","episode-178-asco-2022-germline-variants-in-men-of-african-descent-with-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/53151974/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-7%2F991fd5c5-b8b8-b49b-7219-2c962eaa403e.mp3",16427857,1227,"2022-06-07T15:17:57Z",178,"fdc37d42-d33c-49e7-828f-b3141911a366","Episode 179: PSMA PET for Lutetium-177 in prostate cancer","episode-179-psma-pet-for-lutetium-177-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/53741977/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-20%2Ffe6293d0-954d-81f5-e8e0-a669481bc56e.mp3",26932431,1933,"2022-06-20T11:13:29Z",179,"5d89a3a9-f9d1-4981-a1c2-e7a52156868e","Episode 180: Enzalutamide vs active surveillance in early prostate cancer","episode-180-enzalutamide-vs-active-surveillance-in-early-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/53764220/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-20%2F4483d23c-143f-6352-b4a0-b57dd4065382.mp3",23670217,1654,"2022-06-20T20:15:35Z",180,"a74d9ab0-aaeb-4734-adc2-f940121430d1","Episode 181: Relapsed Germ Cell Tumours","episode-181-relapsed-germ-cell-tumours","https://anchor.fm/s/13347ea8/podcast/play/54068568/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-5-27%2F1e12484e-8e33-55cf-1570-8fe0f2b42c74.mp3",23686568,1650,"2022-06-27T14:22:17Z",181,"b73b4723-d910-46db-8d7c-9efb86ff4688","Episode 182: ASCO Kidney Cancer Guidelines","episode-182-asco-kidney-cancer-guidelines","https://anchor.fm/s/13347ea8/podcast/play/54668831/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-6-11%2Fe2a5e4e6-0b1a-bf5a-aaa1-43a5076e2138.mp3",23011801,1951,"2022-07-11T09:57:25Z",182,"9cd8ccac-3000-4880-8bcb-e129761c9915","Episode 183: Oliver Sartor - The Uromigos Legends Series","episode-183-oliver-sartor-the-uromigos-legends-series","https://anchor.fm/s/13347ea8/podcast/play/54975297/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-6-18%2F9f7f5b55-68bc-d85d-2ac2-3da75b7b5166.mp3",18685069,1633,"2022-07-18T10:57:49Z",183,"483688e2-f4ee-4e19-a725-cd3e15ccb1ea","Episode 184: Active surveillance in prostate cancer and the seeds of doubt","episode-184-active-surveillance-in-prostate-cancer-and-the-seeds-of-doubt","https://anchor.fm/s/13347ea8/podcast/play/55342462/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-6-26%2F13b9af73-d056-2881-f7b3-13ae223663b3.mp3",30857309,2201,"2022-07-26T15:02:04Z",184,"7b72cb50-543c-4478-895f-4ea62ef0a7e5","Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer","episode-185-the-uromigos-paper-of-the-month-ctdna-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/55587616/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-7-1%2Fbef42060-2d6e-2055-9ad0-2376649a2578.mp3",22328659,1542,"2022-08-01T11:52:08Z",185,"6e62f92e-42fe-4be6-8659-c26ca0deff3f","Episode 186: Bernard Escudier - The Uromigos Legends Series","episode-186-bernard-escudier-the-uromigos-legends-series","https://anchor.fm/s/13347ea8/podcast/play/55945843/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-7-10%2F29f22d85-4994-cdf5-ec68-9e03d33c3204.mp3",18679705,"2022-08-10T14:47:37Z",186,"a502dc33-fb10-4f90-8b6a-fa604c7ba2e8","Episode 187: Cora Sternberg - The Uromigos Legends Series","episode-187-cora-sternberg-the-uromigos-legends-series","https://anchor.fm/s/13347ea8/podcast/play/56195807/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-7-15%2F152ac596-7509-1e6f-32c9-23166d15ffbe.mp3",24620821,1969,"2022-08-15T13:26:14Z",187,"19c5d367-697d-4e68-9ea5-ab81d1dec2e4","Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting","episode-188-the-1st-uromigos-live-and-unplugged-face-to-face-meeting","https://anchor.fm/s/13347ea8/podcast/play/56210834/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-7-15%2F6051fe4e-4682-0ba7-f8a9-44ce25944b55.mp3",19408331,1384,"2022-08-15T19:12:33Z",188,"6e8d0e2b-cc01-492c-89c6-8f56e83ee5a8","Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy","episode-189-the-uromigos-paper-of-the-month-robotic-vs-open-cystectomy","https://anchor.fm/s/13347ea8/podcast/play/56486488/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-7-22%2Fea7f6f4f-ae70-93c7-c7ed-4ec8135e242b.mp3",18737446,1418,"2022-08-22T11:53:56Z",189,"b3d429a3-ab1a-4d22-8cda-894638ef18bf","Episode 190: ESMO 2022 Preview","episode-190-esmo-2022-preview","https://anchor.fm/s/13347ea8/podcast/play/56994583/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-2%2F5e367407-cd26-9cd7-123e-8022d2ff7fed.mp3",20776523,1485,"2022-09-02T12:39:08Z",190,"4b9bf1d4-d8d6-49e3-8809-f69fdf30431f","Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC","episode-191-esmo-2022-prosper-study-of-neoadjuvant-nivolumab-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/57366338/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-10%2Fc94c055d-0dea-5d3d-2f4b-16e89fb6717b.mp3",21837861,1565,"2022-09-10T17:34:18Z",191,"ccbb8403-68da-4512-96e6-da20a2f5b0fa","Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials","episode-192-esmo-2022-summary-of-esmo-adjuvant-rcc-trials","https://anchor.fm/s/13347ea8/podcast/play/57366269/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-10%2F308bcaa0-86f3-7733-54aa-ec202d40b1c0.mp3",23764360,1707,"2022-09-11T15:30:58Z",192,"393b3b68-8c8d-4c40-9b40-ec1039348c00","Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer","episode-193-esmo-2022-presto-a-phase-iii-trial-of-androgen-annihilation-in-biochemically-relapsed-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/57406795/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-11%2F10c887de-11d1-cd40-8013-67ba58b59aca.mp3",16569514,1171,"2022-09-11T19:32:55Z",193,"abea3f50-f4f0-45ba-8f15-e2f90ff34659","Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer","episode-194-esmo-2022-pegylated-il-2-nivolumab-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/57366386/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-10%2Fc511af08-049e-3228-96f3-8ea92d059947.mp3",20583606,1475,"2022-09-12T14:27:57Z",194,"1abb1619-62cf-40f7-841b-2507ff5921ce","Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer","episode-195-esmo-2022-ev-pembrolizumab-in-1st-line-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/57489603/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-13%2F0b066510-f12d-ea09-938c-2ec276aaa7e1.mp3",16691563,"2022-09-13T09:42:53Z","586b0819-557e-4c06-9cd9-ed477583d88d","Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer","episode-196-the-cosmic-313-trial-caboipinivo-in-1st-line-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/57571767/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-14%2Fb937be8f-6203-cadd-95f6-f1878c21c49f.mp3",26326877,"2022-09-14T18:01:30Z",196,"84eab703-e6dc-47aa-9a28-5c5e5fc6f559","Episode 197: The Uromigos Nashville 2022","episode-197-the-uromigos-nashville-2022","https://anchor.fm/s/13347ea8/podcast/play/58317258/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-8-29%2F1e8e336a-0f71-0d27-cd80-afacd02220c5.mp3",8294167,582,"2022-09-29T14:45:54Z",197,"44544790-b564-41b1-82e3-16cdadda52e1","Episode 198: The RADICALS trial in prostate cancer","episode-198-the-radicals-trial-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/58727913/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-9-7%2Fd662020c-137a-ac41-bf2a-2ee247a3e37b.mp3",20701344,1450,"2022-10-07T20:15:32Z","93ed1959-0094-4921-9385-195667d2330a","Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer","episode-199-the-uromigos-paper-of-the-month-fgfr-inhibition-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/59189948/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-9-17%2F4f530b80-6b66-e155-1dd5-805dee178165.mp3",17493217,"2022-10-17T14:32:04Z",199,"0edf9c5e-9dfc-4845-bbcc-2bbd5f65b699","Episode 200: Chromophobe renal cancer","episode-200-chromophobe-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/59547270/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-9-25%2Fdc9fe24b-9d8c-e616-ef7a-22b226e08d01.mp3",15939977,1242,"2022-10-25T11:34:56Z","f9f5168c-fdb9-4d51-a08c-6ce1693231e2","Episode 201: PARPi in CRPC","episode-201-parpi-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/59904404/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-1%2F23dfafcb-d2f7-e5f2-4a7f-bbdb82bcb57a.mp3",24242142,1667,"2022-11-01T13:42:56Z",201,"166e287c-160d-4317-b4e0-7c7f4a99405c","Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC","episode-202-the-uromigos-paper-of-the-month-docetaxel-with-or-without-continuous-enza-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/60224030/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-7%2Fb6947512-ce6d-4efd-027d-c29689e0964f.mp3",19100369,1386,"2022-11-07T12:33:27Z",202,"b7d9b199-b561-4a23-9db3-316572f03002","Episode 203: Renee Saliby in the Rising Star series","episode-203-renee-saliby-in-the-rising-star-series","https://anchor.fm/s/13347ea8/podcast/play/60606085/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-14%2F8ecb51ad-8a34-86ad-1281-f24c6f36d158.mp3",23044768,"2022-11-14T13:22:34Z",203,"3c8c19f2-9d9f-4323-8ecb-0a4904a4a6ad","Episode 204: Scott Haake in the Rising Star series","episode-204-scott-haake-in-the-rising-star-series","https://anchor.fm/s/13347ea8/podcast/play/60607794/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-14%2F90ae69c0-b0b3-60de-1ffe-6889a45b85ef.mp3",27799297,"2022-11-14T13:59:26Z",204,"9fffac67-a465-4fd4-95d5-982253be99eb","Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer","episode-205-paper-of-the-month-nab-paclitaxel-and-pembrolizumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/60987050/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-21%2F80f19456-681f-15dc-1ee0-efeaeb124a72.mp3",24992770,1387,"2022-11-21T19:01:27Z",205,"e5c3b619-e07d-49cf-a4b0-69d1d7558894","Episode 206: Dan Shapiro in the Rising Star series","episode-206-dan-shapiro-in-the-rising-star-series","https://anchor.fm/s/13347ea8/podcast/play/61325533/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-10-28%2F09763e1c-18f3-7e22-6a77-c75f5d69f97f.mp3",14031343,"2022-11-28T13:50:02Z",206,"d6b634a8-6262-44d5-8926-a721e5b49173","Episode 207: Editorial on COSMIC-313","episode-207-editorial-on-cosmic-313","https://anchor.fm/s/13347ea8/podcast/play/61688394/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-11-5%2Fe13acc9f-33d2-a765-b2d5-d0f48db7b017.mp3",32409701,1765,"2022-12-05T11:47:58Z",207,"5b116f1f-e91d-4044-a6be-16a028d86818","Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer","episode-208-christmas-kidney-cancer-debate-ipilimumab-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/62068788/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-11-12%2Ffa8b37c8-3c30-147e-c408-cabbf6145a1b.mp3",37130068,2049,"2022-12-12T14:34:30Z","f0ed8f09-40fd-4488-8111-991b2aa00e76","Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer","episode-209-christmas-bladder-cancer-debate-cisplatin-vs-carboplatin-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/62340210/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-11-17%2F68f28c41-6a6c-0882-85dc-5431c51e9f79.mp3",22724388,1691,"2022-12-17T17:35:57Z",209,"0ce03646-2271-4b60-8708-d4b21f300912","Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients","episode-210-christmas-prostate-cancer-debate-olaparib-and-abiraterone-in-selected-or-unselected-patients","https://anchor.fm/s/13347ea8/podcast/play/62559380/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-11-22%2F284daeeb-b2a1-8f88-3d54-6a4a3d1c5963.mp3",30633467,1564,"2022-12-22T15:26:23Z",210,"c218ee82-2ca2-4c62-bc25-0e8e9ca7d6a3","Episode 211: CAR-T cell therapy in RCC","episode-211-car-t-cell-therapy-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/62789495/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2022-11-28%2Fda8cd7d1-67a9-ba75-57db-98248ebe3f88.mp3",34684874,1796,"2022-12-29T19:42:42Z",211,"cf6e8007-c0e1-4fe0-8add-502fa66f8017","Episode 212: What's coming in GU Cancers in 2023","episode-212-whats-coming-in-gu-cancers-in-2023","https://anchor.fm/s/13347ea8/podcast/play/62969157/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-0-2%2F20186510-e76f-5a28-f4d1-2058491d2df8.mp3",40612270,2171,"2023-01-02T14:06:01Z",212,"4cca0b24-a6d0-4ef7-a2d5-657ad9d9344f","Episode 213: IL-15RaFc superagonist in NMIBC","episode-213-il-15rafc-superagonist-in-nmibc","https://anchor.fm/s/13347ea8/podcast/play/63247439/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-0-9%2F78ef140e-bb45-e184-037e-746e9393fb50.mp3",18079895,1407,"2023-01-09T12:11:37Z",213,"286e499a-ca38-4a65-a34a-705762ba4148","Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal","episode-214-resumen-de-la-reunión-en-las-islas-canarias-sobre-cáncer-renal","https://anchor.fm/s/13347ea8/podcast/play/63793002/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-0-20%2F7d0e1d8f-f889-be6a-6e22-cdf329eef211.mp3",12554917,1292,"2023-01-21T09:08:58Z",214,"fc6553da-a2b2-4634-9e7f-00bd8543f9eb","Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD","episode-216-adcs-in-bladder-cancer-with-petros-grivas-md-phd","https://anchor.fm/s/13347ea8/podcast/play/64244482/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-0-30%2F8a1be5ee-46a2-319b-db55-e5aff33bb173.mp3",22452450,"2023-01-30T11:41:43Z",216,"582a8c88-d088-4990-beb7-fcc3cc5886db","Episode 217: Rising Star: Vadim Koshkin and ADCs","episode-217-rising-star-vadim-koshkin-and-adcs","https://anchor.fm/s/13347ea8/podcast/play/64468044/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-3%2Fe484ec7a-a422-10f8-934c-1a7f8c4954c2.mp3",14693708,1110,"2023-02-03T19:54:18Z",217,"737cf273-cbe7-4500-a061-431dbbf3877a","Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD","episode-218-discussing-the-cost-of-cancer-drugs-with-daniel-goldstein-md","https://anchor.fm/s/13347ea8/podcast/play/64593610/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-6%2F595903a4-c387-ff7f-48da-fa4ac91d71d2.mp3",19235515,"2023-02-07T08:15:01Z",218,"1978efbb-4970-4a73-8142-385ccc1e7020","Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study","episode-219-asco-gu-2023-neeraj-agarwal-md-fasco-discusses-the-talapro-2-study","https://anchor.fm/s/13347ea8/podcast/play/65207367/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-17%2Fb6de3772-7996-cfcc-a1db-79422bc89ad0.mp3",18491099,1329,"2023-02-17T17:59:51Z",219,"7267460b-196e-42f2-8f5b-b69ec79823d7","Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD","episode-220-asco-gu-2023-discussing-parpi-for-crpc-with-michael-morris-md","https://anchor.fm/s/13347ea8/podcast/play/65220070/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-17%2F20a67b32-4ab3-5321-fd8f-e286866f270d.mp3",21914534,1520,"2023-02-17T20:36:29Z",220,"1b267a78-4aa6-4f81-8e95-463c4b9e3f0d","Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial","episode-221-asco-gu-2023-matt-galsky-md-gives-an-update-on-the-checkmate-274-trial","https://anchor.fm/s/13347ea8/podcast/play/65217225/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-17%2F731bd77c-3fd3-023e-95c1-26ea620f161e.mp3",24076847,1813,"2023-02-17T22:59:29Z",221,"560f462a-bc1c-4e78-889d-d5a1eb69bc07","Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD","episode-222-asco-gu-2023-new-data-from-imvigor130-with-enrique-grande-md","https://anchor.fm/s/13347ea8/podcast/play/65211315/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-17%2Fc6d1c65a-5daf-3901-640e-f92249b09b91.mp3",16562904,1209,"2023-02-17T22:59:42Z",222,"034121d0-f701-4f06-a459-8b00bc936e3f","Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD","episode-223-asco-gu-2023-discussing-keynote-057-with-andrea-necchi-md","https://anchor.fm/s/13347ea8/podcast/play/65156384/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-16%2F2ecf03b6-e4bc-bda0-3398-5df7d6d8a528.mp3",20204042,1467,"2023-02-17T22:59:52Z",223,"54c0eed4-01c3-4948-9362-80bb0c9d5961","Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger","episode-224-asco-gu-2023-discussing-mir371-for-germ-cell-tumors-with-christian-kollmannsberger","https://anchor.fm/s/13347ea8/podcast/play/65166376/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-16%2F06171c87-2e01-88f8-7fc3-436d2705ba31.mp3",23073386,1637,"2023-02-20T19:34:21Z",224,"44ec1f68-ec44-40ee-854c-0bfd7dd48d72","Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC","episode-225-asco-gu-2023-brian-shuch-md-discusses-the-zircon-phase-iii-study-of-girentuximab-petct-imaging-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/65360621/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-20%2Fed4ea2c7-2e6f-9d34-7821-4a9587bebcf4.mp3",21273148,1487,"2023-02-20T19:36:14Z",225,"3f808b6b-99b8-43ab-ab73-add1ad0d1c70","Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George","episode-226-2023-asco-gu-prostate-and-rcc-highlights-with-dan-george","https://anchor.fm/s/13347ea8/podcast/play/65687865/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-1-27%2F81abd156-f4b3-54f9-fea6-8e021154e834.mp3",21957074,1530,"2023-02-27T12:31:35Z",226,"af60a265-65f8-43ba-ae0c-ff30d6166d83","Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden","episode-227-2023-asco-gu-bladder-highlights-and-paper-of-the-month-with-michiel-van-der-heijden","https://anchor.fm/s/13347ea8/podcast/play/66053851/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-2-6%2Fd428c490-8295-cb4a-78a6-1b9a1e3e3538.mp3",27535014,1918,"2023-03-06T12:34:58Z",227,"c071c263-13b3-425f-bd90-d068d70e81d8","Episode 228: Karine Tawagi, MD in the Rising Star Series","episode-228-karine-tawagi-md-in-the-rising-star-series","https://anchor.fm/s/13347ea8/podcast/play/66612364/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-2-15%2F0073017a-3d68-4ed1-cfdb-ba2b4f5fc6fe.mp3",18686712,1399,"2023-03-15T13:04:29Z",228,"2673f1ee-3e7f-48d6-b52f-1cd991a71907","Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer","episode-229-kala-sridhar-md-on-pet-in-early-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/66943739/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-2-20%2Fb8776791-1750-29f0-ab01-cd1d17a4a74e.mp3",20280724,1543,"2023-03-20T14:59:08Z",229,"357c9589-7cec-4e82-b7ec-5cc3461abdc6","Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand","episode-230-fgfr-inhibition-in-nmibc-with-sia-daneshmand","https://anchor.fm/s/13347ea8/podcast/play/67460823/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-2-28%2F2400d75f-79f9-495a-17be-cce29b06b7c1.mp3",29726208,1563,"2023-03-28T11:00:42Z",230,"6e8adf6b-fb09-45a9-bf21-442098edc8d0","Episode 231: Ursula Vogl, MD in the Rising Star Series","episode-231-ursula-vogl-md-in-the-rising-star-series","https://anchor.fm/s/13347ea8/podcast/play/68010300/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-3-5%2F16d0d428-a120-35e5-6dc7-af3776aebea6.mp3",23435108,"2023-04-05T13:20:22Z",231,"86e57651-d5a9-49fb-acb4-cae74f868816","Episode 232: Belzutifan in early and late renal cancer","episode-232-belzutifan-in-early-and-late-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/68601879/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-3-14%2F77aee2c4-3afc-b479-0915-1148a71bf00b.mp3",25939812,"2023-04-14T12:24:43Z",232,"fc4523c7-a5b1-438b-9314-119024e12a82","Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico","episode-233-destaques-da-14ª-reunião-internacional-brasileira-de-câncer-urológico","https://anchor.fm/s/13347ea8/podcast/play/68676490/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-3-15%2F467b401b-64cc-3bbc-ed30-d910045e4edd.mp3",11368335,933,"2023-04-15T20:47:56Z",233,"9a6c7f25-f9ab-4a68-b3b9-8553905cf7f2","Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer","episode-234-amar-kishan-md-on-neoadjuvant-or-adjuvant-radiotherapy-for-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/68906596/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-3-19%2F2a9ca48d-c61a-d80a-5e76-238c8a547739.mp3",15954883,1235,"2023-04-19T20:34:45Z",234,"2fcb2132-298e-422e-9645-f41dbaf5f31c","Episode 235: Danny Heng and the IMDC classification in renal cancer","episode-235-danny-heng-and-the-imdc-classification-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/69193598/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-3-24%2Ff3caab54-6040-e0e3-3611-566b9962185f.mp3",23039307,1680,"2023-04-24T11:50:05Z",235,"e1c3443c-e35b-4a4f-8aa5-680448fbc399","Episode 236: ODAC for olaparib","episode-236-odac-for-olaparib","https://anchor.fm/s/13347ea8/podcast/play/69665856/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-4-2%2F7f102ebe-380e-1281-3854-8bafa5e6d834.mp3",28776517,2030,"2023-05-02T14:51:53Z",236,"380f101f-bb80-4e0a-9d63-e479b3d20e79","Episode 237: 2023 AUA Highlights","episode-237-2023-aua-highlights","https://anchor.fm/s/13347ea8/podcast/play/70059973/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-4-9%2F45ce74a9-55cc-c26f-0d33-6180cc053b85.mp3",22659426,1576,"2023-05-09T10:53:50Z",237,"a2fb6532-6fbb-48ed-880d-9bdfd7c8e18b","Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy","episode-238-paper-of-the-month-biomarkers-for-neoadjuvant-pdl1-therapy","https://anchor.fm/s/13347ea8/podcast/play/70373057/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-4-14%2F329487128-44100-2-3521b8a841185.m4a",24132936,1492,"2023-05-14T18:44:28Z","800abec8-498a-4770-a5f4-72b7971066e5","Episode 239: The STAMPEDE trial","episode-239-the-stampede-trial","https://anchor.fm/s/13347ea8/podcast/play/70849821/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2Fexports%2F13347ea8%2F70849821%2Fc158c632674044d3877ad20a4b34f14f.m4a",132103733,8168,"2023-05-22T17:42:53Z","8349ce93-6dc5-419e-9ba3-d883d8c3a0c2","Episode 240: Preview of GU Cancer at ASCO 2023","episode-240-preview-of-gu-cancer-at-asco-2023","https://anchor.fm/s/13347ea8/podcast/play/71305121/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-4-30%2F332482406-44100-2-e2dcd85f5634d.m4a",26230630,1621,"2023-05-30T21:29:07Z","c0ae2f53-7019-4a20-9d04-1e07cb864893","Episode 241: Statistics for clinical trials","episode-241-statistics-for-clinical-trials","https://anchor.fm/s/13347ea8/podcast/play/71402216/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-1%2F332775801-44100-2-d85ca01b82bf5.m4a",37045214,2290,"2023-06-01T08:08:53Z","40f65fc7-3153-4661-a652-bbbdcb0c4be5","Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer","episode-242-asco-2023-thor-study-erdafitinib-vs-chemo-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/71638924/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-5%2F333477921-44100-2-d98dc219e61ae.m4a",25696618,1588,"2023-06-05T12:45:41Z","cad6ca15-96a1-412c-9b1b-368f13262de7","Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide","episode-243-asco-2023-talapro-2-phase-3-study-of-talazoparib-enzalutamide","https://anchor.fm/s/13347ea8/podcast/play/71650337/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-5%2Fe3f938c7-30b2-a277-a59f-50103aa00624.mp3",6590338,976,"2023-06-05T17:26:04Z","30fc6095-16cc-4b2b-a4af-47ebc93f34c4","Episode 244: ASCO 2023 PEACE-1 in CRPC","episode-244-asco-2023-peace-1-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/71650365/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-5%2Fdf758ceb-debe-67ab-f9e6-b474e5ef9f13.mp3",10118590,1495,"2023-06-05T17:28:39Z","f037ad71-874f-44cb-9c8e-b45afbddbca3","Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer","episode-245-asco-2023-contact-03-cabozantinib-atezolizumab-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/71659765/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-5%2F333546259-44100-2-b323247dd096a.m4a",26955326,"2023-06-05T19:00:13Z","bd90adb7-2dee-486a-a69f-9297cee6855a","Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC","episode-246-asco-2023-ev-pembro-and-erdafitinib-cetrelimab-in-1st-line-uc","https://anchor.fm/s/13347ea8/podcast/play/71660114/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-5%2F333551120-44100-2-d1f0dc7a5cd17.m4a",23728126,"2023-06-05T19:08:30Z","2460e975-3285-436e-888a-f125de330f3e","Episode 248: ASCO23 GU highlights","episode-248-asco23-gu-highlights","https://anchor.fm/s/13347ea8/podcast/play/72116010/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-14%2F335035901-44100-2-b55c3a0f74d1f.m4a",34413579,2127,"2023-06-14T12:29:58Z","59a89900-74ca-4451-9bf0-1f85f42c3789","Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer","episode-249-asco-2023-emergency-podcast-ipinivo-vs-vegfpd1-in-kidney-cancer","https://anchor.fm/s/13347ea8/podcast/play/72259634/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2Fexports%2F13347ea8%2F72259634%2F24dcbf9d6c43db173061f9753605fd03.m4a",35739938,2209,"2023-06-18T15:01:45Z","09e789cd-c7ff-496c-a44d-62de1e6e6cbe","Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1","episode-250-bob-motzer-discusses-ipinivo-vs-vegfpd1","https://anchor.fm/s/13347ea8/podcast/play/72253422/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-17%2F8037691e-3ef2-2308-3b62-8c4f7f2d0303.mp3",10311946,1812,"2023-06-18T15:17:49Z",249,"f48eb32c-e6c5-4b0e-a80b-f5938093e743","Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion","episode-251-final-part-of-vegftki-vs-ipinivo-discussion","https://anchor.fm/s/13347ea8/podcast/play/72628660/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-5-26%2Ffd3cef15-7f00-a355-b022-b6b7e759192e.mp3",21014890,3036,"2023-06-26T17:47:16Z",251,"7f95a1d5-52e6-4e8b-ad1d-2de5e5ddc10a","Episode 252: Talazoparib and its FDA approval in CRPC","episode-252-talazoparib-and-its-fda-approval-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/72972260/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-6-4%2Fdd7d05e9-b1b6-5670-e85d-b6150fc5495a.mp3",14585758,"2023-07-04T18:21:15Z",253,"a9d081bf-2a74-479c-8507-373422b0a72e","Episode 253: Patients' perspectives on adjuvant and 1st line RCC","episode-253-patients-perspectives-on-adjuvant-and-1st-line-rcc","https://anchor.fm/s/13347ea8/podcast/play/73319862/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-6-12%2F8e75c8bb-671a-1833-a078-c6c324e00b4e.mp3",11729338,1622,"2023-07-13T13:26:35Z","ff848e32-4fea-4c40-bf18-80f393dca844","Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges","episode-254-new-rcc-studies-at-kcrs-2023-with-laurence-albiges","https://anchor.fm/s/13347ea8/podcast/play/73509830/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-6-17%2Fff74bd98-9565-6f36-069f-574e232b021b.mp3",9925342,1692,"2023-07-17T15:46:08Z",255,"ff348d9c-e660-471a-ad14-49bbdc42c433","Episode 255: How to get an academic paper accepted","episode-255-how-to-get-an-academic-paper-accepted","https://anchor.fm/s/13347ea8/podcast/play/72925703/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-6-3%2F75ce12cd-a5a0-68a8-b747-18fb14939aed.mp3",13304806,1821,"2023-07-26T09:29:33Z",252,"f5d8958c-282d-4b1a-988d-24b61cf66b75","Episode 256: ctDNA in urothelial studies.","episode-256-ctdna-in-urothelial-studies","https://anchor.fm/s/13347ea8/podcast/play/73319102/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-6-12%2Fe96107ba-5b63-08a3-d233-879570dec62f.mp3",16560934,2266,"2023-07-27T20:01:35Z",254,"8cceeb08-ec87-4145-a636-b6e8893e42f6","Episode 257: Chana Weinstock from the FDA","episode-257-chana-weinstock-from-the-fda","https://anchor.fm/s/13347ea8/podcast/play/74273095/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-7-5%2F87803b10-7459-faa9-a9d2-774fb4e1d55e.mp3",12419306,2182,"2023-08-07T07:49:19Z",257,"beb702a0-b91a-48b6-90ae-72116de082a3","Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1","episode-258-curative-radiotherapy-for-bladder-cancer-golden-ticket-winner-1","https://anchor.fm/s/13347ea8/podcast/play/74653066/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-7-15%2F1cad715d-127d-c193-aa4f-1eb0140548fe.mp3",15675802,2779,"2023-08-15T15:39:54Z",258,"d19e87e5-dc14-4b64-8d7c-1fffe5828600","Episode 259: Cystectomy for bladder cancer","episode-259-cystectomy-for-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/75007989/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-7-24%2Fdcb17cb1-ef8c-7c11-30bb-272a7088fada.mp3",8654866,1529,"2023-08-24T12:29:26Z",259,"73193a8f-8411-4ab2-a05a-709be5107f7f","Episode 260: Celeste Simon: how to make a career in translation science work.","episode-260-celeste-simon-how-to-make-a-career-in-translation-science-work","https://anchor.fm/s/13347ea8/podcast/play/75051900/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-7-25%2F9b59d272-e3d4-0643-c1e3-68d7684f96f8.mp3",11702670,"2023-08-30T13:36:43Z",260,"66423d06-39c9-473e-a76e-569a2d6e42ad","Episode 261: part 2 ctDNA in bladder cancer","episode-261-part-2-ctdna-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/75419173/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-8-3%2F345548880-44100-2-8ed7cc9681bc9.m4a",39288323,2429,"2023-09-04T08:25:35Z",261,"fb295d96-2f09-4aea-a2cf-dcb1e7e9fa96","Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.","episode-262-paper-of-the-month-abiraterone-cabazitaxel-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/75797709/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-8-12%2F346720363-44100-2-735f0f9bf8ff.m4a",29679475,1835,"2023-09-12T20:39:13Z",263,"4337e513-8a15-4314-a625-d1c8bd229496","Episode 263: Toni Choueiri and papillary renal cancer","episode-263-toni-choueiri-and-papillary-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/76152270/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-8-20%2F347824758-44100-2-08e845a862d4f.m4a",35269995,2180,"2023-09-20T21:36:18Z","1d9d5e3c-e367-4aad-8379-577c68e08ac9","Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial","episode-264-prostatectomy-vs-rt-vs-surveillance-the-protect-trial","https://anchor.fm/s/13347ea8/podcast/play/76412605/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-8-26%2F348621017-44100-2-2110aee87f3a.m4a",28974586,1791,"2023-09-27T07:22:01Z",264,"caa3a815-ebb8-464a-bc56-2b886aeedc2e","Episode 265: Brachytherapy with Jeff Michalski","episode-265-brachytherapy-with-jeff-michalski","https://anchor.fm/s/13347ea8/podcast/play/75419238/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-8-3%2Fe118c17e-e2a4-8d61-9ca8-fd7293430072.mp3",16922418,2402,"2023-10-03T14:15:58Z",265,"b611d65e-2705-4fbf-9a49-79322df4cbc6","Episode 266: Radiotherapy for prostate cancer","episode-266-radiotherapy-for-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/76725776/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-3%2F349594107-44100-2-c5f71fbf4f032.m4a",27909888,1725,"2023-10-10T08:11:06Z",266,"737191d4-900b-4132-bc56-089f4c9d8400","Episode 267: ESMO preview - things to look out for at the meeting","episode-267-esmo-preview-things-to-look-out-for-at-the-meeting","https://anchor.fm/s/13347ea8/podcast/play/77031161/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-10%2F350555237-44100-2-a33f8fdf1824d.m4a",26295232,1625,"2023-10-11T21:40:22Z",267,"b1c12e83-55ce-4334-8b66-6b5889b0bc74","Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett","episode-268-esmo-2023-enzalutamide-and-177lu-psma-617-in-crpc-with-louise-emmett","https://anchor.fm/s/13347ea8/podcast/play/77341238/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-17%2F351534333-44100-2-bc0621a96df52.m4a",26307212,1626,"2023-10-20T18:05:54Z",272,"b7379a00-afaf-4266-bb62-b9965c00c912","Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC","episode-269-esmo-2023-antibody-drug-conjugate-doublets-in-uc","https://anchor.fm/s/13347ea8/podcast/play/77030577/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-10%2F350553576-44100-2-429a9c05937d1.m4a",24140858,"2023-10-21T11:21:39Z","6b5c1dcc-1dd3-4d8c-83c6-e033cd70b73d","Episode 270: ESMO 2023 - Belzutifan in renal cancer","episode-270-esmo-2023-belzutifan-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/77296772/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-16%2F351392894-44100-2-cfc6047872bd.m4a",27594876,1706,"2023-10-21T13:19:59Z",270,"088e68e0-b774-4e66-a794-cf285f7a6791","Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer","episode-271-esmo-2023-thor-erdafitinib-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/77551371/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-22%2F352196716-44100-2-510870af1bb5a.m4a",22816749,1410,"2023-10-22T16:40:13Z","6c2e1c12-f4b8-4f8e-af13-1341f0ab604f","Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer","episode-272-esmo-2023-ev302-and-cm901-in-1st-line-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/77296644/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-16%2F351392390-44100-2-4830b74dd701b.m4a",30602550,1892,"2023-10-22T16:43:08Z",269,"91add4f5-acc1-4ee7-9af2-e1a1cb7e0fa1","Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC","episode-273-esmo-2023-toripalimab-and-axitinib-in-clear-cell-rcc","https://anchor.fm/s/13347ea8/podcast/play/77296971/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-16%2F351393192-44100-2-650edca595fcb.m4a",13376921,827,"2023-10-26T20:19:17Z",271,"6d1f348d-b3b2-48d8-bb7e-398193148ca6","Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise","episode-274-esmo-2023-steap1bite-in-crpc-shows-promise","https://anchor.fm/s/13347ea8/podcast/play/77799862/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-27%2F352966496-44100-2-9863cd064031d.m4a",19194829,1186,"2023-10-27T18:12:32Z",274,"15ed6124-bde6-443b-8f25-d9c0e3ff2ad2","Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville","episode-275-live-meeting-preview-for-uromigoslive-2023-in-nashville","https://anchor.fm/s/13347ea8/podcast/play/77819666/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-4%2F9550df8e-2fb3-1bd3-faa7-fca07886fa76.mp3",9865700,796,"2023-10-27T20:46:27Z",275,"2bf8441c-d456-4a6a-a45a-ce06b96dcced","Episode 276: ESMO 2023 Highlights","episode-276-esmo-2023-highlights","https://anchor.fm/s/13347ea8/podcast/play/77849243/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-9-28%2F353118954-44100-2-12b38a82918f1.m4a",47677984,2948,"2023-10-28T17:46:30Z",276,"bab240ce-d38a-4fbe-9a1b-198c8c99e88b","Episode 277: NMIBC Discussion at #UromigosLive 2023","episode-277-nmibc-discussion-at-uromigoslive-2023","https://anchor.fm/s/13347ea8/podcast/play/78149778/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-10%2F6dbc2eb0-dc9f-8632-70c3-811aff4b388e.mp3",40418811,2630,"2023-11-04T02:48:30Z",277,"eca43505-6780-4b2e-8426-c089c93547bf","Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023","episode-278-current-and-future-status-of-radioligand-therapy-at-uromigoslive-2023","https://anchor.fm/s/13347ea8/podcast/play/78167741/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-10%2F588fbfd2-7a37-588e-be90-b7743b1543b6.mp3",35653915,2357,"2023-11-04T17:29:35Z",278,"0e09e618-912d-4800-9c4e-da7814209887","Episode 279: Management of IO-resistant RCC at #UromigosLive 2023","episode-279-management-of-io-resistant-rcc-at-uromigoslive-2023","https://anchor.fm/s/13347ea8/podcast/play/78245190/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-10%2Fce794ec6-073d-07d5-15f1-c30795c1824e.mp3",53492287,3623,"2023-11-06T16:37:21Z",279,"30e06374-ffa8-42a2-b8ed-b70e288cf8b0","An apology","an-apology","https://anchor.fm/s/13347ea8/podcast/play/78595204/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-13%2F355408704-44100-2-c56e0cd649cf5.m4a",1742479,"2023-11-13T23:26:29Z","1feb665c-40ea-43f4-a55f-2ac221a9403c","Episode 280: IKCS 2023 Overview","episode-280-ikcs-2023-overview","https://anchor.fm/s/13347ea8/podcast/play/78636405/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-14%2Fb2940773-bd6c-f0ea-2646-8529b6a778f4.mp3",28578692,2124,"2023-11-16T22:02:44Z",280,"107cfdc8-4bc4-49bd-bb37-16dc2909d032","Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer","episode-281-the-uromigos-paper-of-the-month-lu-177-with-pembrolizumab-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/79747440/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-11-8%2F733195ef-b9f5-faa9-93a8-5ad89f63a435.mp3",11656924,1523,"2023-12-08T11:50:50Z",281,"48d3ddf2-722b-4f57-b0dc-93a4ed520330","Episode 282: Holiday Special: Bladder Cancer in 2023","episode-282-holiday-special-bladder-cancer-in-2023","https://anchor.fm/s/13347ea8/podcast/play/79930386/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-11-12%2F833d29d7-a429-1284-fe9b-0ec67331e950.mp3",31026967,2292,"2023-12-13T18:04:00Z",282,"1e5ecddf-62be-4658-b1a9-2645f794552d","Episode 283: Holiday Special: Prostate Cancer in 2023","episode-283-holiday-special-prostate-cancer-in-2023","https://anchor.fm/s/13347ea8/podcast/play/80258402/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-11-20%2F360658315-44100-2-fb63952281cee.m4a",33545470,2074,"2023-12-20T13:11:03Z",283,"1c506a8b-98cc-4ef1-a7eb-98a54dbd5416","Episode 285: Holiday Special: Renal Cancer in 2023","episode-285-holiday-special-renal-cancer-in-2023","https://anchor.fm/s/13347ea8/podcast/play/80347417/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-11-22%2F4ceaba44-5d8e-14ba-fe5d-5c777dbc97e9.mp3",20297103,1562,"2023-12-22T11:53:04Z",285,"c6b9769f-f4d0-4f3a-bb6c-f9322fa594d1","Episode 286: APCCC Prostate Cancer Meeting Overview","episode-286-apccc-prostate-cancer-meeting-overview","https://anchor.fm/s/13347ea8/podcast/play/80730287/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-2%2Fa9f57512-7337-bfdf-47a9-0fdb99dc2df1.mp3",26012834,1822,"2024-01-03T12:37:42Z",286,"5ac90918-bfab-4d28-b501-bc119315a8eb","Episode 287 APCCC: Early Discontinuation of Therapy in HSPC","episode-287-apccc-early-discontinuation-of-therapy-in-hspc","https://anchor.fm/s/13347ea8/podcast/play/80730717/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-2%2Fb875afbe-f3c4-3b6d-5dae-6b416dcb227f.mp3",28527589,2088,"2024-01-04T15:09:46Z",287,"476fce21-e723-4411-800a-427d0b5879f3","Episode 288: APCCC #3: Controversies around Radiotherapy","episode-288-apccc-3-controversies-around-radiotherapy","https://anchor.fm/s/13347ea8/podcast/play/81073235/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-10%2Feff74bfc-38ac-afa5-0bc1-b9c31884d57a.mp3",30623269,2189,"2024-01-10T14:14:09Z",289,"d83fc904-afa1-4114-954e-850f46f40792","Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine","episode-289-the-uromigos-paper-of-the-month-talapro2-in-nature-medicine","https://anchor.fm/s/13347ea8/podcast/play/81071397/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-10%2F362896100-44100-2-6e0c050857aa7.m4a",34970158,2162,"2024-01-15T17:51:54Z",288,"a9bf601d-16c5-447b-a23f-db4ce3e75b91","Episode 290: ASCO GU 2024 Preview","episode-290-asco-gu-2024-preview","https://anchor.fm/s/13347ea8/podcast/play/81361198/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-16%2F688a3dfe-2241-302b-db66-29448dd7be97.mp3",23413487,1618,"2024-01-17T10:23:49Z",290,"f3ff96b3-52ac-4eb5-8fa0-fc1cb0f98525","Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer","episode-291-asco-gu-2024-contact2-cabozantinib-and-atezolizumab-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/81744527/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-24%2F93569bbf-43cb-22d0-3be9-f7f10249962f.mp3",25329169,"2024-01-25T16:37:35Z",291,"728a18b5-d41d-49c9-bc6e-37d31efa949a","Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer","episode-292-asco-gu-2024-hpn328-a-tri-specific-t-cell-engager-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/81744416/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-24%2F364815424-44100-2-7559f23ba6de8.m4a",25304620,"2024-01-26T03:08:55Z",292,"cc8d2d60-0a44-4532-9c97-e1dcbd70c351","Episode 293: ASCO GU 2024: BRCAaway and CONTACT2","episode-293-asco-gu-2024-brcaaway-and-contact2","https://anchor.fm/s/13347ea8/podcast/play/81837198/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-26%2Fd33c758c-b233-d7eb-5ea8-40db45562f8b.mp3",18529661,"2024-01-26T21:04:55Z",293,"738addbf-0456-4417-8156-2f2ef43b1dea","Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer","episode-294-asco-gu-2024-adjuvant-pembrolizumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/81789779/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-25%2F1989f3c1-0314-fc10-717c-b3ddcfd6a4e4.mp3",28811143,1997,"2024-01-27T01:00:13Z",294,"1905501a-e853-4f1b-af63-f2c6340240bc","Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer","episode-295-asco-gu-2024-adjuvant-therapy-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/81790275/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-25%2F068e897f-0a96-38e8-e562-d95b74631ae5.mp3",28874922,1966,"2024-01-27T16:48:15Z",295,"2a892987-8453-4e6d-a5d8-e38b5d79024c","Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan","episode-296-asco-gu-2024-novel-approaches-to-qol-and-belzutifan","https://anchor.fm/s/13347ea8/podcast/play/81792093/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-25%2F364956606-44100-2-466eefe156b1f.m4a",23260588,1438,"2024-01-27T22:14:46Z",296,"2f7d3c70-d5d3-4935-a1d2-7cd4b21dd6da","Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath","episode-297-asco-gu-2024-contact2-part-2-the-aftermath","https://anchor.fm/s/13347ea8/podcast/play/81988202/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-30%2Fb318b48c-ab17-eb03-2e51-34ece05eb5d9.mp3",18855194,1366,"2024-01-30T13:07:10Z",297,"f29b8954-520a-4868-9a3a-eb886d993d1b","Episode 298: ASCO GU 2024 Highlights","episode-298-asco-gu-2024-highlights","https://anchor.fm/s/13347ea8/podcast/play/82065839/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-0-31%2F96cda422-fe9d-8dd1-129b-61a6e4ec80da.mp3",22929014,1635,"2024-01-31T23:05:47Z",298,"e22fae7d-6221-4c23-a52b-844bddf48056","Episode 299: Androgen receptor ligand-directed degrader BMS-986365","episode-299-androgen-receptor-ligand-directed-degrader-bms-986365","https://anchor.fm/s/13347ea8/podcast/play/82330917/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-1-6%2F12842f56-e3ab-7e33-7ccb-6e1933f57c66.mp3",12795226,2200,"2024-02-07T09:27:15Z",299,"8e0875ed-95d1-4c14-b8d8-858bea75a197","Episode 300: Adjuvant PD1 Therapy in Solid Tumours","episode-300-adjuvant-pd1-therapy-in-solid-tumours","https://anchor.fm/s/13347ea8/podcast/play/82530133/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-1-11%2F75efcc79-8688-3122-6f4a-e5b0e42b3cbd.mp3",35921838,2535,"2024-02-11T17:19:09Z",300,"bf8a8ef5-bfd7-4c3f-bdf6-f3d841173333","Episode 301: Cancer research from a global perspective.","episode-301-cancer-research-from-a-global-perspective","https://anchor.fm/s/13347ea8/podcast/play/82330881/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-1-6%2F3c4b2db7-69ee-b521-8bd5-23ac8d2a2473.mp3",10040254,1866,"2024-02-20T16:01:17Z",301,"f4887beb-4054-4b92-8d1c-8ab9108141ce","Episode 302: Part 2- Adjuvant Therapy in solid tumors","episode-302-part-2-adjuvant-therapy-in-solid-tumors","https://anchor.fm/s/13347ea8/podcast/play/83176073/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-1-25%2F6e5956ac-e465-219b-091c-c2deb9f37cff.mp3",29698587,2077,"2024-02-25T21:34:29Z",302,"aa21a9d1-f3bd-47b1-aadb-8e4bbaa3ab4b","Episode 303: Community GU Oncology","episode-303-community-gu-oncology","https://anchor.fm/s/13347ea8/podcast/play/83625438/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-2-5%2F23b9546d-5873-f1b9-d7e9-8eaaaa2b1e6f.mp3",20299647,1456,"2024-03-05T22:53:19Z",303,"f489eceb-aca4-4f84-8137-0e356886f100","Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC","episode-304-a-psma-cd3-bispecific-t-cell-engager-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/83882054/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-2-11%2F24c33d2c-eeec-fc9a-101a-4593f36d835b.mp3",26297772,1843,"2024-03-11T22:57:20Z",304,"925dd89d-23c9-48fa-ab65-d53ea82fdef0","Episode 305: FDA and Oncology Clinical Trials","episode-305-fda-and-oncology-clinical-trials","https://anchor.fm/s/13347ea8/podcast/play/84255172/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-2-19%2Fbb0549b8-e4a9-d51c-c638-bf9a76b8371e.mp3",13657642,1775,"2024-03-19T18:22:40Z",305,"d97ac4b6-9a7a-4138-ba95-ab51048f0b3e","Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC","episode-306-the-uromigos-paper-of-the-month-chemonivo-as-a-bladder-sparing-approach-in-uc","https://anchor.fm/s/13347ea8/podcast/play/84673485/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-2-28%2F2f3dcd2e-1d23-dbc6-b901-d1a14e6d95d6.mp3",25041493,"2024-03-28T17:36:39Z",306,"d7b6ca20-1346-42dd-a7d7-38a1ff93b180","Episode 307: Bladder-Sparing Approaches Part 2","episode-307-bladder-sparing-approaches-part-2","https://anchor.fm/s/13347ea8/podcast/play/84877266/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-2%2Fafc95b77-d9d6-6255-afe8-e83614dbaa98.mp3",30893374,2114,"2024-04-02T21:29:25Z",307,"11e4186e-0ce9-48f9-869a-623ce968117a","Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy","episode-308-eau24-imvigor-011-outcome-of-ctdna-negative-patients-post-cystectomy","https://anchor.fm/s/13347ea8/podcast/play/85095844/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-7%2F5aaacaba-725d-b50c-1724-1dd23d443817.mp3",19836973,1389,"2024-04-07T19:09:19Z",308,"7f91725c-83be-4e5f-aea0-4d6ec43bbd4e","Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer","episode-309-eau24-checkmate-274-os-for-adjuvant-nivolumab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/85050064/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-6%2F8313e4bb-d77e-3d4f-1245-9d42fdb2bc90.mp3",22438742,"2024-04-07T19:09:25Z",309,"9c0bb5aa-6ce9-47ad-8e80-e985eea99411","Episode 310: Dosing and duration of drugs from a cost perspective","episode-310-dosing-and-duration-of-drugs-from-a-cost-perspective","https://anchor.fm/s/13347ea8/podcast/play/85551293/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-17%2F7f335d63-2827-a264-fd4f-148f73549dd2.mp3",24742579,1708,"2024-04-17T17:50:14Z",310,"e9e8f5c0-4b2a-477f-bb3d-7d35769275cf","Episode 311: The Uromigos Paper of the Month - The POUT Trial","episode-311-the-uromigos-paper-of-the-month-the-pout-trial","https://anchor.fm/s/13347ea8/podcast/play/85818766/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-23%2Fc0202ac5-cb43-50be-6f13-c2e367fea704.mp3",27201854,"2024-04-23T18:46:16Z",311,"1494bd69-7455-437b-8078-7bee59113fab","Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer","episode-312-apccc-2024-radiation-therapy-after-surgery-for-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/85965209/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-26%2F99faefda-ace7-4f32-2915-bed0288e20bb.mp3",21097869,1436,"2024-04-26T17:16:55Z",312,"b7cc27e1-7458-49f4-bca5-5b58299eba30","Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease","episode-313-apccc-2024-debate-radiation-therapy-in-advanced-disease","https://anchor.fm/s/13347ea8/podcast/play/85965572/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-26%2Fe6e78685-dfa4-9de4-9776-18f8af6a9706.mp3",32057497,2140,"2024-04-26T17:17:08Z",313,"c93b5067-8308-4fe6-ae15-6437db4c6cd6","Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer","episode-314-apccc-2024-cardiovascular-risks-with-hormone-therapy-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/85991581/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-27%2Fd44538b7-15c2-75af-056d-e512215bd46d.mp3",22486499,1515,"2024-04-27T11:39:11Z",314,"1730cb3d-00e3-4909-ae99-c169d9e7fc07","Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer","episode-315-apccc-2024-quickfire-bone-health-hot-flashes-and-gynecomastia-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/85992032/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-27%2F3b716f2b-8bdb-3d26-12b2-b9e1ebfef14f.mp3",16357758,"2024-04-27T12:55:22Z",315,"9b2467fc-fddb-43fb-b2f0-4d0ea05d3723","Episode 316: APCCC 2024 Summary with Silke Gillessen","episode-316-apccc-2024-summary-with-silke-gillessen","https://anchor.fm/s/13347ea8/podcast/play/86028371/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-3-28%2F33c21389-63c5-0e93-6b9d-07ce0ee635d9.mp3",35123844,2471,"2024-04-28T18:26:28Z",316,"bcbd4079-1bb9-4bd2-8548-f79bd901f0a1","Episode 317: AUA 2024 Preview with the AUA Secretary","episode-317-aua-2024-preview-with-the-aua-secretary","https://anchor.fm/s/13347ea8/podcast/play/86180452/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-1%2Fc8205008-e40d-99c7-7f4e-f0b23687520b.mp3",17344785,1336,"2024-05-01T18:31:22Z",317,"aeb83b24-19bc-4851-858a-2e35a9ffeac3","Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases","episode-318-the-lancet-commission-on-prostate-cancer-planning-for-a-surge-in-cases","https://anchor.fm/s/13347ea8/podcast/play/86688365/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-13%2F37a48dc4-c5b6-064c-5ed1-165226dea86b.mp3",28538856,1919,"2024-05-13T19:03:58Z",318,"b9dea1f3-612b-4641-a476-d1018bfed014","Episode 319: ASCO 2024: A Preview of GU Data","episode-319-asco-2024-a-preview-of-gu-data","https://anchor.fm/s/13347ea8/podcast/play/86940788/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-19%2Fbe3c222b-7df2-5740-47c1-50768b4fbcf0.mp3",28978529,2029,"2024-05-19T21:51:01Z",319,"cf2a93a8-e9f5-41d0-9ea2-4167bc4bfe0e","Episode 320: Team Canada's entry for the Uromigos Cup","episode-320-team-canadas-entry-for-the-uromigos-cup","https://anchor.fm/s/13347ea8/podcast/play/87194709/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-25%2Fe9547031-338d-9d96-3661-aa98438ec4c8.mp3",19262479,"2024-05-25T14:00:29Z",320,"2922a22d-8895-4770-93e0-2023ec5d78de","Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?","episode-321-asco24-chaarted-2-in-prostate-cancer-is-the-sequel-as-good-as-the-original","https://anchor.fm/s/13347ea8/podcast/play/87462685/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-31%2F67b32c62-9c22-225d-2a0a-02bbbaa70718.mp3",21423151,1405,"2024-06-01T22:16:51Z",321,"2a0c93ce-9375-4627-a612-925cb7cea536","Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)","episode-322-asco24-the-role-of-ctdna-in-the-therap-trial-lupsma-vs-cabazitaxel-in-crpc","https://anchor.fm/s/13347ea8/podcast/play/87462999/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-31%2F79e5dcfd-8c6a-6fbc-212e-f7197fd5ba90.mp3",19548065,"2024-06-02T13:54:45Z","ff952139-4d7e-42d2-a986-ea2ea0edb1ed","Episode 323 ASCO24: TDXD in Bladder Cancer","episode-323-asco24-tdxd-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/87523935/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-2%2Fd9881c63-6f82-1b05-0d4c-93dfe2f09ea6.mp3",26090054,1787,"2024-06-02T19:38:33Z","672fbf91-b7b4-4d68-bee3-ab9767b83608","Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC","episode-324-asco24-sure1-neoadjuvant-sacituzumab-govitecan-in-uc","https://anchor.fm/s/13347ea8/podcast/play/87524189/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-2%2F9eeb9193-7e5f-9561-57a5-a838c81d6bfa.mp3",17546958,1243,"2024-06-02T19:38:41Z","5bcdf10c-6075-4376-bf31-1ea9125cd0da","Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer","episode-325-asco24-kn426-and-the-clear-trial-tissue-based-biomarkers-for-kidney-cancer","https://anchor.fm/s/13347ea8/podcast/play/87463790/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-31%2Fb838f46c-9041-62e0-0aa9-97a55957e191.mp3",28460732,2024,"2024-06-03T14:57:43Z","1aade059-b97f-43aa-b2c8-4df41a2f57d0","Episode 326 ASCO24: KIM-1 in Renal Cancer","episode-326-asco24-kim-1-in-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/87565963/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-3%2Ff368c821-943e-4782-2c53-7574b1433853.mp3",15300960,1088,"2024-06-03T19:09:07Z","33cdafd5-035a-4d86-a1b8-c3ae9ab07541","Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates","episode-327-asco24-cm901-and-ev302-efficacy-and-qol-updates","https://anchor.fm/s/13347ea8/podcast/play/87461903/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-4-31%2F6a98943f-9bf4-55b9-45ae-079faab2ed81.mp3",20865278,1442,"2024-06-04T00:29:16Z","cf56bc2d-398c-4124-b849-f50ad19fecdd","Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies","episode-328-asco24-emergency-podcast-what-the-nadina-trial-means-for-preoperative-gu-cancer-studies","https://anchor.fm/s/13347ea8/podcast/play/87645492/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-5%2F5bd82800-f112-6a21-b53b-4534eab7c667.mp3",22330720,1592,"2024-06-05T13:48:54Z",328,"ba9b77c9-f31c-42cf-b8ec-8c4c1c971f3e","Episode 330: ASCO 2024 Highlights","episode-330-asco-2024-highlights","https://anchor.fm/s/13347ea8/podcast/play/87840766/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-10%2F177bb56a-38a8-2292-63e8-0251c35e8a0c.mp3",44634894,3167,"2024-06-10T13:10:06Z",330,"a421c85f-f8d9-4e99-a124-9300a4b8a41c","Episode 331: AUA 2024 NMIBC Highlights","episode-331-aua-2024-nmibc-highlights","https://anchor.fm/s/13347ea8/podcast/play/88296593/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-21%2F756eaeaa-5fdd-6b81-472d-beb1f15612bb.mp3",28254106,2036,"2024-06-21T13:36:44Z",331,"4bd1cd94-fa65-487c-84e7-164664dbbfc2","Episode 332: The Uromigos Cup - Germany's Entry","episode-332-the-uromigos-cup-germanys-entry","https://anchor.fm/s/13347ea8/podcast/play/88447742/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-5-25%2Fe89df4cc-2cf0-e305-4894-f3ab047428c1.mp3",14236918,2155,"2024-06-26T09:28:07Z",332,"4be59afc-26a0-4d3d-8372-928a51514ef4","Episode 333: The Uromigos Cup - The Netherlands","episode-333-the-uromigos-cup-the-netherlands","https://anchor.fm/s/13347ea8/podcast/play/88837629/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-6-5%2F3769a7d3-c642-767f-684b-58fbb6d0901c.mp3",11968774,1580,"2024-07-05T18:39:26Z",333,"b7953ff7-a59a-4467-9e8b-709ae445fdb8","Episode 335: Novel immune therapies for renal cancer","episode-335-novel-immune-therapies-for-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/89420074/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-6-19%2F56805b7f-44df-f48a-4e10-e3c396e35966.mp3",15331822,2251,"2024-07-19T11:42:15Z",335,"5afa0296-416a-4775-a985-22aebe86e81a","Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer","episode-336-which-patients-are-not-suitable-for-1st-line-evp-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/89573499/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-6-23%2F83092188-1e36-19bb-f071-360443659ff2.mp3",14035174,2135,"2024-07-24T11:01:30Z",336,"28df356c-543d-4d1a-86e0-24b947a52afc","Episode 337: Updated NCCN Guidelines in RCC","episode-337-updated-nccn-guidelines-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/89841357/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-6-30%2F384040875-44100-2-818105b7f41fb.m4a",41378083,2558,"2024-07-30T12:30:29Z","affa9b7e-23a2-40d6-9513-3ca71033a2c6","Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More","episode-338-rcc-debulking-nephrectomy-adjuvant-therapy-future-and-more","https://anchor.fm/s/13347ea8/podcast/play/90114078/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-7-6%2F384375703-44100-2-58ca1e758d56a.m4a",24892032,1539,"2024-08-06T11:51:01Z","9e140f3f-fead-4ad8-8d3b-0d66c6cd772f","Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU","episode-339-tres-uramigas-analizan-lineamientos-de-esmo-para-gu","https://anchor.fm/s/13347ea8/podcast/play/90248418/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-7-9%2F384541004-44100-2-b3922da6da0f4.m4a",18079229,1117,"2024-08-09T15:55:38Z","7b198b33-0ba4-4c23-b5d2-efd876d8bda6","Episode 340: Cancer Immunity Cycle Update","episode-340-cancer-immunity-cycle-update","https://anchor.fm/s/13347ea8/podcast/play/90608836/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-7-19%2F384981533-44100-2-a8410e6593efd.m4a",40600003,2510,"2024-08-19T11:56:33Z","d4bd56d2-ab72-43a1-bfbe-cd261e4be088","Episode 341: Hormone Resistance in Prostate Cancer","episode-341-hormone-resistance-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/90962716/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-7-27%2F385418559-44100-2-89570860c69b5.m4a",32115465,1985,"2024-08-27T20:55:37Z","7ce111bb-acf6-41c5-9449-683d4294cd0d","Episode 342: ESMO 2024 Preview with Silke Gillessen","episode-342-esmo-2024-preview-with-silke-gillessen","https://anchor.fm/s/13347ea8/podcast/play/91232556/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-3%2F385748692-44100-2-13c332d951563.m4a",31451275,1944,"2024-09-03T11:29:06Z","f4137fbd-acef-4659-9afc-4322e884905e","Episode 343: ESMO 2024 - TiNivo-2 Trial","episode-343-esmo-2024-tinivo-2-trial","https://anchor.fm/s/13347ea8/podcast/play/91694153/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-14%2F386338750-44100-2-4151db2f2bd7c.m4a",30459840,1883,"2024-09-14T05:28:34Z","74313ebb-0f9d-4334-96d1-42c913363059","Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC","episode-344-esmo-2024-nkt2152-a-hif-inhibitor-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/91694222/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-14%2F386338857-44100-2-f7a4b8f46d37.m4a",21869745,1352,"2024-09-14T05:35:14Z","92196278-e449-4de1-8603-9d73f3f69ebc","Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC","episode-345-esmo-2024-sunniforecast-ipinivo-vs-soc-in-non-clear-cell-rcc","https://anchor.fm/s/13347ea8/podcast/play/91694456/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-14%2F386339265-44100-2-7bf4c1bae6438.m4a",30251379,1870,"2024-09-14T05:54:16Z","fe997ae6-5a1a-4cd3-a16b-e5dad7a18527","Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC","episode-346-esmo-2024-peace-3-enzaradium-223-vs-enza-in-mcrpc","https://anchor.fm/s/13347ea8/podcast/play/91714048/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-14%2F386369906-44100-2-a4a0eb4275d3c.m4a",25026020,"2024-09-14T21:26:42Z","0d0a9425-b88d-458b-8229-11f741e92dca","Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer","episode-347-esmo-2024-dv-pembro-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/91732665/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-15%2F386399264-44100-2-90bb264b033e8.m4a",17454373,1079,"2024-09-15T13:51:14Z","fc3ab00a-71d7-4983-ad68-04cd257abb54","Episode 348: ESMO 2024 - UpFrontPSMA","episode-348-esmo-2024-upfrontpsma","https://anchor.fm/s/13347ea8/podcast/play/91732787/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-15%2F386399442-44100-2-ff60d7f918056.m4a",32876307,2032,"2024-09-15T13:56:01Z","024a1796-211f-4220-bc97-158c6b5f2649","Episode 350: ESMO 2024 - NIAGARA","episode-350-esmo-2024-niagara","https://anchor.fm/s/13347ea8/podcast/play/91786549/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-16%2F386475263-44100-2-da02bd163cc0a.m4a",23158072,"2024-09-16T16:48:10Z","f8725469-5a07-4f07-8265-091ef20900c4","Episode 351: ESMO 2024 review part 1: prostate cancer","episode-351-esmo-2024-review-part-1-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/92017196/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-21%2F386781939-44100-2-74f91705196af.m4a",18248613,1128,"2024-09-21T22:06:53Z","1be835f5-c90b-4a86-b101-bf9b4868b326","Episode 352: ESMO 2024 - RCC and Bladder review","episode-352-esmo-2024-rcc-and-bladder-review","https://anchor.fm/s/13347ea8/podcast/play/92084443/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-23%2F386888051-44100-2-ab1c689bfaee9.m4a",25643003,1585,"2024-09-23T14:50:25Z","db34b8f4-ba48-4dcf-b784-db082b485a08","Episode 353: #UromigosLive24 ADC session","episode-353-uromigoslive24-adc-session","https://anchor.fm/s/13347ea8/podcast/play/92304967/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-28%2F387187697-44100-2-045447727987c.m4a",51896498,3208,"2024-09-28T03:25:30Z","d1ce59ae-2e9c-4134-899e-16a510a95e84","Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer","episode-354-uromigoslive24-t-cell-directed-therapy-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/92325339/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-28%2F387213191-44100-2-42805422d0911.m4a",42703742,2640,"2024-09-28T20:05:14Z","3cc36c76-4664-48fc-9d11-166dbee4fcb9","Episode 355: #UromigosLive24 - Radioligands in prostate cancer","episode-355-uromigoslive24-radioligands-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/92325521/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-28%2F387213430-44100-2-c72271313db73.m4a",52785828,3263,"2024-09-28T20:14:56Z","0a8cf17b-4913-49d0-b4e2-51717669ae65","Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC","episode-356-uromigoslive24-front-line-therapy-in-papillary-and-non-clear-cell-rcc","https://anchor.fm/s/13347ea8/podcast/play/92326255/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-28%2F387214359-44100-2-45b0b7ed69a8c.m4a",25597589,1582,"2024-09-28T20:49:06Z","b9cd87c7-38de-4e34-a5fd-5aeb39d02c28","Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer","episode-357-uromigoslive24-peri-operative-therapy-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/92387461/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-30%2F387290793-44100-2-9c0f39af3052b.m4a",61309192,3790,"2024-09-30T15:14:47Z","e65cf43a-1705-4931-8f0d-dbe88e1f7e3e","Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville","episode-358-noticias-del-dia-1-de-uromigos-live-2024-en-nashville","https://anchor.fm/s/13347ea8/podcast/play/92394023/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-8-30%2F387298668-44100-2-1276d889181b2.m4a",21338058,1319,"2024-09-30T17:06:33Z","ec55edc5-cf87-4dd8-a0d2-28763e0373f3","Episode 359: #UromigosLive24 - IO after IO in RCC","episode-359-uromigoslive24-io-after-io-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/92802868/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-9-9%2F387810804-44100-2-1da46bde152.m4a",39485554,2441,"2024-10-09T18:20:42Z","0369cdab-cbcb-4e7a-a806-6b94d8b40bba","Episode 360: The SUNRISE Program in Bladder Cancer","episode-360-the-sunrise-program-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/93088341/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-9-15%2F388156854-44100-2-27bee1f626f88.mp3",44467094,"2024-10-15T17:55:36Z","e2bb7209-c5ff-4f48-8925-91aec53d22ea","Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer","episode-361-the-role-of-monotherapy-ar-inhibition-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/93379405/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-9-22%2F388518299-44100-2-eecbdaedd524b.m4a",24963696,"2024-10-22T11:53:28Z","b7c67d32-66b4-4b04-87bb-e924acced045","Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)","episode-365-a-review-of-the-advanced-prostate-cancer-consensus-conference-apccc","https://anchor.fm/s/13347ea8/podcast/play/93640024/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-9-28%2F388842205-44100-2-79af0ed2a5a97.m4a",46576097,2879,"2024-10-28T13:40:10Z","028645ff-3be8-4f2d-aa3d-14b59e338d64","Episode 366: ARPIs in Prostate Cancer - Are They Different?","episode-366-arpis-in-prostate-cancer-are-they-different","https://anchor.fm/s/13347ea8/podcast/play/93965789/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-10-4%2F389247964-44100-2-62fd21a31194.m4a",30916208,"2024-11-04T18:56:50Z","33b6ed3b-d510-486e-9973-c82dc69f930e","Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer","episode-367-abiraterone-vs-ar-inhibitors-fanta-vs-coke-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/94258552/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-10-11%2F389611501-44100-2-14592a4feb83e.m4a",55126911,3408,"2024-11-11T14:01:59Z","a4a7803d-3927-491a-9a42-3592d75d0206","Episode 368: Radiomics in RCC: Live from IKCS","episode-368-radiomics-in-rcc-live-from-ikcs","https://anchor.fm/s/13347ea8/podcast/play/94642362/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-10-19%2F390084976-44100-2-380504262cdbe.m4a",35911238,2220,"2024-11-19T12:13:54Z","14c345d2-6f3d-4d86-95bb-0264ba27c308","Episode 369: Paper of the Month with Bishoy Faltas","episode-369-paper-of-the-month-with-bishoy-faltas","https://anchor.fm/s/13347ea8/podcast/play/94931535/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-10-25%2F390440803-44100-2-e13b3a39c935a.m4a",44498013,2751,"2024-11-25T13:57:26Z","af617b87-2fe6-407c-9cf9-18a7e26636eb","Episode 370: Artificial Intelligence in Medical Oncology","episode-370-artificial-intelligence-in-medical-oncology","https://anchor.fm/s/13347ea8/podcast/play/95261051/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-2%2F390852839-44100-2-7e7e5efb98e06.m4a",43446943,2686,"2024-12-02T20:33:18Z","c0094184-c59a-4c5d-88df-70d42b39ccb3","Episode 371: TROPICS-04 Results from ESMO Asia","episode-371-tropics-04-results-from-esmo-asia","https://anchor.fm/s/13347ea8/podcast/play/95463574/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-6%2F391101762-44100-2-a72926e746b95.m4a",32734029,2023,"2024-12-07T03:00:00Z","9ed120f1-b653-471b-a6cf-4850508166ca","Episode 372: FDA Accelerated Approval Process","episode-372-fda-accelerated-approval-process","https://anchor.fm/s/13347ea8/podcast/play/95598654/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-9%2F391266085-44100-2-9e166233e9bd8.m4a",30581920,1890,"2024-12-09T18:30:34Z","edcc2573-1cc0-48c7-8e64-19d773501fa6","Episode 374: Mechanisms of HIF Resistance","episode-374-mechanisms-of-hif-resistance","https://anchor.fm/s/13347ea8/podcast/play/95989508/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-8%2F394519268-44100-2-c7a667b6e4af2.m4a",33594651,"2024-12-18T12:58:05Z","f95c9782-ad1a-47c2-82f3-bbd15a518f19","Episode 375: Renal Cancer 2024 Highlights","episode-375-renal-cancer-2024-highlights","https://anchor.fm/s/13347ea8/podcast/play/96006748/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-18%2F391777902-44100-2-f64ea628af52b.m4a",41911381,2591,"2024-12-23T13:00:00Z","1fb3aae3-0fe6-4cff-b022-fdf49ad4dd67","Episode 376: Bladder Cancer 2024 Highlights","episode-376-bladder-cancer-2024-highlights","https://anchor.fm/s/13347ea8/podcast/play/96010645/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-18%2F391782897-44100-2-d21bf3c91bb1a.m4a",24862694,1537,"91190e18-ce93-4c7b-bc8e-9065d514eff8","Episode 377: Prostate Cancer 2024 Highlights","episode-377-prostate-cancer-2024-highlights","https://anchor.fm/s/13347ea8/podcast/play/96011920/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-11-18%2F391784472-44100-2-99fc5a22659fe.m4a",34171840,2112,"48fc9de7-d967-4ffd-abcb-e48fe69f643d","Episode 378: 2025 Preview of Important GU Data","episode-378-2025-preview-of-important-gu-data","https://anchor.fm/s/13347ea8/podcast/play/96696376/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-0-6%2F392635512-44100-2-bfd524acd721.m4a",40467857,2502,"2025-01-06T23:10:48Z","2270e183-40cb-4c37-be29-053ec569030f","Episode 380: The Role of SBRT in RCC","episode-380-the-role-of-sbrt-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/96989186/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-0-13%2F392996822-44100-2-5060d92f9c262.m4a",40797175,2522,"2025-01-13T14:36:58Z","290d8c9d-3a1f-414c-b222-397b2ae56b54","Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","episode-381-molecular-heterogeneity-in-urothelial-carcinoma-and-determinants-of-clinical-benefit-to-pd-l1-blockade","https://anchor.fm/s/13347ea8/podcast/play/97642490/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-0-27%2F393809921-44100-2-519688b596294.m4a",38904586,2405,"2025-01-27T18:11:11Z","59b71cfe-519d-44f1-9028-bbd29c70c24a","Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC","episode-383-a-neoantigen-vaccine-generates-anti-tumor-immunity-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/98085301/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-5%2F394362327-44100-2-9b650bc8608d5.m4a",32215037,1991,"2025-02-05T22:26:18Z","b455ab60-5d51-41d0-95ea-33d7ee8b18bc","Episode 384: ASCO GU Preview","episode-384-asco-gu-preview","https://anchor.fm/s/13347ea8/podcast/play/98111738/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-6%2F394395629-44100-2-7f668d14e8658.m4a",34345646,2123,"2025-02-06T14:07:44Z","c1836a5a-e3a5-476d-821e-b362fa701499","Episode 385: ASCO GU 2025 - TALAPRO-2","episode-385-asco-gu-2025-talapro-2","https://anchor.fm/s/13347ea8/podcast/play/98392160/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-12%2F394744791-44100-2-091c522d7d082.m4a",31077454,1921,"2025-02-13T17:30:00Z","f4551f72-ee80-461f-aa0e-2a6be252a9c5","Episode 386: ASCO GU 2025 - APRI Meta-analysis","episode-386-asco-gu-2025-apri-meta-analysis","https://anchor.fm/s/13347ea8/podcast/play/98391875/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-12%2F394744460-44100-2-00a25326a8d08.mp3",27817690,1738,"2025-02-13T17:32:00Z","630502d0-748b-48a0-b8c5-21c6c38390c5","Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes","episode-389-asco-gu-2025-niagara-pathologic-cr-updates-and-outcomes","https://anchor.fm/s/13347ea8/podcast/play/98300213/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-10%2F394629476-44100-2-8216845b39705.m4a",27550561,1703,"2025-02-14T16:45:00Z","242a08f4-6bdd-4718-857c-299865cb9cab","Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results","episode-387-asco-gu-2025-neoadjuvant-disitamab-vedotin-toripalimab-in-her2-mibc-updated-efficacy-and-safety-results","https://anchor.fm/s/13347ea8/podcast/play/98301538/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-10%2F394631077-44100-2-40587b3a5af4d.m4a",26323044,1627,"2025-02-14T17:00:00Z","9fe3fc7e-e5c8-49ba-af48-36a49d462258","Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer","episode-388-asco-gu-2025-fgf3-inhibition-with-loxo-435-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/98301055/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-10%2F394630480-44100-2-9b03f5142578a.m4a",24715866,1528,"2025-02-15T00:15:00Z","9989d79a-22ea-4b95-8987-46aee4664e50","Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update","episode-390-asco-gu-2025-pembro-based-doublets-in-refractory-rcc-and-cosmic-313-os-update","https://anchor.fm/s/13347ea8/podcast/play/98392363/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-12%2F394745061-44100-2-bf97af41cfc8e.m4a",29162018,1803,"2025-02-15T17:00:00Z","21d96865-1f66-4756-9f63-6c7cbd5f1553","Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214","episode-391-asco-gu-2025-kim-1-data-from-checkmate-214","https://anchor.fm/s/13347ea8/podcast/play/98392508/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-12%2F394745274-44100-2-159023d9c7a48.m4a",22773344,1408,"2025-02-15T19:00:00Z","b65e3f73-7875-4ca4-a558-96a06bba0618","Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC","episode-392-asco-gu-2025-hif-inhibition-with-casdatifan-in-refractory-rcc","https://anchor.fm/s/13347ea8/podcast/play/98392442/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-12%2F394745170-44100-2-8b396f1d9a4ab.m4a",29271585,1809,"2025-02-15T21:00:00Z","8887ecc5-3efb-489c-b482-264589f7c4d4","Episode 393: ASCO GU 2025 Review Podcast","episode-393-asco-gu-2025-review-podcast","https://anchor.fm/s/13347ea8/podcast/play/99076913/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-1-26%2F395599376-44100-2-d8fb06a807d6.m4a",44747242,2766,"2025-02-26T19:25:46Z","75361fc8-25c1-48f1-a342-b1c123e448f5","Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025","episode-394-apccc-advanced-prostate-cancer-consensus-conference-diagnostics-2025","https://anchor.fm/s/13347ea8/podcast/play/99212603/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-1%2F395767941-44100-2-33a89b79519a7.m4a",29558894,1827,"2025-03-01T13:01:43Z","d04d887d-c165-4d2c-b1ca-909ff6bad6a2","Episode 397: APCCC Diagnostics Conference recap","episode-397-apccc-diagnostics-conference-recap","https://anchor.fm/s/13347ea8/podcast/play/99634667/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-10%2F396296207-44100-2-f6a6da2be46e6.m4a",41970325,2595,"2025-03-10T12:42:01Z","571b35c9-15ec-4e02-a0c4-208098303f17","Episode 398: Reflections on the Felix Feng Symposium at ASCO GU","episode-398-reflections-on-the-felix-feng-symposium-at-asco-gu","https://anchor.fm/s/13347ea8/podcast/play/99997220/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-17%2F396750765-44100-2-ac4e015891ec1.m4a",31134968,"2025-03-17T19:40:51Z","8b1a33b6-1d2f-40a7-842c-d2d426310236","Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?","episode-399-a-pd1vegf-bispecific-in-lung-cancer-lessons-for-gu-cancers","https://anchor.fm/s/13347ea8/podcast/play/100300604/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-24%2F397137927-44100-2-d520a2be6a898.m4a",35656756,2204,"2025-03-24T14:22:19Z","85081852-765f-4f1f-b36e-09aa8bed4a2b","Episode 400: The Uromigos Score for Urothelial Cancer","episode-400-the-uromigos-score-for-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/100522530/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-28%2F397420469-44100-2-3d124bc6feca2.m4a",19720652,1219,"2025-03-28T19:48:07Z","aa6e7110-2f95-441b-82a8-676397b828ac","Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands","episode-401-adcs-in-bladder-cancer-part-1-from-the-canary-islands","https://anchor.fm/s/13347ea8/podcast/play/100554755/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-2-29%2F397461222-44100-2-a390a42402b8d.m4a",29581812,1829,"2025-03-29T18:31:22Z","98e94a0d-9c78-4472-aeb6-df6c8c4752a9","Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands","episode-403-adcs-in-bladder-cancer-part-2-from-the-canary-islands","https://anchor.fm/s/13347ea8/podcast/play/100732634/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-2%2F397686429-44100-2-78f006132cfd4.m4a",36570374,2261,"2025-04-02T13:01:49Z","cab5b037-3e30-43a7-8e54-8c671f2dc8e1","Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands","episode-404-177-lu-psma-pre-chemotherapy-in-mcrpc-final-podcast-from-the-canary-islands","https://anchor.fm/s/13347ea8/podcast/play/100954467/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-7%2F397968522-44100-2-6b5a82ef5c0c2.m4a",26360644,"2025-04-07T13:29:28Z","a07f4356-eeb4-424d-8219-404401a95de0","Episode 405: The Good News About Cancer podcast","episode-405-the-good-news-about-cancer-podcast","https://anchor.fm/s/13347ea8/podcast/play/101166629/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-11%2F398240207-44100-2-e923e0087ba3a.m4a",17364952,1073,"2025-04-11T16:04:39Z","c6052e1b-f1b0-4ea7-bc53-8efd3ebb3a2f","Episode 406: Drug Development in China: Part 1 of 2","episode-406-drug-development-in-china-part-1-of-2","https://anchor.fm/s/13347ea8/podcast/play/101271727/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-14%2F398374140-44100-2-f75441ca56ab9.m4a",29152654,1802,"2025-04-14T13:27:46Z","71046e00-bac5-47c6-9b49-a8dc438cdb6f","Episode 407: Drug Development in China: Part 2 of 2","episode-407-drug-development-in-china-part-2-of-2","https://anchor.fm/s/13347ea8/podcast/play/101565559/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-21%2F398747273-44100-2-67ad77c49c1fc.m4a",24603234,1521,"2025-04-21T12:44:18Z","bcaf9489-7859-4cf5-b7d0-a2d99ea7332c","Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC","episode-409-aua-2025-crest-bcg-sasanlimab-in-high-risk-nmibc","https://anchor.fm/s/13347ea8/podcast/play/101817774/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-3-26%2F399130931-44100-2-cac0661c507d5.m4a",46054489,2847,"2025-04-26T17:52:22Z","00957a74-c6b9-4357-936c-bbfeab0c80b0","Episode 411: Live from EIKCS in Amsterdam - RCC Highlights","episode-411-live-from-eikcs-in-amsterdam-rcc-highlights","https://anchor.fm/s/13347ea8/podcast/play/102120726/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-3%2F399520059-44100-2-3c3d8ce4f6879.m4a",19844478,1226,"2025-05-03T13:05:56Z","bc7f21e7-808c-4fcf-a77c-42acfcffca13","Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1","episode-412-aua-2025-tar-200-monotherapy-in-bcg-unresponsive-nmuibc-from-sunrise-1","https://anchor.fm/s/13347ea8/podcast/play/102198493/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-5%2F399625810-44100-2-78bac2a178a3a.m4a",36232686,2240,"2025-05-05T11:48:29Z","fcc5d110-46c8-4b45-8e6f-4cc19c653e3c","Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC","episode-410-aua-2025-bond-003-cohort-c-cretostimogene-in-bcg-unresponsive-nmibc","https://anchor.fm/s/13347ea8/podcast/play/102230682/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-5%2F399669388-44100-2-37ff4d2017e0d.m4a",28012477,1732,"2025-05-05T23:03:03Z","794db11f-b5a9-4a6d-aed0-50642928cb8f","Episode 413: The Uromigos Score for Advanced Prostate Cancer","episode-413-the-uromigos-score-for-advanced-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/102533107/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-12%2F400080195-44100-2-252ef4f242499.m4a",35952289,2222,"2025-05-12T11:01:55Z","f04d1e92-46b3-4160-8f6f-85afd34bc701","Episode 416: ASCO 2025 Preview","episode-416-asco-2025-preview","https://anchor.fm/s/13347ea8/podcast/play/102884303/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-19%2F400581588-44100-2-ee06e993b2a29.m4a",39513646,2443,"2025-05-19T16:27:12Z","521be3c2-1236-46af-8b94-9fda92d0b64e","Episode 418: ASCO 2025 - Biomarkers in RCC","episode-418-asco-2025-biomarkers-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/103481862/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-31%2F401348333-44100-2-ed0c80019c39a.m4a",43602108,2695,"2025-05-31T22:49:35Z","809cf912-a497-4664-9928-385eea5017a0","Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study","episode-419-asco-2025-correlate-data-from-the-immotion-010-rcc-adjuvant-study","https://anchor.fm/s/13347ea8/podcast/play/103482065/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-4-31%2F401348581-44100-2-cc9717853f1d5.m4a",23120979,"2025-05-31T23:00:21Z","30fd4763-aebb-4cd7-9c24-b457f82be611","Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer","episode-420-asco-2025-checkmate-901-ipinivo-vs-chemo-for-cis-ineligible-metastatic-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/103505396/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-1%2F401376854-44100-2-6a6868d1998.m4a",23594453,1458,"2025-06-01T15:18:09Z","f1e3c446-9900-45c2-b00c-328ad3a81f43","Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer","episode-421-asco-2025-maintenance-avelumab-sg-in-advanced-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/103506037/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-1%2F401377683-44100-2-b65e5dc507144.m4a",33796681,2089,"2025-06-01T15:38:20Z","2a21d5f6-0c2e-42e9-b9a6-1fdead524870","Episode 422: ACSO 2025 - ctDNA data from NIAGARA","episode-422-acso-2025-ctdna-data-from-niagara","https://anchor.fm/s/13347ea8/podcast/play/103507037/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-1%2F401378971-44100-2-46a90680caa04.m4a",31704339,1960,"2025-06-01T16:03:50Z","5a6d9416-0c1e-491d-b2e6-09cfcb55950c","Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC","episode-423-asco-2025-casdatifan-plus-cabo-in-refractory-rcc","https://anchor.fm/s/13347ea8/podcast/play/103508769/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-1%2F401381138-44100-2-ef4cf47e695c7.m4a",29910384,"2025-06-01T17:07:24Z","b777e962-6cda-4efb-bf89-8ce7c440cc88","Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session","episode-424-asco-2025-emergency-podcast-on-the-prostate-rapid-oral-session","https://anchor.fm/s/13347ea8/podcast/play/103547437/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-2%2F401429424-44100-2-7ebca5c74229.m4a",29285939,1810,"2025-06-02T13:12:35Z","d356f757-d41c-413e-b1b1-d1340f3d3cb4","Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI","episode-425-asco-2025-ai-enabled-selection-of-patients-for-benefit-of-adt-arpi","https://anchor.fm/s/13347ea8/podcast/play/103649707/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-4%2F401559650-44100-2-eccab4f12ca01.m4a",19080344,1179,"2025-06-04T12:25:11Z","6cbfbde0-a82c-4a0a-a018-f099bd8bd6d7","Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC","episode-426-asco-2025-amplitude-phase-3-of-parpi-in-mhspc","https://anchor.fm/s/13347ea8/podcast/play/103756403/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-7%2F401748854-44100-2-b5ccd0d3e38d2.m4a",36265804,2242,"2025-06-06T14:01:06Z","92998d02-04ff-4345-b0e8-36fb66e4dcad","Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)","episode-427-emerging-data-in-non-muscle-invasive-bladder-cancer-nmibc","https://anchor.fm/s/13347ea8/podcast/play/104082946/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-13%2F402102821-44100-2-4604915cea28f.m4a",39254997,2427,"2025-06-13T15:18:24Z","4bc87444-1962-4331-b326-94279d789fa8","Episode 428: ASCO 2025 Recap","episode-428-asco-2025-recap","https://anchor.fm/s/13347ea8/podcast/play/104203133/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-5-16%2F402252109-44100-2-72dca16510baf.m4a",52729028,3260,"2025-06-16T13:19:07Z","74206b7f-465f-4757-a271-91e62f0e1c4c","Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?","episode-430-structured-exercise-improves-dfsos-after-adjuvant-therapy-in-colorectal-cancer-does-this-apply-to-gu-cancers","https://anchor.fm/s/13347ea8/podcast/play/105160501/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-6-7%2F403474133-44100-2-6e27138b2cffe.m4a",44422498,2746,"2025-07-07T18:04:35Z","0b6878b9-d8eb-41f7-b659-dd44f83b8d03","Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials","episode-431-impact-series-axel-bex-on-impactful-rcc-clinical-trials","https://anchor.fm/s/13347ea8/podcast/play/105482249/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-6-14%2F403889799-44100-2-a460c84bd9db4.m4a",42686676,2639,"2025-07-14T14:32:03Z","2db80953-185e-477e-bb69-7f78fca11e1e","Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap","episode-432-asco-2025-rapid-oral-session-rccbladder-recap","https://anchor.fm/s/13347ea8/podcast/play/105797454/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-6-21%2F404291801-44100-2-688847b52f9be.m4a",26998184,"2025-07-21T17:56:35Z","5bb21daf-0812-4f0c-8392-6b9d46b1f1d9","Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC","episode-434-impact-series-a-walk-through-the-history-of-vegf-tki-development-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/106441470/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-7-4%2F405116284-44100-2-e362b70d06291.m4a",47417955,2931,"2025-08-04T21:22:39Z","cdfbd2d2-2c70-4191-aece-85700db5443b","Episode 435: The History of IO in RCC - Part 1","episode-435-the-history-of-io-in-rcc-part-1","https://anchor.fm/s/13347ea8/podcast/play/107021021/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-7-18%2F405861453-44100-2-9477527ffa08e.m4a",27050744,1672,"2025-08-18T16:05:17Z","d8f460ad-4c41-4774-ae43-465f2ef7bd9c","Episode 436: The History of IO in RCC - Part 2","episode-436-the-history-of-io-in-rcc-part-2","https://anchor.fm/s/13347ea8/podcast/play/107319913/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-7-25%2F406245381-44100-2-6a4f792a773ec.m4a",35405681,"2025-08-25T13:04:12Z","5702f04e-d2f4-4335-ab16-ea511a61aad6","Episode 438: The History of Testis Cancer Treatment","episode-438-the-history-of-testis-cancer-treatment","https://anchor.fm/s/13347ea8/podcast/play/108011676/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-8-8%2F407115010-44100-2-8f38d2f6ca825.m4a",38202960,2362,"2025-09-08T14:14:31Z","065dd630-7cfa-496e-9181-9389b23af440","Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer","episode-439-transcriptome-expression-and-treatment-sensitivity-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/108335383/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-8-15%2F407525820-44100-2-f582ea4113bbf.m4a",40182701,2484,"2025-09-15T15:35:34Z","cddf344a-dbd6-449c-a7d0-ea86c6b60645","Episode 440: The History of IO in Urothelial Cancer - Part 1","episode-440-the-history-of-io-in-urothelial-cancer-part-1","https://anchor.fm/s/13347ea8/podcast/play/108653372/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-8-22%2F407935228-44100-2-00d13d60ad5b1.m4a",44303482,2739,"2025-09-22T14:43:55Z","be957bf1-ff4a-4e79-a283-12caa236e8d8","Episode 441: The History of IO in Urothelial Cancer - Part 2","episode-441-the-history-of-io-in-urothelial-cancer-part-2","https://anchor.fm/s/13347ea8/podcast/play/108960301/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-8-29%2F408333812-44100-2-4aaa25e30be4e.m4a",32289997,1996,"2025-09-29T12:18:21Z","4de33c97-3ea7-4ad4-8296-0fa087acd9a7","Episode 443: ESMO 2025 Bladder Cancer Preview","episode-443-esmo-2025-bladder-cancer-preview","https://anchor.fm/s/13347ea8/podcast/play/109114639/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-2%2F408534403-44100-2-827eab4948602.m4a",31204343,1929,"2025-10-02T12:07:07Z","b261e11c-67b7-45cb-b21c-d6838b14d2fc","Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer","episode-444-esmo-2025-preview-prostate-and-renal-cancer","https://anchor.fm/s/13347ea8/podcast/play/109393587/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-8%2F408897200-44100-2-4f31a75f78fbb.m4a",40729158,2518,"2025-10-08T17:14:40Z","9c484797-0955-4bef-9ade-3ab5c58156d4","Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)","episode-445-esmo-2025-systemic-checkpoint-inhibition-plus-bcg-in-nmibc-potomac-and-alban","https://anchor.fm/s/13347ea8/podcast/play/109810445/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-17%2F409442573-44100-2-8a07008001efa.m4a",35820690,2214,"2025-10-17T12:47:33Z","a20400d6-756a-4fcc-9bae-83cede5b7a5e","Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets","episode-446-esmo-2025-optic-and-front-line-rcc-triplets","https://anchor.fm/s/13347ea8/podcast/play/109844230/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-18%2F409487011-44100-2-b1a4cae91eb3.m4a",35271668,"2025-10-18T07:54:38Z","61f024eb-c49e-4a6c-a9af-0ebe20284e52","Episode 447: ESMO 2025 - RAMPART","episode-447-esmo-2025-rampart","https://anchor.fm/s/13347ea8/podcast/play/109844809/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-18%2F409487651-44100-2-8fd6418eb2927.m4a",35605857,"2025-10-18T08:29:45Z","7b504edc-dfb1-4a7c-a6b0-6f2bcb28fe79","Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC","episode-448-neoadjuvant-evpembro-in-cis-ineligible-mibc","https://anchor.fm/s/13347ea8/podcast/play/109853313/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-18%2F409499226-44100-2-7eae6dc50ab17.mp3",44504710,2781,"2025-10-18T15:51:05Z","bac429c6-0882-486f-b47e-501931b1953a","Episode 449: ESMO 2025 - ENZARAD","episode-449-esmo-2025-enzarad","https://anchor.fm/s/13347ea8/podcast/play/109880685/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-19%2F409534145-44100-2-1622509e9f587.m4a",27185688,"2025-10-19T12:41:11Z","f9ca9812-6407-4b87-a14c-e9971c042b63","Episode 450: ESMO 2025 - CAPITELLO","episode-450-esmo-2025-capitello","https://anchor.fm/s/13347ea8/podcast/play/109880758/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-19%2F409534240-44100-2-0a6570ad78887.m4a",20951536,1295,"2025-10-19T12:43:54Z","ca9428ea-976f-449e-96fe-c971f0c1ccc3","Episode 451: ESMO 2025 - PSMAddition","episode-451-esmo-2025-psmaddition","https://anchor.fm/s/13347ea8/podcast/play/109880840/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-19%2F409534346-44100-2-597619fa8f68d.m4a",29620019,1831,"2025-10-19T23:00:01Z","f54d4fe3-9c14-4d3e-82fd-cc57767ee3f5","Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer","episode-452-esmo-2025-dv-toripalimab-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/109880956/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-19%2F409534508-44100-2-1e9e43e829c7b.m4a",41591730,2571,"2025-10-19T23:15:00Z","db1de297-505d-4866-8991-030c3e8fe988","Episode 453: ESMO 2025 - IMvigor011","episode-453-esmo-2025-imvigor011","https://anchor.fm/s/13347ea8/podcast/play/109881066/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-19%2F409534630-44100-2-2b8fc91d52bae.m4a",36353192,2247,"2025-10-20T22:00:00Z","fbb4c60e-3cf5-449b-9fa8-4b63975f87ef","Episode 454: ESMO 2025 Prostate and Kidney Cancer Review","episode-454-esmo-2025-prostate-and-kidney-cancer-review","https://anchor.fm/s/13347ea8/podcast/play/110101364/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-23%2F409822920-44100-2-898888ce0b70b.m4a",44882030,2775,"2025-10-23T12:02:57Z","09189577-da43-483c-a873-45198f319bff","Episode 455: ESMO 2025 Urothelial Cancer Review","episode-455-esmo-2025-urothelial-cancer-review","https://anchor.fm/s/13347ea8/podcast/play/110101571/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-9-23%2F409823201-44100-2-abc01aab71aae.m4a",26511499,1639,"2025-10-23T12:08:37Z","b7685565-7f58-450e-a310-1e5b13666f65","Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer","episode-456-uromigoslive-2025-peri-operative-therapy-for-urothlial-cancer","https://anchor.fm/s/13347ea8/podcast/play/110857045/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-7%2F410818898-44100-2-657650a161a35.m4a",50313864,3111,"2025-11-07T20:37:59Z","9db9e2d6-d8ea-485c-9fb2-e88567420cd1","Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer","episode-457-uromigoslive-2025-adcs-in-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/110862615/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-7%2F410939590-44100-2-7ff4f9319a4d2.m4a",55119792,"2025-11-07T23:09:37Z","1fb3c076-ee9f-4664-94bf-6acf750e225f","Episode 458: #UromigosLive 2025 - Mock ODAC","episode-458-uromigoslive-2025-mock-odac","https://anchor.fm/s/13347ea8/podcast/play/110881720/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-8%2F412084493-44100-2-c8e61949f0d99.m4a",44025514,2722,"2025-11-08T14:52:12Z","1ef8039e-ed89-4495-8a38-1475c9181b2d","Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer","episode-459-uromigoslive-2025-radioligands-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/110889897/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-8%2F412095127-44100-2-bff376dfebf99.m4a",36554990,2260,"2025-11-08T19:36:45Z","e00158b1-c527-44e8-ae78-6d9a020017bb","Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC","episode-464-uromigoslive-2025-the-evolving-landscape-of-mhspc","https://anchor.fm/s/13347ea8/podcast/play/110961726/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-10%2F412187300-44100-2-33bf3dc4880df.m4a",48589675,3004,"2025-11-10T13:59:51Z","a09606d8-e5e2-42ec-9704-b27b653b9562","Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC","episode-465-uromigoslive-2025-adjuvant-therapy-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/110962256/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-10%2F412188011-44100-2-04a90521b6cb4.m4a",43495281,2689,"2025-11-10T14:11:28Z","4fa49b79-e976-4db4-93c7-7d198e7a8ff1","Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC","episode-466-uromigoslive-2025-novel-therapy-in-mrcc","https://anchor.fm/s/13347ea8/podcast/play/110963151/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-10%2F412189141-44100-2-7e2faec84b8b2.m4a",51491968,3183,"2025-11-10T14:27:38Z","a848af36-a192-45db-8daa-8bcf80530f7b","Episode 442: The History of ARPI Development in Prostate Cancer","episode-442-the-history-of-arpi-development-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/108961647/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-8-29%2F408335515-44100-2-bbba0fb95ab62.m4a",49696506,3072,"2025-11-24T12:45:19Z","c550bb87-d530-4803-a644-590099be2ca6","Episode 468: RCC Year in Review","episode-468-rcc-year-in-review","https://anchor.fm/s/13347ea8/podcast/play/112681011/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-11-15%2F414443508-44100-2-88a00f5872e6c.m4a",40563674,2508,"2025-12-15T20:27:24Z","82d794f7-e2bc-4515-a9e7-96803086ddc5","Episode 469: Prostate Cancer year in Review","episode-469-prostate-cancer-year-in-review","https://anchor.fm/s/13347ea8/podcast/play/112774804/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-11-17%2F414564814-44100-2-fd904c178653b.m4a",43909139,2714,"2025-12-22T12:00:00Z","03c50fa5-f9d3-4c14-81e7-105e3543b253","Episode 470: Bladder Cancer Year in Review","episode-470-bladder-cancer-year-in-review","https://anchor.fm/s/13347ea8/podcast/play/113146991/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-11-26%2F415041640-44100-2-ec4f9f107e1f8.m4a",48414671,2993,"2025-12-29T12:00:00Z","216521d7-a0c8-4d50-840a-f7d57cb1d874","Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer","episode-471-uromigos-shorts-adcs-and-bites-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/113257578/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-11-29%2F415181021-44100-2-395344e8149d1.m4a",34150520,2111,"2026-01-05T12:00:00Z","917603f4-90d8-4182-83e8-e2db079727a3","Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer","episode-472-uromigos-shorts-variant-histology-bladder-cancer","https://anchor.fm/s/13347ea8/podcast/play/113331301/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-11-31%2F415274553-44100-2-feabd057c4af6.m4a",26491289,"2026-01-12T13:00:00Z","18cbdfa6-36e3-4038-8625-886fba144768","Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer","episode-473-uromigos-shorts-embark-and-bcr-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/114176217/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-0-18%2F416346454-44100-2-50204d06f86d9.m4a",32660064,2019,"2026-01-19T12:00:00Z","8deb77fc-a87c-4307-87c7-d5dabb93659c","Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer","episode-474-uromigos-shorts-io-refractory-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/114227498/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-0-19%2F416411419-44100-2-b887db35a497c.m4a",29794009,1842,"2026-01-26T12:00:00Z","eaa247d7-1b9b-4417-b621-9f07e1f92509","Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis","episode-475-depth-of-response-and-overall-survival-for-io-based-regimens-in-mrcc-results-of-an-fda-analysis","https://anchor.fm/s/13347ea8/podcast/play/114707716/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-0-28%2F417038366-44100-2-1be856810ad7d.m4a",29580346,1828,"2026-02-02T11:00:00Z","483a77bc-13a2-4f63-a874-881aaa6ef1e7","Episode 476: ASCO GU 2026 Preview","episode-476-asco-gu-2026-preview","https://anchor.fm/s/13347ea8/podcast/play/115266072/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-9%2F417782890-44100-2-5351c61b4e9a7.m4a",47384886,2929,"2026-02-09T20:30:19Z","9eeb30c2-fbe0-4f4b-b815-3ab789cd93f5","Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria","episode-478-prostate-cancer-working-group-4-pcwg-4-criteria","https://anchor.fm/s/13347ea8/podcast/play/115601790/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-16%2F418230576-44100-2-3872047cced11.m4a",44629437,2759,"2026-02-16T21:04:34Z","d2355f87-947a-403c-99db-a22af1cf3d2d","Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis","episode-479-does-the-timing-of-io-infusion-impact-clinical-outcomes-a-critical-analysis","https://anchor.fm/s/13347ea8/podcast/play/115923982/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-23%2F418661473-44100-2-ed3e7268ff2d6.m4a",38615472,2387,"2026-02-23T16:19:16Z","ad11b9cc-c315-494c-a13f-ef410990ce1a","Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results","episode-480-asco-gu-2026-peace-3-and-brcaway-final-os-results","https://anchor.fm/s/13347ea8/podcast/play/115928991/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-23%2F418668275-44100-2-00cb468116efc.m4a",41860746,2588,"2026-02-26T17:30:00Z","49fde8be-2a5d-48e1-8c6f-40e527d663dc","Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC","episode-483-asco-gu-2026-keynote-b15-neoadjuvant-evp-vs-gemcis-in-cis-eligible-mibc","https://anchor.fm/s/13347ea8/podcast/play/116050699/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-25%2F418831540-44100-2-0898e018cd9b2.m4a",41061577,2538,"2026-02-27T18:00:00Z","3e2117e1-7e12-4b47-aeb1-70a1e955ebe0","Episode 482: ASCO GU 2026 - SUNRISE 2","episode-482-asco-gu-2026-sunrise-2","https://anchor.fm/s/13347ea8/podcast/play/115834953/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-21%2F418544057-44100-2-9ec18865a3051.m4a",32407303,2003,"2026-02-28T01:00:00Z","ffafe1fd-8c00-4486-b92a-e238d584c1af","Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC","episode-484-asco-gu-2026-litespark-022-adjuvant-pembro-belzutifan-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/116047876/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-25%2F418827696-44100-2-4a0fd551fb566.m4a",35796013,2213,"2026-02-28T18:30:00Z","b3ad4f11-d5d4-4ff1-8d1d-29ab1da938e8","Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo","episode-485-asco-gu-2026-litespark-011-lenbelzu-vs-cabo","https://anchor.fm/s/13347ea8/podcast/play/116049991/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-25%2F418830529-44100-2-b7c309b2e3b3a.m4a",30519995,1887,"1e4788ac-9ea5-48d0-bd55-75c271837bcd","Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer","episode-486-ctdna-and-utdna-data-in-peri-operative-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/116387563/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-4%2F419283236-44100-2-38348a98bde8e.m4a",44192281,2732,"2026-03-04T16:43:06Z","e4d1de58-fa94-4a54-855f-57567a4ca723","Episode 487: ASCO GU 2026 recap","episode-487-asco-gu-2026-recap","https://anchor.fm/s/13347ea8/podcast/play/116587479/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-8%2F419556150-44100-2-82199219f5d99.m4a",54508295,3370,"2026-03-08T18:45:03Z","742e46d3-479a-40d7-b3b3-d53fd76fd166","Episode 489: Live Podcast From EAU","episode-489-live-podcast-from-eau","https://anchor.fm/s/13347ea8/podcast/play/116996368/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-16%2F420114054-44100-2-d123919aeda97.mp3",46373406,2898,"2026-03-16T11:37:02Z","6a917f83-071c-45fd-99cb-480eed9df0bd","Episode 490: Systemic Therapy Only in Patients wtih MIBC","episode-490-systemic-therapy-only-in-patients-wtih-mibc","https://anchor.fm/s/13347ea8/podcast/play/117636014/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-29%2F420980040-44100-2-f91a1341b809c.m4a",46872641,"2026-03-30T10:30:00Z","704ed0bd-e275-4e99-a1f7-57100253d21a","Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors","episode-492-novel-biomarkers-and-targets-in-germ-cell-tumors","https://anchor.fm/s/13347ea8/podcast/play/117849706/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-2%2F421267842-44100-2-8dc0ebe46d00f.m4a",32435431,2005,"2026-04-06T10:00:00Z","e35bf364-b3f7-4c07-8dd4-8db00dd0ed57","Episode 493: The Role of Chemotherapy in mHSPC","episode-493-the-role-of-chemotherapy-in-mhspc","https://anchor.fm/s/13347ea8/podcast/play/118158797/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-8%2F421676514-44100-2-63b619ed171f5.m4a",45981894,2843,"2026-04-13T10:00:00Z","b2074d25-9cab-4dd0-a707-d6ea8c4e2307","Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist","episode-494-duration-of-evp-in-multiple-urothelial-cancer-settings-paper-of-the-month-pparg-inverse-agonist","https://anchor.fm/s/13347ea8/podcast/play/119116846/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-27%2F422964046-44100-2-1d47d67f1b43f.m4a",38901921,"2026-04-27T14:50:20Z","a6f43f10-c031-4524-8db3-58864488c48b","Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer","episode-495-apccc-2026-locally-advanced-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/119293159/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-30%2F423207868-44100-2-99d96ba1a56c6.m4a",30193609,"2026-04-30T15:28:49Z","2e65e08f-4105-4f94-bcb3-9bc76f3f1f67","Episode 496: APCCC 2026 - mHSPC Landscape","episode-496-apccc-2026-mhspc-landscape","https://anchor.fm/s/13347ea8/podcast/play/119342017/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-1%2F423274077-44100-2-ad3ed4c1b5b97.m4a",26101440,1613,"2026-05-01T16:03:45Z","cbb833be-5888-4fff-b569-5ba559b3360f","Episode 497: Reflections on the capivasertib ODAC","episode-497-reflections-on-the-capivasertib-odac","https://anchor.fm/s/13347ea8/podcast/play/119357850/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-1%2F423296441-44100-2-b41921c85ea58.m4a",20623065,1275,"2026-05-01T21:52:50Z","da75f461-d6ff-4a4b-951f-bf92297e9df6","Episode 498: APCCC 2026 - mCRPC","episode-498-apccc-2026-mcrpc","https://anchor.fm/s/13347ea8/podcast/play/119344309/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-1%2F423277678-44100-2-98eb23f05af38.m4a",20874311,1290,"2026-05-02T04:31:00Z","40feef84-1b15-48ba-94bf-478a51e5befe","Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)","episode-500-ras-inhibition-in-pancreatic-cancer-yes-this-is-the-uromigos-podcast","https://anchor.fm/s/13347ea8/podcast/play/119833040/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-11%2F423941717-44100-2-4354664512fed.m4a",34231088,2116,"2026-05-11T17:46:58Z","dc8bbddd-f8e6-4894-b5a1-5ad29663fab6","Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer","episode-501-apccc-2026-biochemically-relapsed-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/120165863/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-18%2F424387756-44100-2-b1e9d3704da03.m4a",19070976,"2026-05-18T13:55:21Z","e5767e3b-56a0-4699-a3a0-5c00c8f64726","Episode 502: AUA 2026 and FDA bladder cancer meeting","episode-502-aua-2026-and-fda-bladder-cancer-meeting","https://anchor.fm/s/13347ea8/podcast/play/120285090/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424548128-44100-2-4ce93ed7c5d5a.m4a",34231899,"2026-05-20T15:22:24Z","bc12a6c1-2348-451f-9192-496c1bce0311","Episode 503: ASCO 2026 Preview","episode-503-asco-2026-preview","https://anchor.fm/s/13347ea8/podcast/play/120297552/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fproduction%2Fexports%2F13347ea8%2F120297552%2F7629d6ba099720e81a9fcb43ea2b4585.m4a",79740814,4930,"2026-05-22T06:00:00Z","283017b7-e4d2-46d0-b930-4a80163ae358","Episode 499: APCCC 2026 - Radioligands in Prostate Cancer","episode-499-apccc-2026-radioligands-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/120514984/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-25%2F424852580-44100-2-46a63ba4af103.m4a",36209028,2238,"2026-05-25T14:43:37Z","a0c7446a-f503-40a9-b330-8ed4ad4d3b02","Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer","episode-504-asco-2026-adc-drug-development-in-urothelial-cancer","https://anchor.fm/s/13347ea8/podcast/play/120514136/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-25%2F424851413-44100-2-cf14be68f94d8.m4a",39347327,2432,"2026-05-29T22:30:00Z","1b77ab57-a997-4b5b-93f3-2068443ef021","Episode 505 : ASCO 2026 - RAMPART","episode-505-asco-2026-rampart","https://anchor.fm/s/13347ea8/podcast/play/120280559/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424542149-44100-2-d2b1721d3afce.m4a",28657356,1771,"2026-05-30T15:00:00Z","22f091c0-d1e4-48b2-9e4f-c13291275f8a","Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?","episode-506-asco-2026-how-do-we-measure-quality-of-life-in-gu-patients","https://anchor.fm/s/13347ea8/podcast/play/120769713/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-30%2F425193900-44100-2-b81017b2fb4c3.m4a",19191146,"2026-05-30T19:22:29Z","Episode 507: ASCO 2026 - TALAPRO-3","episode-507-asco-2026-talapro-3","https://anchor.fm/s/13347ea8/podcast/play/120470670/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-24%2F424794338-44100-2-6d6e4c9015d05.m4a",40515547,2505,"2026-05-30T23:30:00Z","18c24f74-4791-48ec-8664-05ee341b1148","Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer","episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/120219309/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-19%2F424459091-44100-2-9da0f181e09c.m4a",38502065,2380,"2026-05-31T18:30:00Z","f887c8c8-907d-4505-a806-5cef5ea7b00e","Episode 509: ASCO 2026 Review","episode-509-asco-2026-review","https://anchor.fm/s/13347ea8/podcast/play/121138928/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-7%2F425687559-44100-2-9effe48080a3c.m4a",53575429,3312,"2026-06-08T07:00:00Z","570c5a8a-242a-42b6-b53b-72f96078a997","Episode 510: ADCs in Prostate Cancer","episode-510-adcs-in-prostate-cancer","https://anchor.fm/s/13347ea8/podcast/play/121502831/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-15%2F426173003-44100-2-d76fc9cd3be71.m4a",29491348,1823,"2026-06-15T12:53:24Z","e6d144d4-b3ac-4483-9994-92dee5d515f7","Episode 512: ENZA-P Nature Medicine translational data","episode-512-enza-p-nature-medicine-translational-data","https://anchor.fm/s/13347ea8/podcast/play/121781162/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-21%2F426545498-44100-2-e06f88030175b.m4a",30290325,"2026-07-06T06:00:00Z","18614fdd-e693-4e1a-aa23-d8e3e2c4d282","Episode 513: Trials and Tribulations of Investigator-initiated Research","episode-513-trials-and-tribulations-of-investigator-initiated-research","https://anchor.fm/s/13347ea8/podcast/play/122500334/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-7%2F427508846-44100-2-3138ecdea54e7.m4a",24824355,1534,"2026-07-13T10:57:00Z","076586a5-c27f-4857-b4e0-b65070b3fec8","Episode 514: Artificial Intelligence in Cancer Drug Development","episode-514-artificial-intelligence-in-cancer-drug-development","https://anchor.fm/s/13347ea8/podcast/play/122767082/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-13%2F427865837-44100-2-13c9627923d2d.m4a",39204965,2424,"2026-07-20T06:00:00Z","b4ebeb82-f254-4c43-818f-aa7143602316","Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala","episode-515-proteus-a-reflection-on-the-data-and-controversies-with-neha-vapiwala","https://anchor.fm/s/13347ea8/podcast/play/122820002/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-14%2F427936652-44100-2-c9b5b114a6349.m4a",41830280,2586,"2026-08-03T06:00:00Z","88160530-7c72-4d69-a0ad-6a046997f520","Episode 516: The Influence of Hypoxia on Response and Resistance in RCC","episode-516-the-influence-of-hypoxia-on-response-and-resistance-in-rcc","https://anchor.fm/s/13347ea8/podcast/play/124333987/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-7-17%2F429993700-44100-2-20c6a1d21688a.m4a",46431558,2870,"2026-08-17T12:41:34Z","a820fa12-01af-4d8b-89c6-d8a9fff37a91","Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates","episode-517-casdatifan-clinical-data-in-rcc-and-translational-correlates","https://anchor.fm/s/13347ea8/podcast/play/124674029/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-7-24%2F430455789-44100-2-ffb8a0067f981.m4a",39675738,2453,"2026-08-31T06:50:00Z","theme","baseURL","https://pocketcasts.com","locale","en","region","global"]

Episode 507: ASCO 2026 - TALAPRO-3

Episode Description

Never lose your place, on any device